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Transplantation of pancreatic islet in an immunoisolation device
Abstract
Background: Type-1 diabetes is caused by autoimmune destruction of insulin-producing 
p-cells in the pancreas. Today, transplantation of whole pancreas or islets is the only 
treatment that can restore endogenous insulin production. Within the past 20 years, 
pancreatic islet transplantation has become a clinical reality and an option in diabetes 
treatment. However, large use of this therapy is limited by shortage in organ donations and 
use of immunosuppressive drugs. Immunoisolation potentially allows elimination of 
immunosuppressive drugs and use of xenogenic tissue solving the problem of a shortage 
in organ donation.
Aims: The present work was designed to ameliorate isolation of islets from different 
species and encapsulation of islets in immunoisolation devices (hollow fibres and 
microcapsules). Moreover, a mathematical model for immunoisolation membrane 
selection was developed.
Results and conclusions: The application of the automated method allows significant 
increase in the number of islets obtained. These islets were then used for in vitro or in vivo 
studies of immunoisolation devices, tested in different protocols. Experimental results 
indicate that islet transplantation using alginate gel microcapsule in the peritoneal cavity 
successfully control glycaemia in diabetic animals. However, it is not possible to translate 
in human application for the implantation site. An alternative strategy was developed 
based on membrane device to be used in the subcutaneous space. Despite permeability 
properties have been proved to be adequate, the in vivo functional response of transplanted
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islet in hollow fibre device was only temporary, probably for development of fibrotic 
tissue around the device.
Future work: The use of theoretical model allows evaluation and selection of new 
membrane materials for islet immunoisolation. Efficacy of new devices would be 
determined by performing alio- or xeno- transplantations into diabetic recipients, 
exploring new sites of implantation that minimize surgical procedures and reduce implant 
failure.
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Introduction
Diabetes mellitus (DM), long considered a disease of minor significance to world health, 
is now taking its place as one of the main risks to human health in the 21st century. The 
past two decades have seen an explosive increase in the number of people diagnosed with 
diabetes. Significant changes in the human environment and in human behaviour and 
lifestyle, have accompanied globalization and these have resulted in escalating rates of 
both obesity and diabetes. There are two main forms of diabetes. Type 1 diabetes is due 
primarily to autoimmune-mediated destruction of |3-cells of pancreatic islets, resulting in 
absolute insulin deficiency. People with type 1 diabetes must take exogenous insulin for 
survival to prevent development of ketoacidosis. Its frequency is low relative to type 2 
diabetes, which accounts for over 90% of cases globally. Type 2 diabetes is characterized 
by insulin resistance and/or abnormal insulin secretion, either of which may predominate. 
People with type 2 diabetes are not dependent on exogenous insulin, but may require it for 
control of blood glucose levels if this is not achieved with diet alone or with oral 
hypoglycaemic agents.
The global figure of people with diabetes is set to rise from the current estimate of 150 
million to 220 million in 2010, and 300 million in 2025, as shown in Figure 1.1 modified 
from (1). Most cases will be of type 2 diabetes, which is strongly associated with a 
sedentary lifestyle and obesity. This trend of increasing prevalence of diabetes and obesity 
has already imposed a huge burden on health-care systems and this will continue to 
increase in the future.
2
Introduction
In 2000: 151 milion 
In 2010: 221 milion 
an increase of 46%
Figure 1.1 N um bers o f  people with diabetes (in millions) for 2000 and 2010 (top and middle values, 
respectively), and the percentage o f  the increase (1).
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1.1 Pathophysiology of diabetes mellitus
Diabetes mellitus is a disease that causes abnormally high levels of glucose in the blood 
due either to insulin deficiency or to resistance of the body’s cells to action of insulin. 
Glucose level in blood is usually between 60-120 mg/dl. When we eat, glucose gets 
absorbed into the bloodstream and circulates to each of the cells of the body to provide 
them with energy. The cell membrane separates a cell from the external medium. Hence 
blood glucose cannot just enter into the cell body to provide energy. The main function of 
insulin, a protein produced by the pancreas, is to allow glucose to cross the lipid bilayer 
and get into the cell.
1.1.1 Anatomy andfunction o f the pancreas
The pancreas is located deep in the abdominal cavity behind the stomach. It is formed of a 
large dense portion, the head, that is in contact with the duodenum, a middle portion, the 
body and a final portion the tail (Figure 1.2) (2).
4
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bile -w Pancreas in situ
stom ach
duodenum
plicae ^ — — 
circular e s ' -'"
duodenal /  
papilla /  
(papilla o f Vater)
hepatopancreatic ampulla 
(ampulla o f  Vater)
capillary network
islet o f Langerhans
Figure 1.2 Human pancreas. The pancreas is attached to the duodenum , the upper portion o f  the small 
intestine. A large main duct, the duct o f  W irsung, collects pancreatic ju ice and empties into the duodenum . 
Enzymes active in digestion o f  carbohydrates, fat, and protein continuously flow from the pancreas through
the duct (2).
The human pancreas is composed of two different functional cell populations. The large 
portion of pancreatic tissue approximately more than 95%, is exocrine tissue, which 
produces a range of powerful digestive enzymes and pro-enzymes for fats, starches and 
proteins. These digestive enzymes flow in pancreatic ducts into the small intestine where 
they process ingested food. The enzymes split foodstuffs into simpler substances, which 
are absorbed into the bloodstream and transported throughout the body for immediate use 
by tissues or for later use. The smaller portion is endocrine tissue, which is composed of
5
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islets o f Langerhans; the name is that of a student, who in 1869 discovered them. 
Pancreatic islets contain different kind of cells (Figure 1.3 (3)):
• a  cells produce and release glucagon, which raises the blood glucose level, exactly the 
opposite function of insulin. There is a proper balance in secretion of insulin and 
glucagon, which is very important in maintaining the appropriate blood glucose level
• |3 cells produce, store and release insulin for the blood stream as per demand. The 
product of these cells determines blood glucose levels within seconds and responds to how 
much insulin needs to be secreted
• 6 cells produce somatostatin that probably mediates on behalf of insulin by blocking the 
action of glucagon
• cp cells produce further minor pancreatic polypeptide hormones
Capillaries
Figure 1.3 Different cells in a pancreatic islet: schem atic figure showing exocrine and endocrine parts o f  the
pancreas, specifying the cells contained in an islet (3).
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A human pancreas has more than one million pancreatic islets and each islet contains 
1,000 to 2,000 p cells that can communicate with one another through gap junctions that 
allow transmission of chemical and electrical signals.
P cells occupy the central portion of the islet and are surrounded by a band of a  and 5 
cells. Aside from insulin, glucagon and somatostatin, a number of other minor hormones 
have been identified as products of pancreatic islet cells.
Islets are richly vascularized, allowing their secreted hormones ready access to the blood 
circulation. Although islets comprise only 1-2% of the mass of the pancreas, they receive 
about 10 to 15% of pancreatic blood flow. Additionally, they are innervated by 
parasympathetic and sympathetic neurons, and nervous signals clearly modulate secretion 
of insulin and glucagon.
1.1.2 Insulin
Insulin is a rather small protein, with a molecular weight of 5,734 Da. It is composed of 
two peptide chains referred to as the A chain and B chain. A and B chains are linked 
together by two disulphide bonds. In most species, the A chain consists of 21 amino acids 
and the B chain of 30 amino acids. The amino acid sequence is highly conserved among 
vertebrates and insulin from one mammal almost certainly is biologically active in 
another.
Insulin is synthesized in significant quantities only in p cells in the pancreas. Insulin 
mRNA is translated as a single chain precursor called preproinsulin, and removal of its 
signal peptide during insertion into the endoplasmic reticulum generates proinsulin. 
Proinsulin consists of three domains: an amino-terminal B chain, a carboxy-terminal A 
chain and a connecting peptide in the middle known as C peptide. Within the endoplasmic
7
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reticulum, proinsulin is exposed to several specific endopeptidases that excise C peptide, 
thereby generating the mature form of insulin (Figure 1.4 (4)). Insulin and free C peptide 
are packaged in the Golgi apparatus into secretory granules that accumulate in the 
cytoplasm. When the [3 cell is appropriately stimulated, insulin is secreted from the cell by 
exocytosis and diffuses into islet capillary blood. C peptide is also secreted into blood, but 
has no known biological activity.
SH
SH
B- chain
SH
protnsulm
i
insulin (active form)
Figure 1.4 Processing o f  pre/pro/insulin to active insulin: pre/pro/insulin is synthesized as a random coil on 
m em brane-associated ribosomes; after m em brane-transport the leader sequence (yellow) is cleaved o ff by a 
protease and the resulting pro-insulin folds into a stable conformation. The connecting sequence (red) is 
cleaved o ff to form the mature and active insulin molecule. (4)
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Insulin is secreted primarily in response to elevated blood glucose concentrations. Some 
neural stimuli (e.g. sight and taste of food) and increased blood concentration of other fuel 
molecules, including amino acids and fatty acids, also promote insulin secretion. Most 
cells of the body have insulin receptors that bind insulin from the circulation. When a cell 
has insulin attached to it, the cell activates other receptors designed to absorb glucose from 
the blood stream into the cell. Cells use glucose as a source of energy for movement, 
growth, repair, and all other functions.
Despite long intervals between meals or the occasional consumption of meals with a 
substantial carbohydrate load, human blood glucose levels normally remain within a 
remarkably narrow range. In most people this varies from around 70 mg/dl to perhaps 110 
mg/dl (3.9 to 6.1 mmol/1), except shortly after eating when blood glucose level rises 
temporarily.
Insulin is required for all animal life. In humans, insulin deprivation due to removal or 
destruction of the pancreas leads to death in days or at most, weeks. Failure to make 
insulin or to respond to it, is clinically called diabetes mellitus.
1.1.3 Diabetes mellitus
Diabetes mellitus, the most important metabolic disease of man, is a state of insulin 
deficiency. The World Health Organization recognizes three main forms of diabetes 
mellitus:
• Type 1 or insulin-dependent diabetes mellitus is the result of frank deficiency of insulin. 
The onset of this disease typically is in childhood. It is due to destruction of pancreatic p 
cells, by T-cell mediated autoimmune attack. Many of the acute effects of this disease can 
be controlled by insulin replacement therapy. Maintaining tight control of blood glucose 
concentration by monitoring, treatment with insulin and dietary management minimizes
9
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long-term adverse effects of this disorder on blood vessels, nerves and other organ 
systems, allowing healthy life.
• Type 2 diabetes mellitus is due to insulin resistance or reduced insulin sensitivity, 
combined with reduced insulin secretion. Defective responsiveness of body tissues to 
insulin almost certainly involves insulin receptors in cell membranes. In the early stage, 
the predominant abnormality is reduced insulin sensitivity, characterized by elevated 
levels of insulin in the blood. Typically, the onset of this disease is in adulthood. The 
nature of the defect has been difficult to ascertain, in some patients the insulin receptor is 
abnormal, in others, one or more aspects of insulin signalling is defective, and in others, 
no defect has been identified. Because there is not, at least initially, an inability to secrete 
adequate amounts of insulin, insulin injections are not useful for therapy. Rather the 
disease is controlled through dietary therapy and hypoglycaemic agents.
• Gestational diabetes mellitus resembles type 2 diabetes in several aspects, involving a 
combination of inadequate insulin secretion and responsiveness. It occurs in about 2%-5%  
of all pregnancies and may improve or disappear after delivery. Gestational diabetes is 
fully treatable but requires careful medical supervision throughout the pregnancy. About 
20%-50% of affected women develop type 2 diabetes later in life. Even though it may be 
transient, untreated gestational diabetes can damage the health of the foetus or mother.
1.1.4 Diabetes complications
Diabetes is associated with increased risk of a number of serious, sometimes life- 
threatening complications. Diabetes involves damage to the heart, blood vessels, eyes, 
kidneys, and nerves, although the subject may not know that damage is taking place. It's 
important to diagnose and treat diabetes early, because it can cause damage even before it 
makes someone feel ill.
„ 10
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How diabetes causes long-term problems is unclear. However, changes in small blood 
vessels and nerves are common. These changes may be the first step toward many 
problems that diabetes causes. Many people are not even aware that they have diabetes 
until they develop one of its complications
• Retinopathy
Damage to the eye is the most feared complication of diabetes. Total blindness in diabetes 
is uncommon since just under 2% of people with type 1 diabetes actually suffer total 
vision loss. Loss of vision occurs largely through blood vessel damage (5). With high 
blood sugars, damage can occur to blood vessels throughout the body in three ways:
- Leakage: high levels of blood sugars cause damage to individual cells and later is 
associated with as damage to structures like capillaries. Endothelial cells, which form a 
very smooth surface on the inner walls of blood vessels, and helper cells, called pericytes, 
are especially damaged by excess sugar. These cells lose the electrical charge normally 
found at their surface, due to inactivation of mineral transporting enzymes and to depletion 
of energy resources in the high blood sugar environment. As damage progresses, the blood 
vessel walls starts to become porous, letting proteins and other materials leak out 
abnormally.
- Blood vessel blockage: high blood sugars cause partial and total blockages within 
existing blood vessels. Blockage of capillaries is found in background retinopathy, but a 
more serious form of blockage of arterioles occurs in pre-proliferative and proliferative 
retinopathy. Arteriolar blockage slows delivery of oxygen and other nutrients that are 
required to maintain cell health. The oxygen deficit in turn can trigger release of growth 
factors.
11
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- Abnormal growth: as blood vessels become blocked and oxygen deprivation begins, 
excess growth factors start to be released to promote growth of new blood vessels, or 
neovascularization. Proliferative diabetic retinopathy can be seen in the eye with an 
ophthalmoscope, as neovascularization. Neovascularization appears as a twisted collection 
of blood vessels and is quite dangerous because these vessels grow abnormally out of the 
retina into the clear vitreous gel. This abnormal growth of blood vessels can be seen in the 
center of the Figure 1.5. Right above the center is an example of the vessels growing out 
of the retina.
Figure 1.5 Abnorm al growth o f  blood vessels in retinopathy (5)
Because vessels grow beyond the supporting structure of the retina, they are very prone to 
bleeding, especially when they occur near the area where blood vessels and nerves enter 
the eye. Any jerking motion or even a rise in blood pressure can lead to a rupture of one of 
these abnormal vessels and cause an hemorrhage. Before bleeding occurs, someone who 
has neovascularization will usually not be aware they have these abnormal blood vessels. 
But they can be detected at an early stage with regular eye examination, laser treatment at 
this stage will often prevent bleeding from occurring.
12
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• Nephropathy
Diabetic nephropathy, also known as Kimmelstiel-Wilson syndrome and intercapillary 
glomerulonephritis, is a progressive kidney disease caused by angiopathy of capillaries in 
kidney glomeruli. It is characterized by nephrotic syndrome and nodular 
glomerulosclerosis. It is due to longstanding diabetes mellitus, and is a prime cause for the 
requirement of dialysis (6).
During diabetic nephropathy the kidney becomes damaged and more protein than normal 
collects in the urine. As the disease progresses, more of the kidney is destroyed (Figure 
1.6). Over time, the kidney's ability to function starts to decline, which may eventually 
lead to chronic kidney failure.
Normal kidney Kidney disease
Ureter
Figure 1.6 Norm al and diabetic kidney (7)
• healthy function
• proper size
• low urine protein
• granular surface
• decreased function
• smaller size
• high urine protein
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Each kidney is made of hundreds of thousands of units called nephrons. Each nephron 
includes a cluster of blood vessels and epithelial cells called a glomerulus. The function of 
the glomerulus is to filtre blood and form urine, which drains via the ureter.
The earliest histologically detectable change in the course of diabetic nephropathy is 
congestion in the glomerulus. At this stage, the kidney may start allowing more albumin 
than normal to enter urine, and this can be detected by sensitive tests for albumin. This 
stage is called microalbuminuria.
As diabetic nephropathy progresses, increasing numbers of glomeruli are destroyed. Now, 
amounts of albumin being excreted in the urine increase, and may be detected by ordinary 
urinalysis techniques. Now at kidney biopsy diabetic nephropathy changes are evident. 
Protein may appear in the urine for 5 to 10 years before other symptoms develop. High 
blood pressure often accompanies diabetic nephropathy. Over time, the kidney's ability to 
function starts to decline, and diabetic nephropathy may eventually lead to chronic kidney 
failure. The disorder continues to progress toward end-stage kidney disease, often within 2 
to 6 years after the appearance of high protein in the urine (proteinuria).
Treatment for diabetic nephropathy attempts to manage and slow the progression of the 
disease. Aggressive blood pressure control is by far the most important factor in protecting 
kidney function, regardless of the stage of the diabetic nephropathy. 
Angiotensin-converting enzyme (ACE) inhibitors protect the kidneys more effectively 
than other types of high blood pressure medication. A new class of blood pressure 
regulators known as angiotensin-receptor blockers (ARBs) may also offer compatible 
protection.
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• Neuropathy
Diabetic neuropathies comprise a family of nerve disorders caused by diabetes. People 
with diabetes can, over time, have damage to nerves throughout the body. Neuropathies 
lead to numbness and sometimes pain and weakness in hands, arms, feet, and legs. 
Problems may also occur in every organ system, including the digestive tract, heart, and 
sex organs. People with diabetes can develop nerve problems at any time, but the longer a 
person has diabetes, the greater the risk. An estimated 50 percent of those with diabetes 
have some form of neuropathy, but not all with neuropathy have symptoms. The highest 
rates of neuropathy are among people who have had the disease for at least 25 years (8). 
Diabetic neuropathy also appears to be more common in people who have had problems 
controlling their blood glucose levels, in those with high levels of blood fat and blood 
pressure, in overweight people, and in people over the age of 40 (8).
The causes of these complaints are probably different for different varieties of diabetic 
neuropathy. Researchers are studying the effect of glucose on nerves to discover exactly 
how prolonged exposure to high glucose causes neuropathy. Nerve damage is likely to be 
due to a combination of factors: metabolic factors, such as high blood glucose level, long 
duration of diabetes, possibly low levels of insulin, abnormal blood fat levels, 
neurovascular factors, leading to damage to blood vessels that carry oxygen and nutrients 
to the nerves, autoimmune factors that cause inflammation in nerves, mechanical injury to 
nerves (such as carpal tunnel syndrome) inherited traits that increase susceptibility to 
nerve disease and lifestyle factors such as smoking or alcohol use.
Diabetic neuropathies can be classified as peripheral, autonomic, proximal, and focal. 
Each affects different parts of the body in different ways. Peripheral neuropathy causes 
either pain or loss of feeling in the toes, feet, legs, hands, and arms. Autonomic 
neuropathy causes changes in digestion, bowel and bladder function, sexual response, and
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perspiration. It can also affect nerves that serve the heart and control blood pressure. 
Autonomic neuropathy can also cause hypoglycaemia (low blood sugar) unawareness, a 
condition in which people no longer experience the warning signs of hypoglycaemia. 
Proximal neuropathy causes pain in the thighs, hips, or buttocks and leads to weakness in 
the legs. Focal neuropathy results in the sudden weakness of one nerve, or a group of 
nerves, causing muscle weakness or pain. Any nerve in the body may be affected.
• Cardiopathy
Diabetic cardiopathy is a disorder with involvement of myocardial, interstitial, coronary, 
and neural structures. Patients with diabetes mellitus have a heightened rate of 
cardiovascular mortality. Cardiovascular complications are now the leading cause of 
diabetes related morbidity and mortality. It is generally appreciated that the major ones 
include enlarged arteries, epicardial coronary arteries, and damage to the 
microvasculature. It is also now widely appreciated that the mortality after acute 
myocardial infarction is greater in patients with diabetes mellitus, both at 30 days and one 
year after infarction. Stress hyperglycaemia, with and without diabetes mellitus, is 
associated with increased risk of in-hospital mortality of patients with acute myocardial 
infarction.
The incidence of coronary occlusion in persons with clinical diabetes has been estimated 
at from 8-17% with diabetic adults having heart disease death rates 2 to 4 times as high as 
the general population; risk of stroke is also found to be 2 to 4 times higher in people with 
diabetes. Arteriosclerosis obliterans in the lower extremities, a form of peripheral vascular 
disease, may produce disturbances in sensation, decrease in muscular endurance, 
intermittent claudication on effort, absence of peripheral pulses in the lower legs and feet 
and gangrene, ultimately leading to amputation of the extremity.
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• Ketoacidosis
Another acute complication more likely to occur in DM is ketoacidosis, a condition caused 
by a lack of insulin leading to a build-up of ketoacids. Chemical compounds called 
ketones are one of the natural by-products of fat metabolism. Excessive ketones are 
formed by biochemical imbalance in uncontrolled or poorly managed diabetes. The 
condition known as diabetic ketoacidosis can directly cause an acute life-threatening 
event, a diabetic coma. Diabetic ketoacidosis is a life-threatening medical emergency with 
a mortality rate just under 5% in individuals under 40 years of age, but with more serious 
prognosis in the elderly, who suffer mortality rates over 20%. Before the discovery of 
insulin treatment and other intravenous injections, acidosis was the chief cause of death 
among diabetics. Today diabetics can use a simple urine dipstick at home to measure the 
level of excreted ketoacids in their urine (9).
Complications of ketoacidosis are hyperglycaemia and ketoacidaemia, due to insulin lack, 
hyperglucagonaemia, and elevated levels of the stress hormones catecholamines, cortisol, 
and growth hormone.
- Hyperglycaemia results from increased hepatic production of glucose as well as 
diminished glucose uptake by peripheral tissues. Hepatic glucose output is a consequence 
of increased gluconeogenesis resulting from insulinopenia as well as from associated 
hyperglucagonaemia.
- Ketoacidaemia represents the effect of insulin lack at multiple enzyme loci. Insulin lack 
associated with elevated levels of growth hormone, catecholamines, and glucagon 
contributes to an increase in lipolysis from adipose tissue and in hepatic ketogenesis.
- Fluid and electrolyte depletion. Hyperglycaemia results in osmotic diuresis and 
dehydration secondary loss of electrolytes. Ketonuria similarly causes loss of water and 
electrolytes. Balance studies during withdrawal of insulin and treatment in patients with
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type 1 diabetes show that on average water depletion is about 5 L; sodium, 300-500 mmol; 
potassium, 270-400 mmol; chloride, 100-400 mmol per day. Drowsiness is fairly common 
but frank coma only occurs in about 10% of patients. There is correlation between degree 
of depression of sensorium and extracellular osmolarity. When serum hyperosmolality 
exceeds 320-330 mosm/L, central nervous system depression or coma may ensue. Coma 
in a diabetic patient with a low osmolality should urgently prompt a search for cause of 
coma other than hyperosmolality.
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1.2 Conventional treatment for type-1 diabetes
Insulin was the first, and remains the primary means of treatment for type 1 diabetes; it is 
administered by subcutaneous injection. This method is necessary since insulin is 
destroyed by gastric secretions when it is taken by mouth.
1.2.1 Conventional therapy
Conventional insulin injection therapy requires a strict daily schedule to keep glucose 
levels correct. This means not only taking the same doses of insulin at the same times 
every day, but also eating and exercising at the same levels at the same times each day. 
Insulin injections must be balanced with meals and daily activities, and glucose levels 
must be closely monitored through frequent blood sugar testing. Many diabetics need to 
inject insulin only once a day; others require two or more injections. It typically needs a 
mixture of short-acting insulin (to cover breakfast and dinner) and intermediate-acting 
insulin (to regulate glucose between meals and at night).
- Short-acting insulin is used to control blood sugar peak that occurs at mealtimes (bolus 
insulin).
- Intermediate-acting insulin is used to provide an insulin effect all day long or to control 
blood sugar through the night (basal insulin).
- Long-acting insulin has a slow onset and virtually no peak. It lasts for up to 36 hours, 
and can be used as basal insulin.
Negative aspects of this kind of therapy are linked to the standard of life that the patient 
must follow. If the patient introduces any variation into his/her life-style, the therapy must 
be modified to avoid hypo and hyperglycaemia.
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1.2.2 Intensive therapy
A DCCT (diabetes control and complications trial) was a large diabetes study sponsored 
by the National Institute of Health of the USA that ran for 10 years. It began in 1983, with 
randomly assigned 1441 patients with type 1 diabetes to receive either intensive therapy or 
conventional therapy:
- Patients in the intensive therapy group took three or more injections of insulin per day or 
used an insulin pump and checked their blood glucose at least four times per day. They 
were given a blood glucose target level of between 3.9 mmol/L and 6.7 mmol/L before 
meals and less than 10 mmol/L after meals
- Patients in the conventional therapy group took one or two injections of insulin per day 
and had no glucose goals other than avoiding hyperglycaemia or hypoglycaemia.
Study participants were between 13 and 40 years of age at the start of the study and were 
followed up for an average of six and a half years. The study showed that intensive 
diabetes therapy with tight glycaemic control continued to protect against cardiovascular, 
eye, and kidney complications of diabetes over the long term of diabetes. The results were 
so striking that patients in the conventional group were urged to switch to intensive 
therapy, and most of them did so. Thus, intensive therapy has become the recommended 
treatment for all adults and teens with type 1 diabetes (10). More than 10 years after the 
end of this study comparing intensive and conventional therapy, participants who 
originally received intensive therapy showed a very significant reduction in the risk of 
kidney failure (Figure 1.7), high blood pressure, heart attack, stroke, or death from 
cardiovascular disease. Cardiovascular disease being a leading cause of death and 
disability among people with diabetes, plus those who develop kidney complications being 
at greatest risk of this. Intensive diabetes therapy has long-term beneficial effects on the 
risk of cardiovascular disease in patients with type 1 diabetes (11).
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Figure 1.7: Cum ulative incidence o f  a sustained change in nephropathy (urinary album in excretion - AER) 
and retinopathy in patients with 1DDM, receiving intensive or conventional therapy (m odified from (11)).
Maintenance of glucose level near to the physiological one, using intensive insulin 
therapy, could be a way to block progression of diabetic complications. This requires 
precision and care from patients and from their doctor to avoid reduction of glucose 
concentration thus a hypoglycaemic state (under 65 mg/dl).
The scientific community is searching for a way to administer insulin to the diabetic 
patient, avoiding continuous injection and trying to obtain best glucose control, 
minimizing hypo- and hyperglycaemic episodes.
1.2.3 Insulin pump therapy
An insulin pump is a small mechanical device, a little larger than a pager that is worn 
outside the body, often on a belt or in a pocket. It delivers fast-acting insulin into the body 
via a thin plastic tube ending in a small, flexible plastic cannula or a very thin needle. The
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cannula is inserted beneath the skin at the infusion site, usually in the abdomen or upper 
buttocks.
The insulin pump is a computer-driven device that delivers fast-acting insulin in precise 
amounts at pre-programmed times, but wearing the insulin pump might require more 
compliance on the part of the patient than traditional injection therapy, especially if the 
patient is not used to checking blood sugar several times a day (Figure 1.8).
Pump therapy may not be suitable for everyone. It is however being successfully used by 
children, teenagers and adults, including women during pregnancy. Cases are also 
increasing of pump therapy being used with infants and babies, including those that are 
premature. The key to successful use of pump therapy is motivation. Those most suited 
must have received structured education, have a good knowledge and understanding of 
diabetes and of how insulin, exercise and food intake affect blood glucose levels. They 
must be willing to take significant responsibility for their day-to-day diabetes management 
or in the young have reliable adult supervision. This requires commitment to regular 
testing of blood glucose levels and confidence in acting on results.
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Dosage instructions 
are entered into the 
pump's small computer 
and the appropriate 
amount of insulin is 
then injected into the  
body in a calculated, 
controlled manner
Insulin pump
Figure 1.8 Insulin pump. The catheter at the end o f  the insulin pump is inserted through a needle into the 
abdominal fat o f a person with diabetes. Dosage instructions are entered into the pump's small com puter and 
the appropriate am ount o f  insulin is then injected into the body in a calculated controlled m anner (12).
But this kind of therapy presents many problems: difficulty in using a computer for aged 
people, large dimension of the pump and infections at the infusion site. Moreover, these 
systems are not totally safe and precise, as they need to have a security system that would 
block the pump should malfunction occur.
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1.3 Alternative treatment for type-1 diabetes
1.3.1 Pancreas transplantation
Whole pancreas transplantation, first performed in 1966 in combination with a kidney 
transplant in diabetic patients suffering from end-stage renal failure, demonstrated that a 
euglycaemic state could be obtained without the need for exogenous insulin. Early 
procedures however, were complicated by a high morbidity rate. Improvements in 
transplant techniques, immunosuppression therapies and post-transplant monitoring of 
graft function and rejection has resulted in a dramatic improvement in patient morbidity 
and graft survival. With the improved outcomes and demonstrated efficaciousness in 
controlling the diabetic glycaemic state, whole pancreas transplantation is now recognized 
by the American Diabetes Association as an acceptable therapeutic alternative to 
continued insulin therapy in diabetic patients with imminent or established end-stage renal 
disease who have had, or plan to have, kidney transplantation.
Pancreas transplantation may be considered as a group of three separate, clinical entities: 
simultaneous pancreas and kidney transplantation (SPK), pancreas after kidney 
transplantation (PAK) and transplantation of the pancreas alone (PTA). Each form of 
transplantation is characterized by its own indications, risks and outcomes.
- Simultaneous pancreas and kidney transplantation. Diabetes is a major cause of renal 
disease and it is associated with approximately 40% of new cases of end-stage renal 
failure (ESRF) in the US, who will subsequently require renal dialysis or kidney 
transplantation. When a diabetic patient develops ESRF and requires a kidney transplant, 
consideration is now commonly given to whether the patient would also benefit from 
receiving a pancreas as well. SPK transplantation is the most common form of pancreas 
transplantation performed, accounting for 60% of the total number of pancreas transplants
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performed each year in the US (approximately 900/year). The annual number of SPK 
transplants has remained stable over the last 10 years, however this may reflect increasing 
interest in the option of PAK transplantation (living donor kidney transplantation) by the 
patient in ESRF with IDDM.
When SPK transplantation is performed, the patient undergoes only one operation and 
following the surgery may be managed on the same (or very similar) immunosuppressive 
drugs they would have received for a renal transplant alone. The combined procedure 
offers excellent patient and pancreatic graft survival, producing a sustained euglycaemic 
state for exogenous insulin or oral hyperglycaemic agents. The renal transplant provides 
an effective method of surveillance of both grafts for acute rejection (creatinine clearance, 
biopsy) and may in part explain the improved one-year and long-term pancreatic graft 
survival rates when compared to pancreas transplantation without a donor-matched kidney 
transplant. There also has been no evidence that pancreas transplantation may have a 
deleterious effect on the simultaneously transplanted kidney.
- Pancreas after kidney transplantation. As the number of patients with ESRF has 
increased in the past decade, demand for renal transplantation has outpaced the supply of 
cadaveric kidneys available. By 2000, the number of living donor kidney transplants 
performed in the US exceeded the number of cadaveric donor transplants. Whereas SPK 
transplantation is usually restricted to the use of cadaveric organs only, PAK 
transplantation offers the option of using a living donor kidney, and in doing so both 
expands the number of kidneys available for transplantation and allows the diabetic patient 
the opportunity to benefit early from living donor kidney transplant (better long term 
outcome, avoidance of dialysis). With improved surgical techniques, better 
immunosuppressive drugs and rejection monitoring, outcomes for solitary pancreas 
procedures have improved such that PAK transplantation is now routinely considered. The
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kidney transplant recipient is required to demonstrate stable renal function and minimal 
post-procedure complications to be acceptable for subsequent pancreas transplantation. 
PAK transplant option requires the patient to undergo two major operations, however 
post-transplantation immunosuppression and care are similar to those for kidney 
transplantation alone.
- Pancreas transplantation alone. PTA is offered to diabetic patients in some centers when 
there has been difficulty in management of diabetes and the person has suffered severe 
hypoglycaemic episodes (often with hypoglycaemic unawareness), so long as there is little 
or no evidence of renal disease. As with PAK transplantation, improvements in PTA graft 
survival have improved significantly in recent years, although the question of whether or 
not the procedure may have an adverse long-term affect on recipients’ renal function 
(calcineurin antagonist-based immunosuppression) has not been resolved. Normalizing 
blood glucose levels after pancreas transplantation may offer this patient group the 
possibility of long-term improvement in renal function. The American Diabetes 
Association’s 2006 Position Statement on pancreas and islet transplantation recommends 
“In the absence of indications for kidney transplantation, pancreas-alone transplantation 
should only be considered a therapy in patients who exhibit these three criteria: history of 
frequent, acute and severe metabolic complications (hypoglycaemia, marked 
hyperglycaemia, ketoacidosis) requiring medical attention; clinical and emotional 
problems with exogenous insulin therapy that are so severe as to be incapacitating; and 
consistent failure of insulin-based management to prevent acute complications” (13). 
Since 2001, PTA has accounted for approximately 12% of pancreas transplants performed 
annually in the US.
The complexity of the whole pancreas transplant procedure, along with likelihood of pre­
existing disease secondary to their IDDM, exposes the recipient to a variety of significant
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operative and post-operative risks. The extent of the post-operative problems is likely to 
be limited to widespread acceptance of pancreas transplantation in the early era of its 
development. Serious surgical complications following the procedure include: thrombosis 
of graft vessels, intra-abdominal haemorrhage, anastomotic leak (enteric or bladder), graft 
pancreatitis, pancreatic fistula formation and intra-abdominal sepsis, all of which may 
require re-laparotomy and possibility of graft loss. In recent years, with improvements in 
donor and recipient selection criteria, surgical technique, immunosuppression protocols 
(reduced incidence of early, acute rejection) and prophylatic regimes (anti-viral, anti­
bacterial and antithrombotic), there has been a significant decrease in overall incidence of 
serious complications and rate of re-laparotomy.
1.3.2 Stem cell therapy
In developing potential stem cell therapy for patients with diabetes, researchers hope to 
achieve a system that meets several criteria. Ideally, the stem cells should be able to 
multiply in culture and reproduce themselves exactly. A stem cell has the ability to divide 
for many times in culture and to be able to differentiate into specialized cells. This should 
also be possible in vivo to produce a desired cell phenotype. For diabetes therapy, it is not 
clear whether it would be desirable to produce only |3-cells or whether other types of 
pancreatic islet cell are also necessary (14). Studies by Bemat Soria and colleagues (15), 
have indicated that isolated P-cells are less responsive to changes in glucose concentration 
than intact islet clusters made up of all islet cell types. Islet cell clusters typically respond 
to higher-than-normal concentrations of glucose by releasing insulin in two phases: a 
quick release of high concentration insulin and a slower release of lower concentrations. In 
this manner (3-cells would be able to fine-tune their response to glucose. Extremely high 
concentrations of glucose may require that more insulin be released quickly, while
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intermediate concentrations of glucose could be handled by a balance of quickly and 
slowly released insulin.
Many workers believe that it would be preferable to develop a system in which stem or 
precursor cell types could be cultured to produce all the cells of the islet cluster in order to 
generate a population o f cells that would be able to coordinate release of the appropriate 
amount of insulin to the current physiologically relevant concentrations of glucose in the 
blood stream (Figure 1.9 modified from (16)).
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Figure 1.9 Different approaches for generating insulin-producing cells (16)
Foetal tissue as source o f  islet cells
Several groups are investigating the use of foetal tissue as a potential source of islet 
progenitor cells. For example, using mice as recipients, insulin content of implants from 
several sources of stem cells, fresh human foetal pancreatic tissue, purified human islets, 
and cultured islet tissue have been compared (17). It was found that insulin content was 
initially higher in fresh tissue and purified islets. However, with time, insulin 
concentration decreased in the whole grafts, while it remained the same in purified islet 
grafts. When cultured islets were implanted, their insulin content increased over the course
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of three months. It was concluded that precursor cells within the islets were able to 
proliferate and differentiate into functioning islet tissue, but that purified islet cells alone 
could not further proliferate when grafted. Importantly, it was found that it was also 
difficult to expand cultures of foetal islet progenitor cells (18).
Adult tissue as source for islet cells
Many groups have focused on culturing islet cells from human adult cadavers for use in 
developing transplantable material. Although differentiated beta cells are difficult to make 
proliferate and thus to culture, some have had success in engineering such cells to do this. 
F. Levine and his colleagues at the University of California, San Diego, have engineered 
islet cells isolated from human cadavers by adding to the cells' DNA special genes that 
stimulate cell proliferation (19). However, once such cells that could proliferate in culture 
were established, they no longer produced insulin. The cell lines were further engineered 
to express the islet beta cell gene, PDX-1, which stimulates expression of the insulin gene. 
Such cell lines have been shown to propagate in culture and can be induced to differentiate 
to cells that produce insulin. When transplanted into immunodeficient mice, the cells 
secreted insulin in response to glucose. This group is currently investigating whether these 
cells would be able to reverse diabetes in an experimental diabetes model in mice (20). 
These investigators report that their cells do not produce as much insulin as normal islet 
beta cells, but it is within one order of magnitude below.
The major problem in dealing with these cells is maintaining the delicate balance between 
cell population growth and differentiation. Cells that proliferate well do not produce 
insulin efficiently, and those that do produce insulin do not proliferate well. According to 
the study, the major issue was developing technology to be able to grow large numbers of 
these cells that would produce normal amounts of insulin reproducibly (21).
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Another promising source of islet progenitor cells lies in cells that line pancreatic ducts. 
Some believe that multipotent (capable of forming cells from more than one embryonic 
germ layer) stem cells are normally found intermingled with mature, differentiated duct 
cells, while others believe that mature duct cells themselves can undergo differentiation, or 
a reversal of differentiation to a less mature type of cell, which could then differentiate 
into insulin-producing islet cells (22). S. Bonner-Weir and her colleagues have reported 
that when ductal cells isolated from adult human pancreatic tissue were cultured, they 
could be induced to differentiate into clusters that contained both ductal and endocrine 
cells. Over the course of three to four weeks in culture, the cells secreted low amounts of 
insulin when exposed to low concentrations of glucose, and higher amounts of insulin 
when exposed to higher glucose concentrations. It was determined by immunochemistry 
and ultrastructural analysis that these clusters contained all types of endocrine cells of the 
islet. In principle it might be possible to perform a biopsy and remove duct cells from a 
patient’s own pancreas, and then proliferate them in culture to give the patient back his or 
her own islet cells. This could work for patients with type 1 diabetes and who lack 
functioning beta cells, but with pancreatic duct cells still intact. However, autoimmune 
destruction might still be a problem and potentially lead to destruction of these autologous 
transplanted cells (23). Type 2 diabetes patients too might benefit from transplantation of 
cells expanded from their own duct cells since they would not need any 
immunosuppression. Many believe that if there is a genetic component to the death of beta 
cells, then beta cells derived from ductal cells of the same individual would also be 
susceptible to autoimmune attack.
J. Habener has also looked for islet-like stem cells from adult pancreatic tissue. He and his 
colleagues discovered a population of stem-like cells within both adult pancreatic islets 
and pancreatic ducts (24). These cells did not express any marker typical of ductal cells, so
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would be unlikely to be such. Instead, they expressed a marker, nestin, which is typically 
found in developing neural cells. Nestin-positive cells do not express markers typically 
found in mature islet cells. However, depending upon growth factors added, cells 
differentiated into different phenotypes, including liver, neural, exocrine pancreas, and 
endocrine pancreas, judged by the markers they expressed. These could be maintained in 
culture for up to eight months.
Embryonic stem cells
The discovery of methods to isolate and grow human embryonic stem cells, since 1998, 
renewed hopes of doctors, researchers, and diabetes patients and their families, that a cure 
for type 1 diabetes, and perhaps type 2 diabetes as well, may be within striking distance 
(25). In theory, embryonic stem cells can be cultured and coaxed into developing into 
insulin-producing islet cells of the pancreas. With a ready supply of cultured stem cells at 
hand, the theory is that a line of embryonic stem cells could be grown, as needed for 
anyone requiring cell transplantation. The cells would be engineered to avoid immune 
rejection. Before transplantation, they could be placed into non-immunogenic material so 
that they would not be rejected and the patient would avoid the devastating effects of 
immunosuppressant drugs. There is also some evidence that differentiated cells derived 
from embryonic stem cells might be less likely to cause immune rejection (26). Although 
having a replenishable supply of insulin-producing cells for transplantation into humans 
may be a long way off, researchers have been making remarkable progress in their quest 
for it.
Since their discovery, several teams have been investigating the possibility that human 
embryonic stem cells could be developed for a therapy for treating diabetes. Recent 
studies in mice show that embryonic stem cells can be initiated into differentiating into
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insulin-producing beta cells, and new reports indicate that this strategy may be possible 
using human embryonic cells as well (27).
Recently, workers in Spain have reported using mouse embryonic stem cells that were 
engineered to allow cells to be selected that were differentiating into insulin-producing 
cells (28). Soria et al at the Universidad Miguel Hernandez in San Juan, Alicante, Spain, 
added DNA containing part of the insulin gene, to embryonic cells from mice. This gene 
was linked to a further one that rendered the mice resistant to a certain antibiotic drug. By 
growing cells in the presence of the antibiotic, only those that were activating the insulin 
promoter were able to survive. The cells were cloned and then cultured under varying 
conditions. Cells cultured in the presence of low concentrations of glucose differentiated 
and were able to respond to changes in glucose concentration by increasing insulin 
secretion nearly sevenfold. The cells were then implanted into spleens of diabetic mice 
and it was found that symptoms of diabetes were reversed.
Recently Kim et al. described a series of experiments in which they induced mouse 
embryonic cells to differentiate into insulin-secreting structures that resembled pancreatic 
islets (29). They started with embryonic stem cells and let them form embryoid bodies, an 
aggregate of cells containing cells of all three embryonic germ layers. They then selected a 
population of cells from the embryoid bodies that expressed the neural marker nestin. 
Using a sophisticated five-stage culturing technique, they were able to induce the cells to 
form islet-like clusters that resembled those found in native pancreatic islets. The cells 
responded to normal glucose concentrations by secreting insulin, although insulin amounts 
were lower than those secreted by normal islet cells. When the cells were injected into 
diabetic mice, the cells survived, although they did not reverse the symptoms of diabetes. 
A potential advantage in use of embryonic cells is that, in theory, they could be engineered
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to express genes appropriate to allowing them to escape or reduce detection by the 
immune system.
Before any cell-based therapy to treat diabetes arrives at the clinic, many safety issues 
must be addressed. A major consideration is whether any precursor or stem-like cells 
transplanted into the body might revert to a more pluripotent state and induce formation of 
tumours. These risks would seemingly be lessened if fully differentiated cells were used to 
be for transplantation.
However, before any kind of human islet-precursor cells could be used therapeutically, a 
renewable source of human stem cells must be developed. Although many progenitor cells 
have been identified in adult tissue, few of them could be cultured for multiple 
generations. Embryonic stem cells show the greatest promise for generating cell lines free 
of contaminants that can also self renew. Most researchers agree that until a 
therapeutically useful source of human islet cells is developed, all avenues of research 
should be exhaustively investigated, including both adult and embryonic sources of tissue.
1.3.3 Islet transplantation
The Diabetes Control and Complications Trial Research Group reported improved 
glycaemic control through intensive insulin therapy, delaying onset and slowing 
progression of diabetic complications (10). Improved glycaemic control however, was 
hard to sustain and associated with intense insulin therapy was a significant increase in 
severe hypoglycaemic episodes. Whole pancreas transplantation is capable of producing a 
sustained, euglycaemic state, reducing incidence of hypoglycaemia and offering the 
possible benefit of reducing microvascular, macrovascular and neurologic complications. 
Pancreas transplantation however, is a major, complex surgical procedure associated with 
significant risk and cost that may limit its general acceptability, especially when a
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potential diabetic recipient has yet little evidence of renal impairment and does not need a 
combined kidney/pancreas transplant.
Within the past 20 years, pancreatic islet transplantation has become a clinical reality and 
an option in the treatment of diabetes. Islet transplantation has a distinct advantage over 
whole pancreas transplantation with regard to reduced peri-procedure morbidity. The 
procedure avoids major surgery and the risk of associated post-operative complications, 
re-laparotomy and acute (vascularized) graft loss. Islet transplantation, with its ability to 
be cultured for a period of time prior to transplantation, also offers the future possibility of 
reducing immunogenicity (both alio- and auto-) of the graft so that little or no 
immunosuppression would be required (30).
Early efforts to treat diabetic patients with pancreatic islet transplantation were mostly 
unsuccessful. Although the first human pancreatic islet allografts were performed in 1974, 
it wasn’t until 1991 that a pancreatic islet transplant recipient achieved sustained 
euglycaemia off insulin (for 1 year). In 2000, the Edmonton group reported 7 consecutive 
islet transplant recipients achieving exogenous insulin independence (Figure 1.10). All 
recipients received islets from 2 pancreas donors (one received islets from 4 donors), and 
were maintained on a glucocorticoid-free immunosuppression protocol using Sirolimus 
and low-dose Tacrolimus (31).
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Figure 1.10 Improvements in clinical outcom e with high rates o f  insulin independence with patients treated 
using the Edmonton Protocol, com pared to previous reports in the international Islet Transplant Registry.
The success of the Edmonton program has led to general acceptance that islet 
transplantation is a clinically feasible therapy, which may be considered for the treatment 
of patients with diabetes, especially when accompanied by severe hypoglycaemia. Since 
the report of success from Edmonton, interest has grown in islet transplantation and now 
more than 20 centers in North America and many more worldwide are performing this 
procedure (32) (Figure 1.11).
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Figure 1.11 Increase in clinical islet transplantation activity, with 471 patients transplanted at 43 
international institutions (modified from (32)).
Pancreatic islet transplantation, in general, has been restricted to patients with diabetes 
who suffer from hypoglycaemic unawareness or metabolic instability, or have early 
evidence of secondary complications due to their diabetes. The patients require long-term, 
calcineurin-based immunosuppression and thus are subjected to risks from these agents, 
such as nephrotoxicity, infection and malignancy. The patient may also become sensitized 
due to their alloimmune response to the transplant, potentially interfering with subsequent 
transplantation. Patients with evidence of significant diabetic renal impairment are 
excluded from islet transplantation until they either require or have undergone a kidney 
transplant. To improve the likelihood of attaining euglycaemia of insulin, most transplant 
programs and clinical trials will restrict islet transplantation therapy to patients weighing
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less than 70 kg, a body mass index (BMI) < 27 and not requiring an excessive amount of 
daily insulin for glycaemic control (33) (34).
As islet transplantation techniques move forward, one of the first challenges is to achieve 
reliably insulin independence with single-donor grafts. Moreover, future milestones for 
clinical islet transplantation imply xenotransplantation (immunoisolating the islets and 
treating the patient with immunosuppressive drugs), gene therapy and stem cell 
technology. (Figure 1.12). (15)
The
Future
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Stem cell transplantation
Tolerance protocol
• Living donor of islets
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Figure 1.12 Future milestones in clinical islet transplantation
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1.4 Immunoisolation
Routine application of islet transplantation would be tremendously enhanced by an 
unlimited supply of donor tissue, a standard implantation procedure and the ability to 
maintain transplanted tissue without requirement of immunosuppressive drugs. To achieve 
these goals, immunoisolation of islet cells has been proposed to protect cells from attack 
by the host immune system. The term “immunoisolation” refers to encapsulation of a graft 
in a selectively permeable membrane. To support the graft, low molecular weight 
substances, such as oxygen, glucose and other nutrients, should be exchanged across the 
membrane while protection against rejection requires that immune cells and other humoral 
factors detrimental to graft survival should be excluded (35). Clearly, one prerequisite for 
a therapeutic effect is that the cell products, such as insulin, are also exchanged across the 
membrane and are taken up by surrounding microcirculation. Development of 
immunoisolation techniques, by separation of implanted cells from the host immune 
system has been recognized for a long time as an experimental strategy to prevent 
immunorecognition and rejection (35).
Using immunoisolation of islets, chronic administration of immunosuppressive drugs 
could theoretically be eliminated or minimized, as transplanted cells are separated from 
the host immune system by a biocompatible and semipermeable membrane. Moreover, 
immunoisolation of pancreatic islet cells for transplantation into patients with diabetes 
theoretically permits grafting of xenogenic islets, thus expanding a potential supply of 
donor islet tissue. Hence, immunoisolation could open up the possibility of using islets 
harvested from animals, or insulin-producing cells engineered from stem cells without a 
requirement of immunosuppression of transplant recipients. Porcine and bovine insulin
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amino acid sequences have considerable sequence homology with human insulin, and 
therefore pigs and cows are considered attractive as options for xenogeneic donors. 
Immunoisolation of xenogeneic cells requires stringent biological and physical criteria to 
be met. The immunological response to a xenograft has various features that distinguish it 
from an alloresponse. The first difference depends on the species cross, in that the 
recipient may have natural cytotoxic antibodies against xenoantigens of the donor tissue. 
In addition, the major mechanism of recognition of xenoantigens is via an indirect 
pathway, in which xenoantigen is processed and presented by host antigen-presenting cells 
(APCs), to immune T cells. The reaction to xenogeneic cells is very complex and involves 
not only cells and antibodies, but also complement and cytokines, which can inflict cell 
damage (36).
Devices produced from synthetic membranes and loaded with viable cells are being 
developed as substitutes in case of failing organ or tissue dysfunction (37). Thus 
immunoisolation of islets for transplantation may have two potential benefits. First, it may 
permit allo-islet transplantation without the use of pharmacological immunosuppression. 
Secondly, encapsulation may facilitate transplantation of islets from non-human species 
(xenografts) thereby giving access to an unlimited source of insulin-producing tissue. Two 
main types of encapsulation technique have been used so far: micro- and 
macroencapsulation. In microencapsulation, a single islet or small groups of islets are 
encapsulated in a gel capsule usually consisting of alginate. In macroencapsulation a large 
number of islets is entrapped in a chamber surrounded by semipermeable membrane.
There is evidence in the literature that xenotransplantation of islets encapsulated within 
hollow fibres, macrobeads or planar diffusion devices can restore normoglycaemia mostly 
in diabetic mice, when implanted in the peritoneal cavity (38). However, this implantation 
site is not ideal in clinical conditions because it requires invasive procedures (39) (40).
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Subcutaneously has been regarded as a more adequate site for transplantation of a 
bioartificial pancreas, since islets can be implanted with minimally invasive surgical 
procedures, if even it may be less vascularized and has more fibrotic reaction.
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Overview of the thesis and aims
Below, find a summary of each chapter, with the principal aims and methods used to 
obtain successful results.
Chapter 2 deals in greater detail with the process of islet isolation and the method set-up is 
described. The chapter discusses differences between manual methods of islet isolation 
plus the automated procedure. It also shows the application of manual and automatic 
methods for three species of pancreas: rat, bovine and human.
Chapter 3 explains and evaluates the method of islet functionality in vivo using syngeneic, 
allogeneic and xenogenic free islet transplantation. It documents results obtained after 
implanting islets in diabetic rats and discusses the limits of these protocols, offering an 
alternative to ameliorate functionality.
Chapter 4 describes the application of an immunoisolation device in experimental settings. 
It systematically analyzes the results obtained to be able to categorize important 
observations. Also, here appear published (41) results obtained using the immunoisolation 
device in a xenotransplantation model.
Chapter 5 illustrates the set-up and measurement system used to evaluate oxygen 
consumption rate in the tissue. It explains how the data were collected and were elaborated 
to be able to measure free or encapsulated islet viability and functionality. Results 
obtained using this method are planned to be published on Cell Transplantation: The
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Regenerative Medicine Journal (Authors: Comolti R., Figliuzzi M. and Remuzzi A. Title: 
Effect of Micro and Macro Encapsulation on Oxygen Consumption by Pancreatic Islets).
Chapter 6 reveals the in vivo method used to continuously monitor glycaemia in 
transplanted rats, using a Medtronic® continuous glucose monitoring system; after intra- 
peritoneal tolerance test for glucose, responses of syngeneic transplanted islets in 
microcapsules or those placed under recipient kidney capsules were monitored. These 
results are currently being prepared for publication.
Chapter 7 discusses the project development and design of an ideal immunoisolation
!
device. Geometric properties of a polymeric membrane used for immunoisolation were 
experimentally determined and a mathematical model explaining kinetics of molecular and 
metabolite diffusion through the membrane was developed. These results also are 
currently being prepared for publication.
Chapter 8 develops and summarizes goals achieved in this study and presents future work 
to be performed in order to further test and improve the immunoisolation device proposed.
Finally, one appendix is presented and divided in three parts. Appendix A is the MatLab® 
code for the mathematical model developed in chapter 7. Appendix B contains the 
standard operating procedure for human islet isolation and Appendix C is a plan of the 
Islet Laboratory.
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Set-up of methods for islet isolation
The concept of transplanting islet tissue in diabetic patients is not new. The earliest case of 
transplanting a slice of sheep pancreas into the thigh of a dying diabetic child took place in 
1893 (1), but the discovery of insulin in 1922 changed the treatment significantly (2). 
Many researchers began to believe that a cure for the disease had been found since deaths 
rate of diabetics reduced considerably. However, secondary complications resulting from 
diabetes are severe and now are the leading cause of morbidity and mortality; hence, a 
need to find a suitable alternative to the use of exogenous insulin injections is necessary. 
Many of the complications resulting from diabetes include blindness, kidney failure, male 
impotence, myocardial infarction, gangrene (and thus amputation) and death. Two events, 
which took place between 1965 and 1970, gave a boost to research in islet transplantation. 
Moskalewski published his preliminary work (3), which was followed by that of Lacy (4) 
in which methods to obtain islets using collagenase digestion were presented. Setting up a 
method to obtain islets that could be implanted into a diabetic patient minimizes the risk of 
infection due to exogenous injection. Avoiding non-function of the implant though, has to 
be the first step.
Before islets can be transplanted, important parameters such as islet yield, islet viability, 
islet purity and islet sterility need to be assessed. All these factors are mainly controlled by 
the islet isolation procedure. Transplantation of highly purified islets also has potential 
advantages of increased safety, reduced immunogenicity of the graft, and improved islet 
implantation. Presence of impurities adds to an immune response to the implant increasing 
chances of rejection. For these reasons, purity is an important factor in the final outcome; 
islet preparations with only the highest purity should be used for transplantation purposes.
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Viability of islets is affected by many variables, such as procurement of suitable pancreas, 
separating enzymes used, digestion time, solutions used in the isolation process, islet 
purification solutions and forces that act upon them during the isolation process. Since 
viability is a measure of the cells’ effectiveness and state outside the host, it is the main 
indication of how they will fare inside the host, thus a major factor in success of cell 
transplantation. It is crucial that isolated islets should not only be viable but also they 
should respond appropriately to glucose challenge.
A manual method for islet isolation has been first set-up in our laboratory. To improve the 
number of the islets obtained, an automated method was then introduced. The procedure 
applied meets the following requirements: 1) minimal traumatic injury to the islets, 2) 
continuous digestion in which islets progressively liberated could be saved from further 
enzymatic action, 3) minimal human intervention in the digestion process, and 4) high 
yield and purity of the isolated islets. Introduction of the automated method for islet 
isolation resulted in significantly higher yield.
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2.1 Rat islet isolation
Initially, a manual procedure for digestion of rat pancreas was set up for islet isolation 
from one or two pancreata of Lewis rats (rat body weight 250-300g).
2.1.1 Manual procedure  -  materials and methods
Solutions used
Collagenase solution: 30 ml collagenase P (0.3 mg/ml) in HBSS at 4°C
Foetal calf serum (heat-inactivated): 1 x 100 ml at 4°C
HBSS lx + 10% foetal calf serum
HBSS lx  + 2% foetal calf serum
Dithizone solution: (25 ml at 4°C)
a. 50 mg dithizone
b. 5 ml DMSO
c. 15 ml HBSS
Histopaque 1.077: 30 ml at 4°C, 8 = 1.077 
Cell culture medium: (1 x 500 ml)
a. 45.5 ml RPMI 1640 + L-glutamine
b. 5 ml FCS inactivated
c. 0.5 ml penicillin/streptomycin
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Pancreas preparation (Figure 2.1)
Rats weighing 200-215 g were anaesthetized with an intraperitoneal injection of sodium 
pentobarbital. After main bile duct location at its entrance into the gut, it was ligated with 
silk suture. The duct was cannulated with polyethylene tubing (PE 50) connected to a 22- 
gauge cannula and the rat was killed. The pancreas was distended by introduction of 10-12 
ml of collagenase solution, was dissected free from the small bowel, stomach and spleen, 
removed and rinsed in a centrifuge tube containing 15 ml of cold HBSS
Figure 2.1 Pancreatic duct identified (A) and cannulated near the hilus o f  the liver (B). The main pancreatic 
duct was legated at the duodenal junction and 10 ml o f cold collagenase was injected (C). The distended
pancreas was dissected from the duodenum  (D).
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Pancreas digestion
All manipulations were performed in a class 100 biological safety cabinet. The distended 
pancreas was cut into small pieces and these were loaded into the centrifuge tube 
containing collagenase solution and were incubated in a shaking water-bath at 37°C. 
Every four to five minutes the centrifuge tube was shaken for 5 seconds and 0.5 ml sample 
was put into 35 mm petri dish to monitor dissociation of the tissue, microscopically, after 
staining the samples with 0.5 ml of dithizone solution. Digestion was stopped by addition 
of ice cold HBSS containing 10% heat-inactivated foetal calf serum. A stainless steel 
mesh was inserted into the beaker (1L) on ice and digested tissue was passed through the 
stainless steel mesh and then collected into the cooled centrifuge tubes. Tubes were 
centrifuged for 2 min at 800 rpm at 4°C (digested tissue washing, 3 times).
Islet purification
Pellets were collected and resuspended in 30 ml of Histopaque (1.077 density, 1 ml of 
pellet in 30 ml of Histopaque) and slowly 20 ml of HBSS containing 2% of FCS was 
added. The mixture was centrifuged for 5 minutes at 1800 rpm and 4°C.
Islets were situated in the interface between HBSS and Histopaque and purified islet 
fractions were centrifuged in 50 ml tubes containing cold HBSS + 2% FCS for 2 min at 
1500 rpm at 4°C. Supernatant was discarded and washing was repeated for 2 min at 800 
rpm at 4°C.
Islet counting
Taking 200 \il samples of the islet suspension in triplicate, into 35 mm petri dishes, 
staining with 200 \x\ of dithizone was performed. Islets were counted using a microscope 
with an eyepiece containing a calibrated grid.
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Islet culture
Islets were finally resuspended in 8 ml of cell culture medium and were plated in one 
untreated 25 cm2 tissue culture flask. Then they were incubated overnight at 37°C in 5% 
C 0 2
2.1.2 Automatic procedure -  materials and methods
To improve islet number obtained from a rat pancreas, a procedure was developed based 
on the automated method introduced by Ricordi and colleagues (Figure 2.2) (5), and has 
been used to process 10-14 pancreata of Lewis rats (rat body weight 250-300g).
hakmg c'&vioe
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Figure 2.2 Schem atic representation o f  the automated circuit for pancreas digestion and islet isolation,
modified from (6)
To ameliorate enzyme perfusion and digestion of acinar pancreas, perfusion system and 
digestion chamber were modified. The components were designed and constructed.
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Modification of the digestion chamber was made consisting of two holes on the base of 
the chamber inclined at 45° from each other, thus allowing good agitation of the solution 
and better digestion of the pancreas. A finite element model of the chamber for 
fluidodynamic simulation (Figure 2.3) was developed using CFD software (Fluent 6.1, 
FLUENT Inc.) (7).
Figure 2.3 M odified digestion cham ber o f  stainless steel 316. Comparison between finite elem ent models o f 
the cham ber for fluidodynamic sim ulation o f  R icordi’s (5) chamber and the new one described here
Solutions used
Collagenase solution: 750 ml collagenase P (0.3 mg/ml) in HBSS at 4°C,
Eurocollins (500 ml)
Foetal calf serum (heat-inactivated): 1 x 100 ml at 4°C
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HBSS lx + 10% foetal calf serum 
HBSS lx + 2% foetal calf serum 
Dithizone Solution: (25 ml at 4°C)
a. 50 mg dithizone
b. 5 ml DMSO
c. 15 ml HBSS
Histopaque 1.077: 30 ml at 4°C, 8 = 1.077 
Cell culture medium: (1 x 500 ml)
a. 45.5 ml RPMI 1640 + L-glutamine
b. 5 ml FCS inactivated
c. 0.5 ml penicillin/streptomycin
Pancreas preparation
Pancreas preparation was as described above for the manual procedure, page 52.
Pancreas digestion
All manipulations were performed in a class 100 biological safety cabinet. Distended 
pancreas was cut into small pieces and since they leaked collagenase solution, four 
stainless steel ball bearings were loaded into the digestion chamber. A 500 pm stainless 
steel mesh was inserted inside the chamber and the cover was closed. The peristaltic pump 
was activated with a flow rate of 410 ml/min and the system was filled with collagenase 
solution passing through a heating circuit to ensure a stable temperature of 35-37°C during 
the digestion process; collagenase solution recirculated continuously at 410 ml/min 
Every four to five minutes the chamber was shaken for 5 seconds and 0.5 ml sample was 
put into 35 mm petri dish to monitor microscopically dissociation of tissue, after staining
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the samples with 0.5 ml dithizone solution. Digestion continued until acinar tissue free of 
islets appeared in the samples, and when significant numbers of cleaved islets appeared 
digestion was ended. After opening the circuit, ice cold HBSS containing 10% heat- 
inactivated FCS was flushed through and digested tissue was collected, inserting the end 
of the outlet tube into cooled 250 ml conical tubes, until no more islets appeared in 
samples. Tubes filled with digested tissue were centrifuged for 2 min at 1000 rpm at 4°C 
(washing for three times)
Islet purification and counting
This method was as described above for the manual procedure, page 53.
Islet culture
Islets were finally resuspended in 25 ml of cell culture medium and were plated in one 
untreated 75 cm2 tissue culture flask. Finally, they were incubated overnight at 37°C in 
5% C 02
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2.1.3 Islet viability
Staining solutions used
Propidium iodide (PI) stock solution: 20.1 mg propidium iodide was dissolved in 200 ml 
PBS.
Acridine orange (AO) stock solution: 1 mg acridine orange was dissolved in 200 ml PBS.
1 part of PI and 1 part of AO were mixed.
Procedure
10-50 islets were transferred together with 50 pi culture medium into a well of a 96-well 
flat-bottom plate. 100 pi propidium iodide/acridine orange staining solution was added. 
The plate was incubated for about 10 min at room temperature with occasional shaking. 
Islets were transferred to petri dishes with 5 ml culture medium, and then into a glass 
blood counting chamber. Using a fluorescence microscope, islets were illuminated with 
light from the rhodamine filter for red staining of nuclei of dead cells and light from the 
FITC-filter for green staining of cytoplasm of living cells.
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2.1.4 Results
The number of islets isolated per rat pancreas significantly increased after introducing the 
automatic procedure (Figure 2.4). Moreover, manual islet isolation of 2 pancreata involved 
around half-one day’s work, during which 12 pancreata could be isolated using the 
automatic procedure.
1200
Manual Procedure *
Automatic Procedure
Figure 2.4 Islet num ber per  rat pancreas obtained utilizing manual (blue) or autom atic (red) procedure,
* p<0.01
Considering morphology (microscopic appearance, Figure 2.5) and viability (propidium 
iodide - orange acridine staining, Figure 2.6) of islets obtained, there were no quality 
differences between the two alternative methods used.
Figure 2.5 Optical imaging o f  islets isolated using manual (A) or autom atic (B) procedures
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For viability of islets, fluorescent dyes such as propidium iodide were used. It is excluded 
from intact cells but permeates through membranes of dead or dying cells, which bind and 
stain nucleic acids (red fluorescence) intensely. Living cell cytoplasm can be 
counterstained (green) using non-polar substances such as fluoresceine diacetate, calcein 
or others that are hydrolyzed and accumulate in living cells. Acridine orange, at high 
concentration stains nucleic acids orange, but at low concentration it is an excellent green 
stain for cytoplasm of living cells (Figure 2.6) (8).
Figure 2.6 Propidium  iodide (red) -  acridine orange (green) staining o f  islets isolated by manual (A) or
automatic (B) procedures
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2.2 Bovine islet isolation
Islets were isolated from pancreas obtained from 6-month-old calves (9). Although 
porcine islets have been considered to be a good source for xenogenic transplantation, they 
have been shown in the laboratory to be fragile and their isolation is inconsistent because 
of loss of viability and islet fragmentation (10). Very recently, it has been shown that 
pancreas from the adult pig is more suitable for islet isolation and shows a higher degree 
of viability than that of piglets (11). It has also been shown previously that bovine islets 
can be isolated efficiently from pancreas and that they demonstrate satisfactory function in 
vitro and in vivo (12). The main advantage in using bovine pancreas is related to easier 
access to the organ. Thus, for porcine pancreas one must avoid conventional animal 
processing, at the slaughterhouse, that involves lengthy ischaemia time. On the contrary, 
harvesting bovine pancreas is feasible during conventional slaughtering with an acceptable 
time of ischaemia.
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2.2.1 Manual procedure -  materials and methods
The technique established in our laboratory is based on manual passage of the tissue 
through different sized stainless steel meshes.
Solutions used
Collagenase solution: 800 ml collagenase P (2.7 U) in HBSS at 4°C 
Eurocollins (500 ml)
Foetal calf serum (FCS heat-inactivated) at 4°C 
HBSS lx + 10% or 2% FCS 
Histopaque 1.077: 30 ml at 4°C, 8 = 1.077 
Cell culture medium: (1 x 500 ml)
a. 44.5 ml M199 lx 1640 + L-glutamine
b. 5 ml FCS
c. 0.5 ml penicillin/streptomycin 
Pancreas preparation
After pancreas explantation from 6-month-old calves at the slaughterhouse, it was taken as 
quickly as possible to the laboratory; there, all manipulations were performed in a class 
100 biological safety cabinet. Its sterile bag was opened and the gland was removed from 
the transport solution. Peripancreatic fat, lymphnodes and vessels were removed. The 
organ was weighed and the major pancreatic duct was cannulated with an 18-23 gauge 
needle.
Pancreas distension and digestion
After pancreas distension by intraductal injection of the collagenase P solution, it was cut 
into small pieces. Pancreas pieces and the leaked collagenase solution were loaded into an
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airtight case and incubated in a shaking water-bath at 37°C. Every four to five minutes the 
centrifuge tube was shaken for 5 seconds and a 0.5 ml sample was put into a 35 mm petri 
dish to monitor dissociation of the tissue under the microscope. Digestion was stopped by 
addition of ice cold HBSS containing 10% FCS. Two stainless steel meshes (500 pm and 
90 pm) were inserted one above the other. The digested tissue was passed through the 
stainless steel mesh and then collected from the 90 pm stainless steel meshes into cooled 
centrifuge tubes. Tubes were centrifuged for 2 min at 800 rpm at 4°C (digested tissue 
washed 3 times)
Islet purification
The pellet was resuspended in 30 ml of Histopaque (1.077 density, 1 ml of pellet in 30 ml 
of Histopaque) and slowly 20 ml of HBSS containing 2% of FCS was added. The mixture 
was centrifuged for 5 minutes at 1800 rpm at 4°C. Islets were situated in the interface 
between HBSS and Histopaque and purified islet fractions were centrifuged in a 50 ml 
tube containing cold HBSS + 2% FCS for 2 min at 1500 rpm at 4°C. Supernatant was 
discarded and washing was repeated for 2 min at 800 rpm at 4°C.
Islet counting
Taking 200 pi samples of islet suspension in triplicate, into 35 mm petri dishes, islets were 
counted under a microscope using an eyepiece containing a calibrated grid. Each counted 
islet was classified into size range according to mean estimated diameter. The islet 
equivalent number was calculated utilizing corresponding conversion factors (5). Islets 
smaller than 50 pm were not considered for counting.
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Islet diameter (range in pm) Conversion factor
5 0 -1 0 0 0.16
100-150 0.66
150-200 1.7
200 - 250 3.5
250 - 300 6.3
300 - 350 10.4
>350 15.8
Islet culture
25,000 islet equivalents were finally resuspended in 25 ml of cell culture medium and 
were plated in one untreated 75 cm2 tissue culture flask. Finally, they were incubated 
overnight at 37 °C in 5% CO2
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2.2.2 Automatic procedure  -  Materials and methods
Overall strategy-governing optimization of the automated method for islet isolation began 
with the notion that islets must be liberated from surrounding exocrine tissues by 
enzymatic and not mechanical forces. To limit adverse effects on islets during the isolation 
protocol, processing time was minimized. The technique described readily allows three 
people to complete the procedure from arrival of the pancreas at the islet laboratory to 
time when islets were placed in culture.
Solutions used
Collagenase solution: 800 ml collagenase P (2.7 U) in HBSS at 4°C 
Eurocollins (500 ml)
University of Wisconsin solution (UW)
Foetal calf serum (FCS, heat-inactivated): 1 x 100 ml at 4°C 
HBSS lx +  10% FCS 
HBSS lx + 2% FCS
Histopaque 1.077: 30 ml at 4°C, 8 = 1.077 
Cell culture medium: (1 x 500 ml)
a. 45.5 ml M l99 lx  1640 + L-glutamine
b. 5 ml FCS inactivated
c. 0.5 ml penicillin/streptomycin 
Pancreas preparation
Preparation of the pancreas was as described above, page 62.
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Pancreas distension and digestion
After pancreas distension by intraductal injection of collagenase P solution, the pancreas 
was cut into small pieces. Pancreas pieces, the leaked collagenase solution and stainless 
steel ball bearings were loaded into the digestion chamber. Peristaltic pump was activated 
with a flow rate of 410 ml/min and the system was filled with collagenase solution passing 
through a heating circuit for a stable temperature of 35-37°C during the digestion process. 
Continuously collagenase solution recirculated at 410 ml/min. Every four to five minutes 
the chamber was shaken for 5 seconds and a 0.5 ml sample was put into a 35 mm petri 
dish to monitor dissociation of the tissue under the microscope. Digestion continued until 
acinar tissue free of islets appeared in the samples. When significant numbers of cleaved 
islets appeared the digestion was stopped. After opening the circuit, ice cold HBSS 
containing 10% FCS was flushed through. The digested tissue was collected inserting the 
end of the outlet tube into cooled 175 ml conical tubes, until no more islets appeared. 
Tubes filled with digest tissue were centrifuged for 2 min at 1000 rpm at 4°C (washing for 
three times). Pellets were resuspended in UW solution for 25-40 minutes.
Islet purification
The UW pre-incubated tissue was centrifuged for 2 min at 1000 rpm at 4°C and then 
resuspended in 260 ml of Histopaque. Histopaque dissolved tissue was loaded at 40 
ml/min into spinning COBE 2991 (blood cell processor, Figure 2.7). 140 ml of HBSS was 
added and spun for 5 min. 30 ml fractions of the gradient was collected in conical tubes on 
ice and centrifuged for 2 minutes at 1500 rpm. All fractions were pooled in a conical tube 
and resuspended in 100 ml of Ml 99 + 10% FCS.
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Figure 2.7 Purification carried out by density-gradient separation o f  islets, using a COBE 2991 cell
processor
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Islet countins and culture
Islet culture and counting were performed as described previously, page 63.
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2.2.3 Results
The novel techniques introduced here improved the outcome of bovine islet isolation; 
numbers of islets isolated significantly increased with the automated procedure (Figure 
2.8).
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Figure 2.8 Islet equivalent per gram o f  pancreas obtained utilizing manual or autom ated procedure, * p<0.01
These results opened the possibility of obtaining a large number of islets for implantation 
in diabetic models for studying, for example immunorejection. Moreover, such islets can 
be used for testing immunoisolation devices of xenotransplantation.
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2.3 Human islet isolation
Interest in islet grafting as a potential alternative to whole-pancreas transplantation has 
been growing. There is an increase in the number of new centres, with at least 40 more 
sites currently in development in the world. In our laboratory, a programme of human islet 
allotransplatation has been initiated. The first phase of this has set-up a safe and secure 
method for islet isolation. An air-filtered room plus instruments dedicated to this particular 
procedure are used exclusively (Figure 2.9). A detailed description of the Standard 
Operating Procedure for the automatic process and a project of the Human Islet 
Laboratory are specified in Appendix B and C.
Figure 2.9 Schem e and photograph o f  the air-filtered room for human islet isolation
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2.3.1 Manual procedure -  Materials and methods
Solutions used
Liberase solution: 800 ml Liberase P (3 U/mg) in HBSS at 4°C 
Human serum albumin (HSA)
HBSS lx +  10%HSA 
HBSS lx + 2% HSA
Histopaque 1.077: 30 ml at 4°C, 5 = 1.077 
Cell culture medium: (1 x 500 ml)
a. 45.5 ml CMRL lx  + L-glutamine
b. 5 ml HSA
c. 0.5 ml penicillin/streptomycin 
Pancreas preparation
After pancreas explantation from the cadaveric donor at the hospital, tissue was taken as 
rapidly as possible to the laboratory. There, all manipulations were performed in a class 
100 biological safety cabinet. Pancreas sterile bag was opened and the gland was removed 
from transport solution. Peripancreatic fat, lymph nodes and vessels were removed from 
the pancreas. Organ was weighted and the major pancreatic duct cannulated with a 18-23 
gauge needle
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Pancreas distension and digestion
After pancreas distension by intraductal injection of the Liberase solution, pancreas was 
cut into small pieces. Pancreas pieces and the leaked collagenase solution were loaded into 
an airtight case and incubated in a shaking water-bath at 37°C. Every four to five minutes 
the centrifuge tube was shaken for 5 seconds and 0.5 ml sample was put into a 35 mm 
petri dish to monitor the dissociation of the tissue under the microscope, staining the 
samples with 0.5 ml of dithizone solution. Digestion was stopped by addition of ice cold 
HBSS containing 10% HAS. Two stainless steel meshes (500 pm and 90 pm) were 
inserted one above the other. The digested tissue was passed through 500 pm stainless 
steel mesh and then collected from the 90 pm mesh into cooled centrifuge tubes. Tubes 
were centrifugated for 2 min at 800 rpm at 4°C (digested tissue washing 3 times)
Islet purification
Pellets were resuspended in 30 ml of Histopaque (1.077 density, 1 ml of pellet in 30 ml of 
Histopaque) and slowly 20 ml of HBSS containing 2% of FCS was added. The mixture 
was centrifuged for 5 minutes at 1800 rpm and 4°C. Islets were situated in the interface 
between HBSS and Histopaque and purified islet fractions were centrifugated in 50 ml 
tube containing cold HBSS + 2% FCS for 2 min at 1500 rpm at 4°C. Supernatant was 
discarded and washing was repeated for 2 min at 800 rpm at 4°C.
Islet counting
Taking 500 pi samples in triplicate of the islet suspension into a 35 mm petri dish, islets 
were counted under a microscope with a calibrated grid in the eyepiece, staining samples 
with 0.5 ml of dithizone solution. Each counted islet was classified into size range 
according to its mean estimated diameter. The islet equivalent number was calculated
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utilizing the corresponding conversion factor (13). Islets smaller than 50 pm were not 
considered for counting.
Islet diameter (range in pm) Conversion factor
5 0 -1 0 0 0.16
100-150 0.66
150-200 1.7
200 - 250 3.5
250 - 300 6.3
300 - 350 10.4
>350 15.8
Islet culture
25,000 islet equivalents were finally resuspended in 25 ml of cell culture medium and 
plated in one untreated 75 cm2 tissue culture flask. Finally, they were incubated overnight 
at 37 °C in 5% C 02
2.3.2 Automatic procedure -  Materials and methods
Solutions used
Liberase solution: 350 ml Liberase in RPMI at 4°C 
UW solution 
HSA at 4°C
RPMI lx  + 10% or + 2% HSA 
Biocoll 1.1: 250 ml at 4°C, 8=1.1 
Cell culture medium: (1 x 500 ml)
a. 45.5 ml CMRL + L-glutamine
b. 5 ml HSA
c. 0.5 ml penicillin/streptomycin
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Pancreas preparation
Preparation of the pancreas was as described above, page 70.
Pancreas distension and digestion
Pancreas was perfused by intraductal injection of the Liberase solution using the peristaltic 
pump at a pressure of around 80 mmHg, for 5 minutes, and then for an additional 5 
minutes at 180 mmHg (Figure 2.10). After pancreas distension, it was cut into small 
pieces. The pancreas pieces, leaked Liberase solution and stainless steel ball bearings were 
loaded into the digestion chamber, inserting the 500 pm stainless steel mesh inside, then 
the chamber cover was closed. The peristaltic pump was activated with a flow rate of 410 
ml/min and the system was filled with RPMI solution passing through a heating circuit to 
achieve a stable temperature of 35-37°C during the digestion process.
Figure 2.10 Human pancreas perfusion using peristaltic pump
Continuously Liberase solution recirculated at 410 ml/min. Every four to five minutes the 
chamber was shaken for 5 seconds and 0.5 ml sample was put into 35 mm petri dish to 
monitor the dissociation of the tissue under the microscope, staining the samples with 0.5 
ml o f dithizone solution. Digestion continued until islet tissue free of acinar appeared in
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the samples. When significant numbers of cleaved islets appear in the samples the 
digestion was stopped. After opening the circuit, ice cold RPMI containing 2% HSA was 
flushed through. Digested tissue was collected inserting the end of the outlet tube into the 
cooled 250 ml conical tubes, until no more islets appeared. Tubes filled with digested 
tissue were centrifuged for 2 min at 1000 rpm at 4°C (washing three times). Pellets were 
resuspended in UW solution and stored for 25-40 minutes 
Islet purification
The UW pre-incubated tissue was centrifuged for 2 min at 1000 rpm at 4°C and then 
resuspended in 260 ml of Biocol 1.090. Using a gradient mixer, a linear gradient was 
created from 1.090 to 1.070, spinning for 5 min at 2700 rpm. 50 ml fractions of the 
gradient were collected in 250 ml tubes on ice and were centrifuged for 2 minutes at 1500 
rpm. All fractions were pooled in a conical tube and were resuspended in 100 ml CMRL + 
10% HSA and pooled all fractions in a conical tube
Figure 2.11 Human islets before and after purification (islet are stained in red by dithizone) 
Islet counting and culture
Islet counting and culture were as described above, page 71-72.
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2.3.3 Results
Also for human tissue, introduction of the automated procedure significantly improved the 
number of islets obtained from a pancreas (Figure 2.12).
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Figure 2.12 Islets per gram o f human pancreas obtained utilizing manual or automated procedures, * p< 0 .01
Despite initial enthusiasm concerning the use of islet transplantation as a cure for diabetes, 
the majority o f patients with type 1 diabetes will still be more safely managed with 
repetitive insulin injections instead of facing potential risks o f current anti-rejection 
therapies. Moreover clinical trials have shown that insulin independence does not exceed 
an average o f 15 months and if compared to whole-pancreas transplantation, at 5 years 
only 10% of islet recipients are still insulin-independent compared with 90% of pancreas 
recipients (14). To achieve insulin independence, 850,000 islets were required in the 
Edmonton series of patients, suggesting that factors such as presence of autoimmunity and 
diabetogenic immunosuppression may have detrimental effects on islet engraftment and 
function. Additional drawbacks include complications of immunosuppression and 
nephrotoxicity with chronic treatment by Sirolimus and Tacrolimus therapy. However, 
clinical use o f islet transplantation is limited by shortages in organ donation, need of 
immunosuppressive drugs and allosensitization of the patient. The need for relatively large
■  M anual  P r o c e d u r e  
A u t o m a t ic  P r o c e d u r e
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masses of insulin-producing cells to achieve insulin independence has led to the use of 
multiple donors (sequential or pooled islet preparations) per recipient. This may increase 
the risk for allosensitization to multiple anti-human leukocyte antigen (HLA) antibodies, 
limiting the possibility of future solid organ transplantation (15). For these reasons this 
procedure has been abandoned in our establishment, as being in the best interest of 
patients.
Development of immunoisolation techniques by separation of implanted cells from the 
host immune system has been recognized for a long time as an experimental strategy to 
prevent immunorecognition and rejection. Immunoisolation of islets for transplantation 
may have two potential benefits. First, it may permit allo-islet transplantation without the 
use of pharmacological immunosuppression and avoiding allosensitization of the patient. 
Secondly, encapsulation may facilitate transplantation of islets from non-human species 
(xenografts) thereby providing access to an unlimited source of insulin-producing tissue 
( 16).
76
Set-up of methods for islet isolation
References
1. Williams P. Notes on diabetes treated with extracts and grafts of sheep’s pancreas. 
British Medical Journal 1894.
2. Banting FGBCH. The internal secretion of pancreas. Journal of lab Clinical 
medicine 1922.
3. Moskalewski S. Isolation and Culture of the Islets of Langerhans of the Guinea 
Pig. Gen Comp Endocrinol 1965;44:342-353.
4. Lacy PE, Kostianovsky M. Method for the isolation of intact islets of Langerhans 
from the rat pancreas. Diabetes 1967;16:35-39.
5. Ricordi C, Lacy PE, Finke EH, Olack BJ, Scharp DW. Automated method for 
isolation of human pancreatic islets. Diabetes 1988;37:413-420.
6. Ricordi C, Strom TB. Clinical islet transplantation: advances and immunological 
challenges. Nat Rev Immunol 2004;4:259-268.
7. Cattaneo E. Isole di Langerhans: ideazione e sviluppo di un dispositivo per la 
separazione ottimizzata delle isole pancreatiche. Milano: Politecnico di Milano; 2004.
8. Bank HL. Assessment of islet cell viability using fluorescent dyes. Diabetologia 
1987;30:812-816.
9. Figliuzzi M, Zappella S, Morigi M, Rossi P, Marchetti P, Remuzzi A. Influence of 
donor age on bovine pancreatic islet isolation. Transplantation 2000;70:1032-1037.
10. Ricordi C, Finke EH, Lacy PE. A method for the mass isolation of islets from the 
adult pig pancreas. Diabetes 1986;35:649-653.
77
Set-up of methods for islet isolation
11. Brandhorst D, Brandhorst H, Hering BJ, Bretzel RG. Long-term survival, 
morphology and in vitro function of isolated pig islets under different culture conditions. 
Transplantation 1999;67:1533-1541.
12. Marchetti P, Giannarelli R, Cosimi S, Masiello P, Coppelli A, Viacava P et al. 
Massive isolation, morphological and functional characterization, and xenotransplantation 
of bovine pancreatic islets. Diabetes 1995;44:375-381.
13. Ricordi C. Islet isolation assessment. In: Company RGL, (ed). Pancreatic islet cell 
transplantation. Austin, 1992.
14. Ruggenenti P, Remuzzi A, Remuzzi G. Decision time for pancreatic islet-cell 
transplantation. Lancet 2008;371:883-884.
15. Cardani R, Pileggi A, Ricordi C, Gomez C, Baidal DA, Ponte GG et al. 
Allosensitization of islet allograft recipients. Transplantation 2007;84:1413-1427.
16. Narang AS, Mahato RI. Biological and biomaterial approaches for improved islet 
transplantation. Pharmacol Rev 2006;58:194-243.
78
Chapter 3
In vivo functionality of the islets: syngeneic, allogeneic and xenogenic free islet 
transplantation
1.8 Materials and methods
1.9 Results
1.9.1 Syngeneic free islet transplantation
1.9.2 Allogeneic free islet transplantation
1.9.3 Xenogenic free islet transplantation 
Conclusion
References
In vivo functionality of the islets
In vivo functionality of the islets: 
syngeneic, allogeneic and xenogenic free islet transplantation
i
In the last chapter it was explained how islets can be obtained from a pancreas and the 
procedure for purify them from exocrine tissue. To test functionality of the islets, different 
procedures can be applied, in vitro and in vivo. Transplantation of islets into a syngeneic 
recipient is faster than any colorimetric procedure and is indicative of a real and consistent 
functionality. In our laboratory a chemically induced rat model of diabetes has been 
developed. In contrast to clinical studies in which islets are transplanted to patients with 
autoimmune type I diabetes mellitus, the majority of experimental islet transplantation 
studies have been performed on rats, whose native islet damage is induced chemically 
through administration of Streptozotocin® (STZ). STZ was first developed in 1963 as a 
broad spectrum antibiotic isolated from Streptomyces achromiogenes but was 
demonstrated to have beta-cell specific diabetogenic effects (1). It specifically and 
irreversibly destroys pancreatic beta cells by entering them and inducing degranulation, 
Golgi apparatus hypertrophy and DNA breaks, which ultimately result in beta cell 
pyknosis (2) (3). Upon injection of a toxic dose of STZ, animals experience initial 
hyperglycaemia due to inhibition of insulin release. This is followed by hypoglycaemia 
within 6-12 hours due to feedback increase in insulin secretion and beta cell degranulation. 
Permanent hyperglycaemia usually begins 24-48 hours following treatment and is a result 
of irreversible beta cell destruction. Following this, plasma insulin secretion is not 
detectable for more than 12 weeks following treatment. Permanence, rapid tempo, 
reproducibility, and specificity of diabetes induction by high-dose STZ treatment makes it
80
In vivo functionality of the islets
the optimal choice for long-term studies of islet isograft or allograft function with minimal 
concern for recovery of native pancreatic islet function.
In this model of diabetes syngeneic, allogeneic or xenogenic free islets were transplanted 
beneath the kidney capsule. For diabetes induction two different doses of STZ injected 
intravenously were used, on the basis of the species used: for Lewis rats 65 mg/kg and for 
Munich Wistar Fromter rats (MWF) 50 mg/kg.
3.1 Materials and methods
Islet preparation
The day after islet isolation using the manual or the automated procedure, islets were 
resuspended in HBSS. After centrifugation, they were introduced into a polyethylene 
catheter with an internal diameter of 500 pm (PE50), concentrated into pellets.
Islet transplantation
In the laboratory, rats were anaesthetized using Avertin (4) and when the anaesthetic had 
taken effect, the left flank of the rat was shaven. After kidney location (just inferior to the 
spleen), a small incision in the skin permitted peritoneal identification. Making a small 
incision into the peritoneum, the kidney was exposed and externalized. During the 
procedure the kidney was kept moist by showering it with saline. Using a 23 or 25 gauge 
needle, a small scratch was made on the right flank of the kidney, creating a nick in the 
kidney capsule. Into this, the PE50 tubing was carefully and slowly inserted beneath the 
capsule, making a small pocket (Figure 3.1-A). Using a Hamilton syringe, islets were 
slowly advanced into the desired location (Figure 3.1-B). The PE50 tubing was than 
slowly removed and carefully the nick was cauterized using low temperature. The kidney
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was then gently replaced into the peritoneum, prior to closing the rat’s epidermis with a 
suture and skin staples.
B
Islets
Figure 3.1 Kidney capsule incised using the tip o f  a needle and a small PE50 catheter inserted (A). Islets 
were injected using a Hamilton syringe beneath the kidney capsule (B).
Islet functionality in vivo
To verify whether glycaemic control was achieved after islet implantation, non-fasting 
blood glucose was measured daily from tail bleedings using the Glucocard Memory 2. 
Kidney plus islet retrieval
Animal treatment was noted until functional failure o f the grafts (measured as 
hyperglycaemia). Then the kidneys were retrieved under anaesthesia and animals were 
sacrificed.
Morphological evaluation
Kidneys, containing pancreatic islets, recovered from each animal were analyzed using 
tissue chromogens and a fluorescence microscope or a light microscope, to determine the 
presence of insulin and the structure of islets. After kidney removal, samples were fixed in 
paraformaldehyde solution or in Doubosque-Brazil solution, then embedded in OCT 
compound or in liquid paraffin wax. Samples in OCT compound were frozen and 4 pm
PESO catheter
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sections were cut for immunohistochemical detection of insulin. Samples embedded in 
paraffin wax were used for examination using haematoxylin and eosin staining. 
Immunostaininz with fluorescent secondary antibodies. Protocol for insulin 
Non-specific binding was blocked by incubation of sections with 3% bovine serum in PBS 
(block solution). After 1 hour, circles were drawn round dry sections, using PAP pen to 
prevent loss of antibody. Primary antibody was added (insulin rabbit anti-rat, dilution 
1:100 in block solution). These were incubated for 2 hours at room temperature or 
overnight at 4°C. Sections were washed at least 3 times, and at least 5 minutes each wash, 
in PBS and then secondary antibody was applied (goat anti-rabbit, dilution 1:100 in block 
solution); this was incubated for lhr at room temperature. Sections were washed for at 
least 3 times, at least 5 minutes each, in PBS and DAPI (4',6-Diamidino-2-Phenylindole, 
double stranded DNA staining) was applied. This stains nuclei with the DNA intercalating 
fluorescent dye DAPI, to be seen on a fluorescence microscope fitted with appropriate 
blue filters. After mounting with appropriate medium, slides were analysed using a 
fluorescence microscope.
Morphological evaluation with haematoxylin and eosin staininz
Sections were taken to water (quickly twice) and then were placed in haematoxylin for 10 
minutes. They were then washed in tap water (quickly twice) and placed in eosin for 5 
minutes. Then they were washed once quickly and dehydrated in 100% alcohol, then after 
washing in toluene, sections were mounted on glass slides.
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3.2 Results
3.2.1 Syngeneic free islet transplantation
Fourteen transplants were performed using 3,000 syngeneic free islets beneath the kidney 
capsule of Lewis diabetic rats; 10 rats normalized hyperglycaemia within 7 days after islet 
transplantation, as shown in Figure 3.2-A, and this state was maintained until rat sacrifice 
(in some cases for more than 200 days). In 5 of the fourteen animals, after 30 days post 
transplantation, nephrectomy was performed under anaesthesia to determine whether, after 
kidney and islet removal, a hyperglycaemic state was reached. In fact, in the 5- 
nephrectomyzed rats, a hyperglycaemic state was reached the day after kidney removal 
(Figure 3.2-B).
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Figure 3.2-A Average non-fasting blood glucose level after islet implantation in 14 rats
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Figure 3.2-B Average non-fasting blood glucose level after islet im plantation in rat with nephrectom y
In Figures 3.3-A and B it is shown that islet (3 cells beneath the kidney capsule still 
synthesised insulin (immunofluorescence, insulin red and nuclei blue) 3 or 4 months after 
transplantation. Equivalent histology is shown in Figure 3.3-C (haematoxylin and eosin 
staining), where preserved structure of the implanted islets is illustrated.
Figure 3.3-A and B Islet beneath the kidney capsule positive for insulin (im m unofluorescence, insulin in red 
and nuclei in blue) also 3 or 4 months after transplantation (A low magnification and B high magnification).
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Islet
Figure 3.3-C Islet beneath the kidney capsule. H istology o f  the preserved structure (haem atoxylin and eosin
staining)
lOOjJLin
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3.2.2 Allogeneic free islet transplantation
Seven transplants were performed of 3,000 allogeneic free islets beneath kidney capsules 
of diabetic rats (Lewis rats as donors and MWF diabetic rats as recipients). The day of 
transplantation and for the following 20 days, 3 rats were treated with cyclosporine (daily 
intramuscular injection, 5mg/kg), an immunosuppressant drug widely used in human post- 
allogeneic organ transplantation to reduce activity of the patient's immune system and thus 
to reduce the risk of organ rejection. Only rats treated with cyclosporine normalized 
hyperglycaemia within 2-3 days after islet transplantation, as shown in Figure 3.4, blu 
line, and this average state was maintained for 18 days. In the 4 rats in which there was no 
immunosupression, the hyperglycaemic state was maintained with no glycaemic control, 
red line.
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Figure 3.4 A verages o f  non-fasting blood glucose levels after allogeneic islet implantation in rats treated
with cyclosporine (blu line) or w ithout (red line)
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When kidneys were removed after rat sacrifice, morphological evaluation using 
haematoxylin and eosin stained sections no intact islets could be found, only infiltration of 
cells of the host immunosystem (indicative of graft rejection), as shown in Figure 3.5.
200 [im
100 nm
Figure 3.5 Histology o f  cellular infiltrations (indicated by arrows) beneath the kidney capsule at low and
high m agnification
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3.2.3 Xenogenic free islet transplantation
Eleven transplants were performed with an average of 13,000 (from 7,000 to 24,000) 
xenogenic free islets, beneath the kidney capsule (bovine islets transplanted into Lewis or 
MWF diabetic rats). Seven of these animals were treated with a high dose of cyclosporine 
from the day of transplantation until sacrifice (daily intramuscular injection, 30 mg/kg) 
and the other 4 were treated with a low dose (daily intramuscular injection, 10 mg/kg). 
High dose o f cyclosporine allowed normalization of glycaemia for an average of two days 
(range 1-5 days, Figure 3.6) while in low dose animals the hyperglycaemic state was 
maintained.
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Figure 3.6 Averages, non-fasting blood glucose levels after xenogenic islet implantation in rats treated with
a high dose o f  cyclosporine
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Conclusion
Several experiments with syngeneic, allogeneic and xenogenic islets were performed to 
determine a procedure for in vivo evaluation of the success of using transplanted islets. It 
was concluded that syngeneic islets functioned and allowed normalization of glycaemia to 
take place in diabetic rats. Considering allotransplantation, it was observed that only with 
use of an immunosupressant like cyclosporine islet transplants could be successful for a 
short time be permitted, allowing a short-period of normalization of hyperglycaemia. Use 
of the immunosuppressant did not overcome xenogenic free islet acceptance, to control 
islet cell functionality. The use of immunoisolation of the islets is fundamental to test islet 
functionality and moreover to use xenogenic islets in experimental and clinical settings, 
avoiding the immunological response to the xenograft and the transfer of animals proteins 
to the host. Islets from other species used in humans could overcome the problem of organ 
shortage and, if not rejected, could provide successful therapy for diabetes.
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In vivo evaluation of encapsulation: syngeneic, allogeneic and 
xenogenic immunoisolated islet transplantation
Previously, it was explained how islets can be obtained from a pancreas and how they can 
be tested in terms of functionality in vivo. It was concluded that there is need for an 
immunoisolation device to prevent inter-reactions between host and graft in alio- and 
xeno-transplanted islets.
The term “immunoisolation” refers to encapsulation of a graft in a selectively permeable 
membrane that allows exchange of only low molecular weight substances, such as oxygen, 
glucose, insulin and other nutrients. Moreover, this membrane would have to protect from 
host immune cells that cause rejection. Entries in the literature deeply analyze the 
possibility of using such membranes. The term “biohybrid artificial organs” indicates 
devices produced from synthetic membranes loaded with viable cells and these are being 
developed as substitutes in case of failing organ or tissue function (1). A number of studies 
are in progress on the use of such biohybrids for a wide variety of diseases for example in 
endocrine deficiencies such as diabetes (2) (3), hypoparathyroidism (4), treatment of 
neurodegenerative disorders such as Parkinson’s disease (5), Alzheimer’s disease (6) and 
amyotrophic lateral sclerosis (7). A bioartificial liver was assembled encapsulating porcine 
hepatocytes in a perfusion machine and used extra corporally for temporary treatment of 
patients with liver failure (8). The use of immunoisolation in islets for transplantation 
permits their allotransplantation and maybe even xenotransplantation without the use of 
pharmacological immunosuppression; this would provide access to an unlimited source of 
insulin-producing tissue. In the literature two main types of encapsulation can be found,
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micro and macroencapsulation devices with intra- or extravascular implantation (Figure 
4.1).
G lu cose InsulinIntravascular
device
a
Extravascular
device
M acroencapsulation
Microencapsulation
Ai> \
Solid support 
Blood v e sse l 
Nutrients
Figure 4.1 Different kinds o f  immunoisolation devices. In the intravascular device, islets can be distributed 
in a chamber surrounding a selectively perm eable membrane. For the extravascular approach, islets are 
immunoisolated within m em brane-diffusion chambers or enveloped in m icrocapsules, modified from (9)
In microencapsulation a small number of islets are encapsulated in an alginate matrix, 
sometimes covered with an outer layer of poly-L-lysine. This technique was first 
described in 1980 by Lim and Sun (10) where it was shown that microencapsulated islets, 
implanted intraperitoneally in diabetic rats, reversed diabetes for up to 3 weeks. Poor 
biocompatibility of the material used with the host, was the cause of graft failure. Many 
factors influence the success of capsule transplantation: type and purity of the alginate,
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capsule size, wall thickness, mechanical strength, permeability and surface characteristics 
(11) (12) (13).
Recently, two clinical trials using encapsulated xenoislets (14) or alloislets (15) were 
reported but no patient became insulin-independent.
Another technique of immunoisolating islets is macroencapsulation. One kind of device 
is a perfusion chamber. This consists of a permselective tube connected to the recipient 
blood circulation as an Arterio-Venous (A-V) shunt. Housing is placed around the tube, 
creating a space in which the islets are placed (16) (3). This type of encapsulation aims to 
optimize diffusion of oxygen to the transplanted islets, however the system has several 
side effects such as thrombosis and occlusion of the device.
Another type is the diffusion chamber; this could have different geometry: planar sheets 
and hollow fibres. The functionality of this device is dependent on diffusion of nutrients 
and oxygen from implant sites (peritoneal cavity, omentum and subcutaneous space) to the 
islets. Lanza et al used allotransplantation of canine islets encapsulated in tubular 
diffusion devices. Twelve dogs served as recipients and three of them became insulin-free 
for 51 to >90 days (17). In 1993 the same group had studied long-term function of bovine, 
porcine and canine islet xenografts encapsulated in permselective acrylic membrane 
chambers and implanted into STZ-diabetic rats. Twelve months graft survival rates were 
40%, 25% and 10%, respectively (18). A planar device with encapsulated rat islets in 
diabetic mice normalized fasting glycaemia up to 30 days and on histological examination, 
numerous macrophages were found to be adhered to the outer surface of the membrane. 
Many of the remaining islets showed histological signs of damage, and the authors 
concluded that this semipermeable membrane had only been partially efficient in 
protecting the xenoislets (19).
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TheraCyte® is a diffusion chamber constructed from a bilateral polytetrafluoroethylene 
(PTFE) membrane the outer layer of which is 5 pm PTFE; this induces neovascularization 
at the tissue-membrane interface (Figure 4.2).
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& Regulatory ^ rociuct
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f \
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Figure 4.2 The TheraCyte® device
This vascularizing membrane has been glued on to a conventional immunoprotective 
PTFE membrane with a pore size of 0.45 pm. Vascularization around this arrangement 
implanted subcutaneously in rats was evaluated by Sorenby et al (20). Tatarkiewicz K et 
al (21) showed reversal of diabetes in nude mice, using 1200 rat islets encapsulated in 
TheraCyte® and transplanted subcutaneously. Loudovaris et al have explored the 
possibility o f using TheraCyte® for encapsulation of insulinoma cell lines instead of 
primary islets (22). This type of device has also been used in allotransplantation of islets in 
diabetic rats, but no glucose normalization was reached and only weight gain was 
observed with respect to controls (23).
Recently Pileggi et al showed reversal of diabetes by syngeneic mouse pancreatic islet 
transplantation into a subcutaneous device (Figure 4.3); this consists of a stainless-steel 
biocompatible mesh with removable PTFE stoppers on each end. At the time of 
implantation, one of the stoppers is replaced by a PTFE plunger which fills the lumen, in
96
In vivo evaluation o f encapsulation
order to prevent its occlusion by host connective tissue. The plunger is then removed at 
time of islet transplantation, and the device is sealed with a stopper. The strong outer 
frame protects the islets from physical damage and the stainless-steel biocompatible open 
mesh membrane promotes growth of blood vessels inside it, to nourish the islets with 
oxygen and nutrients. The host subcutaneous space is an easily-accessible implantation 
site, which might be of interest for many cell based reparative therapies (24) using this 
appliance.
Figure 4.3 Biocom patible implantable steel and PTFE device, “ s” PTFE stopper and “p” PTFE plunger.
Ruler indicates size in cm.
Despite promising results, a number of problems remain to be solved for successful use of 
such an immunoisolation device in clinical studies. When artificial material is implanted 
into a living body, also if it is biocompatible, it will cause acute and in some cases chronic 
inflammation (25) (26). Moreover, the foreign body reaction causes development of 
granulation tissue, foreign body multinucleate giant cells, macrophages and fibrosis (27) 
(Figure 4.4).
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Figure 4.4 Foreign body reaction is normal when an implanted synthetic m aterial is implanted into a living,
vascular tissue. Diagram modified from (27)
The procedure for implantation of macroencapsulation devices and the surgical trauma 
also contribute to the inflammatory response of the host. Cytokines and other factors 
present in surrounding tissues during the acute phase may cross the protective membrane 
and destroy the cells inside. The avascular fibrotic capsule that develops around the 
implant and the immune cells, can compromise functionality and survival of the 
encapsulated cells. Different immunoisolation approaches offer advantages or limitations, 
linked to their geometry and the site of implantation (Table 4.1, (9))
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System Advantages Limitations
Intravascular
macrocapsule
Extravascular
macrocapsule
Extravascular
microcapsule
Close contact with bloodstream
Minor implantation surgery 
Device can be retrieved 
Miner implantation surgery 
Optimal surface-to-volume ratio 
Implantation in several sites
Thrombosis
Infections
Major implantation surgery 
Large surface-to*volume ratio 
Low seeding density of cells 
Transplantation near blood 
vessels required for optimal 
longevity and function
Table 4.1 Advantages and limitations o f  different immunoisolation approaches
The importance of finding a suitable implantation site can be a problem especially for 
macroencapsulation devices. In most experiments, the epididymal fat pad, peritoneal 
cavity and subcutaneous tissue have been used for hollow fibre and diffusion devices. 
Vascular chambers require access to large diameter major vessels such as the iliac artery 
or vein. The need to implant several of them, chronic treatment with anticoagulants and 
risks connected with vascular surgery (especially in diabetic patients) seem to limit their 
usefulness in a clinical setting. For microcapsules most groups prefer implantation in the 
peritoneal cavity so that volume of the graft does not constitute a problem (28). The major 
drawback here is the risk of inducing intraperitoneal adhesions. The subcutaneous site has 
poor blood supply but, on the other hand is safe and easily accessible for clinical use. As 
discussed above, physiological conditions inside the device will depend on the 
characteristics of the immunoisolating membrane and on properties of the surrounding 
tissue.
Two systems of immunoisolation have been developed in our laboratory: alginate 
microcapsules and hollow fibre systems. Methods for device construction and results of 
transplantations performed, follow.
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4.1 Microcapsules
4.1.1 Materials and methods
Islet microencapsulation
As described above, islets were separated from pancreatic tissue and purified. After 
overnight culture, they were suspended in a solution of 1.7% sodium alginate (Manugel 
DMB, Monsanto pic, Surrey, United Kingdom) at a concentration of 3 IEQ/pl.
The islet-alginate mixture was extruded through an air jet droplet generator into a solution 
of lOOmM C aC f solution. Resulting gel beads had diameters ranging from 800 to 950 
pm. After complete gelification, beads were washed in calcium-free Krebs-Ringer 
solution, then in Krebs-Ringer-Hepes 25mM, and then were cultured overnight once 
more in complete medium at 37°C.
Alginate + islets
M ic r o c a p s u le s
Figure 4.5 Droplet generator and light microscopy o f  m icrocapsules
Microcapsules implantation
Before transplantation, microcapsules were washed in saline solution to eliminate FCS in 
the medium and then were put into a syringe coupled with a Venflon IV canula (14
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gauge). In the treatment facilities, rats were anesthetized with Avertin and when the 
anaesthetic had taken effect, the abdomen of the rats were shaven. A small incision in the 
skin permits view of the peritoneum. Making a small incision also in the peritoneum, the 
canula was inserted and microcapsules were infused; then the rats were closed up with 
sutures. To verify whether glycaemia control had been reached, after islet implantation, 
non-fasting blood glucose was measured daily by tail bleedings using the Glucocard 
Memory 2.
Microcapsules explantation and morphological evaluation
Animals were followed until functional failure of grafts, measured as hyperglycaemia, 
then microcapsules were retrieved under anaesthesia through peritoneal washing using 
saline solution and animals were then sacrificed.
Capsules recovered from each animal were analyzed using light microscopy to estimate 
percentage of capsules with fibrotic overgrowth. Samples of microcapsules were fixed in 
Bourn’s solution and finally embedded in paraffin; 3 pm thick sections were mounted on 
glass slides and used for histological examination using haematoxylin and eosin.
Morphological evaluation
Sections were taken to water (quickly twice) and then were placed in haematoxylin for 10 
minutes. They were then washed in tap water (quickly twice) and placed in eosin for 5 
minutes. Then they were washed once quickly and dehydrated in 100% alcohol, then after 
washing in toluene, sections were mounted on glass slides.
101
In vivo evaluation o f encapsulation
4.1.2 Results
Svnseneic implantation
In order to assess islet functionality inside the microcapsules, avoiding the process of 
rejection o f allotransplantation, 14 transplantations of 3000 syngeneic microencapsulated 
islets were performed into Lewis rats. After encapsulation, islets were transplanted 
intraperitoneally and glycaemia was monitored daily by tail bleedings, using the 
Glucocard Memory 2 system. As shown in Figure 4.6, diabetic rats normalized glycaemia 
for 160±80 days on average, bearing in mind that some of the rats were sacrificed when 
normoglycaemic.
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Figure 4.6 A verage non-fasting blood glucose levels after microencapsulated syngeneic islets implanted into
diabetic rats
These results demonstrate that this system of encapsulation did not damage the islets 
during the process of encapsulation and morphological appearance of encapsulated islet
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cells being typical of healthy tissue (Figure 4.7); moreover the islets worked properly, 
allowing normoglycaemic control.
100 |im
Figure 4.7 Light m icroscopy (haem atoxylin-eosin staining) o f  islet contained in a microcapsule recovered
from 200 day old rat after syngeneic im plantation.
Allogeneic implantation
In order to assess microcapsule functionality, considering the process of rejection in islet 
allotransplantation, 4 transplantations of 3000 allogeneic microencapsulated islets were 
performed in Munich Wistar Fromter (MWF) rats using Lewis rats as donors. After 
encapsulation, islets were transplanted intraperitoneally and glycaemia was monitored 
daily by tail bleedings using the Glucocard Memory 2 system. On the day of 
transplantation and for the following 20 days, 2 rats were treated with cyclosporine (daily 
intramuscular injection, 5mg/kg), an immunosuppressant drug widely used in post- 
allogeneic organ transplantation to reduce activity of the patient's immune system and so 
to reduce the risk of organ rejection. All rats (with or without cyclosporine) normalized
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hyperglycaemia within 2-3 days after islet transplantation, as shown in Figure 4.8, and this 
state was maintained for more than 100 days.
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Figure 4.8 Average non-fasting blood glucose levels after m icroencapsulated allogeneic islet implantation in
diabetic rats
Then, explanted microcapsules were processed and tissue sections were analyzed for 
morphological evaluation of islet structure (Figure 4.9). Sections showed that structure of 
islets was good also after 100 days.
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100 nm
Figure 4.9 Light m icroscopy (hem atoxylin-eosin staining) o f  islets contained in m icrocapsules 100 days after
allogeneic transplantation
Xenogenic implantation
The results of using microcapsules were that they provided a good system of 
encapsulation and immunoisolation, thus the next step was to evaluate their functionality 
using bovine islets was performed. Fourty-eight transplantations were performed using 
16,000 xenogenic bovine microencapsulated islets into Munich Wistar Fromter (MWF) 
rats. After encapsulation, microcapsules were transplanted intraperitoneally and glycaemia 
was monitored daily by tail bleeding using the Glucocard Memory 2 system. The day of 
transplantation and for the following 20 days, 34 rats were treated with cyclosporine (daily 
intramuscular injection, 10 mg/kg), an immunosuppressant drug widely used in organ 
transplantation to reduce activity of a patient's immune system and thus to reduce the risk 
of organ rejection. 41 rats (with or without cyclosporine) normalized hyperglycaemia 
within 2-3 days after islet transplantation and this state was maintained in average for 23 ± 
15 days in rats with cyclosporine (Figure 4.10 in black), for 9 ± 4 days in rats without 
cyclosporine (Figure 4.10 in red).
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Figure 4.10 Average non-fasting blood glucose levels after m icroencapsulated xenogenic islet implantation 
into diabetic rats with (black) or without (red) cyclosporine
Also in this case, after explantation, microcapsules were fixed and then processed for
microscopic evaluation of islet structure. In Figure 4.11 it can be seen that in
microcapsules implanted into animals treated with cyclosporine, islet structure was
maintained, but where cyclosporine had not been given, islets structure was destroyed.
BA
100 \im 200 nm
Figure 4.11 Light m icroscopy (haem atoxylin-eosin staining) o f  xenogenic islets (indicated with arrows) 
contained in microcapsules with cyclosporine (A) or w ithout (B)
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4.2 Hollow fibre device
The subcutaneous site has been regarded as an adequate site for transplantation of 
bioartificial pancreas, as here islets can be implanted with minimally invasive surgical 
procedures. This site can be accessed easily for subsequent retrieval of non-functioning 
implanted material or to replace non-functioning cells with fresh islets within already 
implanted devices (21). However, there have been only a few reports describing successful 
transplantation of islets contained in immunoprotective devices into the subcutaneous 
space. Encouraging results were obtained by pioneering work of Lacy et al (2) that 
obtained normoglycaemia in diabetic mice after subcutaneous transplantation of rat islets 
encapsulated in hollow fibres. Tatarkiewicz et al (21) transplanted rat islets in TheraCyte 
chambers, subcutaneously, into diabetic nude mice. Mice returned to normoglycaemia 
within 3 weeks after transplantation and blood glucose levels were stable until 8 weeks 
after transplantation. Despite these encouraging results, no attempts have been found in 
the literature to extend this technique to larger and immunocompetent animals, even in the 
rat.
4.2.1 Materials and methods
Device construction
Device for subcutaneous implantation has been developed in our laboratory, with an 
internal volume of 270 \x\. This, schematically represented in Figure 4.12, is made as a 
planar “"and parallel array of hollow fibres of polyethersulphone that is 25mm wide and 
62mm long.
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Figure 4.12 Schem atic representation o f  the device: a parallel array o f  hollow  Fibres held together with a
weaving
Three groups of devices were assembled with different polyethersulphone membranes. 
Group 1 with hollow fibres from Fresenius Medical Care (Bad Hamburg, Germany), 490 
pm internal diameter and 65 pm membrane thickness, Group 2 from Spectrum Labs Inc. 
(Breda, Netherlands), 500 pm internal diameter and 68 pm membrane thickness, and
Group 3 from Amicon WR Grace and Co. (Beverly, MA, USA), 570 pm internal diameter
&
and 80 pm membrane thickness. Samples of hollow fibres used for device construction 
were processed for scanning electron microscopy (SEM) analysis. Samples were frozen in 
liquid nitrogen, broken and mounted on aluminium supports. Then they were gold coated 
and viewed on a Leica Stereoscan microscope (Leica, Cambridge, England) at 8 kVolt 
(Figure 4.13).
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Figure 4.13 Representative SEM s o f  m em brane thickness o f  Fresenius (F), Spectrum  (S) and Am icon (A)
hollow fibres.
Fresenius membrane was the most compact material with a selective layer near the inner 
surface. The Spectrum membrane also was of uniform porous material, but more open, 
and the Amicon membrane was characterized by columnar fenestrations that 
communicated with the outer surface but not with the inner one.
Islet encapsulation
After culture, islets were suspended in a solution of 1.7% sodium alginate (Manugel 
DMB) at a concentration of 30 IEQ/pl. In order to insert this solution into the fibres, a 
perfusion system that allows uniform loading of islet solution among the fibres was used. 
After perfusion, the device was immersed into lOOmM CaCh solution for 10 min for 
alginate gelification.
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Device implantation and retrieval
Implantation of devices was performed under Avertin anaesthesia. A skin incision was 
made on the back of the animal, followed by preparation of two subcutaneous pockets, 
gently, with blunt dissection by forceps on the right and left sides; devices were inserted 
into the pockets. Animals were followed until functional failure of the grafts, measured as 
hyperglycaemia, then the devices were retrieved under anaesthesia and animals were 
sacrificed.
Histological evaluation.
Devices containing pancreatic islets recovered from each animal were analyzed using 
fluorescence microscopy or light microscopy to determine the presence and nature of ce ll. 
overgrowth outside the membranes and to evaluate islet structure. To this purpose, after 
device removal, samples of hollow fibres (around 5 mm in length) were fixed in Bourn’s 
solution or in paraformaldehyde solution. Segments of alginate gel containing islets were 
extruded from hollow fibre samples and were fixed in Bouin’s solution. After 4 hours 
fixation in Bouin’s solution samples were embedded in paraffin wax and samples in 
paraformaldehyde solution were embedded in OCT compound and frozen. Three pm thick 
sections were mounted on glass slides and were used for both histological examination 
using hematoxylin and eosin staining and immunohistochemical detection of macrophages 
and T lymphocytes.
Immunostaining with fluorescent secondary antibodies. Protocol for macrophages and T 
lymphocytes
Non-specific binding was blocked first by incubation of sections with 3% bovine serum in 
PBS (block solution) fo r'l hour. To prevent loss of antibody, circles round dry section
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were drawn with PAP pen. Primary antibodies were added (mouse anti-rat mAb anti­
monocyte/macrophage clone EDI, mouse anti rat mAb anti CD8a clone 0X8, goat anti 
human mAb anti CD4 clone, dilution 1:100 in block solution); this incubated was for 2 
hours at room temperature or overnight at 4°C. Sections were washed for at least 3 times, 
at least 5 minutes each time, in PBS. Secondary antibodies were then applied and 
incubated for 1 hour at room temperature. Sections were washed at least 3 times, for at 
least 5 minutes each time, in PBS. DAPI was applied and after mounting, slides were 
analyzed on a fluorescence microscope.
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4.2.2 Results
For this experiment a high number of bovine islets was needed to be able to judge 
functionality in terms of normoglycaemia. With islets obtained from one bovine pancreas 
isolation different experiments were performed, comparing different hollow fibres, in 
order to select the best to use in an allogeneic protocol of transplantation.
Xenogenic implantation
A total of 54 devices containing bovine islets, were implanted under the skin of 27 
diabetic rats to evaluate survival and function of implanted islets. Each device was 
assembled with 8000 IEQ. They were implanted into the subcutaneous site with minor 
surgery and were easily retrieved when required. All STZ-induced diabetic rats 
normalized hyperglycaemia within 1 to 2 days after device implantation, as shown in 
Figure 4.14. Rats implanted with islets contained in Fresenius and Spectrum fibres 
maintained normoglycaemia for 10.5 days on average (range from 3 to 20 days) and for 
9.5 days on average (range from 6 to 17 days) respectively. The device made with Amicon 
fibres maintained normoglycaemia for shorter time periods, 5.8 days on average (range 
from 2 to 10 days).
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Figure 4.14 Non-fasting blood glucose levels after islet implantation into Fresenius, Spectrum and Amicon 
hollow fibre devices, beneath the skin o f  diabetic rats.
After hyperglycaemia was observed, all devices were removed. They appeared to be 
macroscopically intact and histological analysis at light microscopy showed that all 
devices were surrounded by a foreign-body inflammatory reaction.
Morphological appearance of most islets encapsulated in Fresenius and Spectrum hollow 
fibres was preserved from 14 to 28 days after implantation by which time hyperglycaemia
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developed. Islets presented rather spherical structures and there was only limited islet 
destruction, as shown in Figure 4.15 (A and B). A central area affected by cell necrosis 
was occasionally observed, as shown in Figure 4.15 (D) that indicated probable local 
hypoxic damage. In contrast, islets encapsulated in Amicon fibres showed more 
pronounced lysis with only a few islets remaining intact. Most islets were fragmented 
inside the alginate gel as shown in Figure 4.15 (C).
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Figure 4.15 Light m icroscopy (haem atoxylin-eosin staining) o f  islets contained in Fresenius Fibre (A), 
Spectrum fibre (B) and Amicon fibre (C) devices, recovered from rats 2 weeks after implantation. Islets are 
entrapped inside alginate gel. Representative m orphology (D) o f  an islet encapsulated in a hollow fibre 
device 2 weeks after implantation, showing central necrosis (arrow).
Moreover histological analysis at light microscopy showed that all devices were 
surrounded by a foreign-body inflammatory reaction (Figure 4.16).
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Figure 4.16 Light microscopy (hem atoxylin-eosin staining) o f  fibrotic overgrowth around Fresenius fibre 
(A), Spectrum fibre (B) and A m icon fibre (C) device recovered from M W F rats 2 weeks after implantation
Immunohistochemical analysis revealed the presence of a large number of macrophages 
(A) but only few lymphocytes (B) in the fibrotic capsule around membrane devices 
(Figure 4.17). Cell composition of the fibrotic reaction was similar in all three groups.
Figure 4.17 Histological evaluation revealed the presence o f  a large num ber o f  m acrophages, notably near 
m em brane o f devices containing islets (A, ED1+, in red) but only few lym phocytes (B, CD8+, in red) in the
fibrotic capsule
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In conclusion, implantation of devices successfully normalized hyperglycaemia in diabetic 
rats and these results demonstrated that, at least in the first time period after implantation, 
the islets were functional, metabolites were effectively exchanged across membrane walls 
and membrane provided functional immunoprotection to the bovine islets. The reason for 
loss of islet function after a maximum of 20 days seemed independent of islet isolation. 
Thus, bovine islets embedded in alginate gel and transplanted into the peritoneal cavity of 
diabetic rats showed prompt normalization of blood glucose, and normoglycaemia was 
maintained for a long period of time. The reason for loss of function of islets within 
immunoisolation membranes must be related to the presence of the membrane material 
and/or cellular deposition outside the devices. Morphological analysis of the devices 
retrieved and processed, when animals returned to a hyperglycaemic condition, showed 
foreign body inflammatory reaction at the membrane-tissue interface that was comparable 
in all three fibres used. This reaction mainly consisted of a fibrotic capsule with 
predominant presence of macrophages, with only a minority of infiltrating cells, such as T 
lymphocytes. This indicates that the membranes effectively protected these bovine islets 
from xenorejection and that the cellular reaction was mainly related to implantation of 
artificial material.
Most of the islets retrieved from Amicon fibres were broken and fragmented, confirming 
in vitro and in vivo data of a shorter functional duration. In Fresenius and Spectrum 
devices, better preservation islets were noted. However, in islets that showed preserved 
structure frequently presented a central necrotic area. This is probably was caused by 
inadequate oxygenation when islets were isolated from the organ and transplanted. In 
normal physiological conditions, islets in the pancreas are highly vascularized and well 
oxygenated but, when inserted into the device, oxygen transmission is only related to
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diffusion. Poor vasculature of the subcutaneous site may further contribute to this necrosis 
of implanted islets.
Svnzeneic transplantation
Analyzing results obtained from the xenogenic protocol, it was decided to test syngeneic 
transplantation of devices made of Fresenius hollow fibres. These experiments were 
performed to understand whether transplantation site and immunoisolation membrane 
would allow normalization of glycaemia using syngeneic islets. First, it was implanted 
3000 syingenic islets (the same amount used in microcapsules) within devices beneath the 
skin of 5 diabetic rats. No normalization of glucose concentration was obtained but all five 
rats that received encapsulated islets showed prolonged weight gain (Figure 4.18).
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Figure 4.18 Non-fasting blood glucose levels (black) and body weight (red) after islet implantation in 
Fresenius hollow  fibre devices beneath the skin o f  diabetic rats
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Histological evaluation of islets inside the device showed that after 2 weeks islet structure 
was damaged and only few nuclei were seen. Moreover, histological analysis at light 
microscopy showed that all devices were surrounded by the foreign-body reaction, but less 
dense that seen after in xenogenic implantation (see Figure 4.19).
A B
20
Figure 4.19 Light m icroscopy (haematoxylin-eosin staining) o f  fibrotic overgrowth (A) and o f  islets 
contained in Fresenius (B) devices recovered from rats 2 weeks after implantation. Representative 
m orphology (C) o f  an islet encapsulated in a hollow fibre device 2 weeks after implantation, showing central
necrosis (arrow)
Immunohistochemical analysis revealed the presence of a large number of macrophages 
but no lymphocytes in the fibrotic capsule around membrane devices. Cell composition of
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the fibrotic reaction observed around implanted hollow fibres was similar, with or without 
the use of cells inside the device (Figure 4.20).
Figure 4.20 Histological evaluation revealed the presence o f  a large num ber o f  m acrophages ED1+ (in red) 
on membranes o f  devices contained islets (A) or on empty devices (B).
These preliminary experiments demonstrate that material with permeability was needed 
that provides immunoprotection plus tissue nutrition is essential. Immunohistochemical 
detection of macrophages and lymphocytes demonstrated that in xenogenic and syngeneic 
islet transplantation the response was comparable, probably due to tissue response to the 
artificial material implanted and not to the cells inside the device. In both cases central 
necrosis was observed in islet explanted. Next finding a good material for device 
implantation, with ideal porosity and biocompatibility was required.
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In vitro evaluation of encapsulation: 
oxygen consumption rate (OCR) measurements
In the previous chapters it has been explained how islets can be obtained from a pancreas 
and how they can be tested in terms of their functionality in vivo. Islet encapsulation in 
semipermeable matrices, such as alginate gel, or within membrane devices (1), have been 
studied in experimental as well as in clinical settings (2). An immunoisolation device has 
been described here that allows adequate diffusion of oxygen and nutrients to maintain 
islet viability and function yet at the same time, selective enough to prevent permeation of 
host immune proteins.
This chapter presents the rapid and quantitative experimental method by using which 
viability of encapsulated islets has been determined. Previous classical methods have been 
based on selective staining, thus being more qualitative than quantitative, and requiring 
long and often difficult procedures. Recent studies have shown a direct correlation 
between changes in mitochondrial activity and cell function as a whole (3), and according 
to these findings, metabolic follow-up would offer an alternative, valid way to quantify 
cellular activity.
Thus, it has been proposed to couple classical tests for cell viability to a device to measure 
oxygen catabolism of cell cultures (Figure 5.1). This combination allows more reliable, 
precise and indeed faster, measurements to be made. The device consists of:
• oximeter
• measurement chamber
• circulator
• magnetic stirrer
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data recorder/computer-assisted acquisition system
Glass chamber on magnetic stirrer
Thermostatic
Circulator
Data recorder
Figure 5.1 Global view o f  the system used for OCR measurem ents
The main component of the measurement device is the Clark’s electrode (4). 
Measurements are based on the classical polarographic method, in which a potential 
difference is created in two half cells, one of platinum, the cathode, and one of silver, the 
anode (see page 129), permitting reduction of a chemical element, such as oxygen. This 
process results in generation of an electric current, which is converted into a tension signal 
before being sent to a data detection system. Data are subsequently elaborated using Excel 
software to provide an output, which is the oxygen consumption rate (OCR) per vital unit. 
The measurement chamber is made of two compartments, an internal one, in which the 
measurement is carried out, and an external one, the water jacket, which enables changes 
in the operative conditions to be made.
Adequate measurement of viability of pancreatic islets during the time elapsed between 
isolation and transplantation is crucial, in order to prevent transplantation of inefficient 
islets. Correlation between glycaemia and oxygen consumption is crucial in transplanted
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islets, which are exposed to high glycaemic levels and might quickly undergo cell death as 
a response to hypoxia. Moreover, after the isolation process, the islets lack any blood 
supply but with this system they can gather sufficient nutrients thanks to the diffusion 
process alone. This implies that oxygen consumption of islets inside the immunoisolation 
device produces an oxygen gradient that regulates gas flux through the membrane, as per 
its diffusion coefficient, as stated in Fick’s Law. Thus, whenever the diffusion coefficient 
is very low, the oxygen flux to the inner cells of the islet is inferior to oxygen 
consumption, resulting in hypoxia, and eventually in death of the islet cells.
This has been used to investigate the role of glucose in p-cell metabolism. Since insulin 
secretion depends directly on glucose haematic levels, a considerable increase in cellular 
activity, and therefore oxygen consumption, is registered in islets, in response to high 
glycaemic levels.
Therefore, precise measurement of cellular oxygen consumption using appropriate 
techniques is not only an efficient method to quantify the cells’ viability, but it also offers 
a new way to explore the various factors influencing their functionality under different 
operational conditions.
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5.1 Experimental set-up for OCR determination
For measurement of OCR, a thermostated chamber was designed (see Figure 5.2), made of 
two compartments, the inner, in which the measurements are carried out, and the external 
water jacket enabling temperature to be changed during operating conditions.
A Clark oxygen electrode (4) is composed of the two half-cells separated by a salt bridge, 
the platinum electrode is separated from the solid silver by insulating material. The 
electrodes are immersed in a concentrated potassium chloride solution separated by a 
Teflon membrane, attached by an O-ring. The oxygen monitor holds a constant voltage 
difference across the two electrodes so that the platinum electrode is negatively charged 
with respect to the silver one (Figure 5.3). Platinum is a strong catalyst for the covalent 
dissociation or re-association of water; in the Clark electrode, electrons are released from 
it, combining with dissolved molecular oxygen and hydrogen ions to produce water. The 
rate at which electrons are liberated is proportional to the concentration of oxygen that is
Medi 
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M ag n e t ic  b a r  W a te r  ja c k e t
Figure 5.2 Therm ostated chamber
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available to combine with them. Movement of electrons produces the electrical current 
that is then converted to a voltage by the oxygen monitor circuitry.
Figure 5.3 Schematic o f  C lark’s electrode. Pt cathode (green), Ag anode (yellow), insulating material (red)
The system was preliminarily calibrated using distilled water at 37°C in which 
atmospheric oxygen concentration was taken to be [02]=215 pM (5). Null O2 
concentration was obtained by saturating the solution in the chamber using nitrogen gas. 
After 10 minutes recording was constant and taken to correspond to zero [O2]. Oxygen 
consumption was calculated from the slope of oxygen concentration recording vs. time by 
linear regression analysis (as shown in Figure 5.4). OCR per islet equivalent was then 
calculated as
Cathode
Membrane
Insulating material
and the Teflon membrane
0CR  _ A[ ° 2 ] .  V pmol
AT IEQ [IEQ*m\n
where IEQ is the number of islet equivalents in the chamber and V the solution volume.
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Figure 5.4 OCR calculated by linear regression
A representative experiment is reported in Figure 5.5, in which the [O2] was recorded for 
up to complete consumption. As shown in the figure, [O2] changes with time were close to 
constant even for the low levels of [O2] that were reached in more than 160 minutes.
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16060 100 180120 1400 40 6020
Time (mm)
Figure 5.5 Representative experiment o f  OCR vs. time
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5.2 OCR measurements and results
Islet encapsulation in microcapsules and in polvsulphone hollow fibres 
After islet isolation and 24 hours in culture, for the production of capsules, islets were 
suspended in a solution of 1.7% sodium alginate (Manugel DMB, Monsanto pic, Surrey, 
United Kingdom) at a concentration of 3 islet equivalents (IEQ)/pl. The islet-alginate 
mixture was then extruded through an air jet droplet generator into a solution of 100 mM 
CaCB solution. Gel beads resulted with diameters ranging from 800 to 950 pm (Figure 
5.6-A). For islet encapsulation in polysulphone hollow fibres, alginate solution was 
inserted into them (490 pm inner diameter and 70 pm membrane thickness, Fresenius 
Medical Care, Bad Hamburg, Germany) using a perfusion system, to allow uniform 
loading of islet solution among the fibres at a concentration of 50 IEQ/pl (Figure 5.6-B). 
After perfusion, fibres were sealed and immersed into 100 mM CaC f solution for 10 
minutes to allow alginate gelification, and then the loaded fibres were immersed in culture 
medium.
lO O jx m  A  lO O jx m  3
Figure 5.6 Islets encapsulated in microcapsules (A) or in hollow  fibres (B).
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Oxvsen consumption measurements.
For these measurements, islets from four different preparations were used. The number of 
islets in each sample was calculated on the basis of total islet number per isolation, using a 
dilution of islet suspension. Each sample contained on average 997 IEQ (650-1200 IEQ). 
Islets were centrifuged for 2 min at 800 rpm, supernatant was removed and the pellet was 
suspended in 200 pi of pre-warmed (37°C) M l99 serum-free medium (glucose 
concentration = 5.5 mM). The islet suspension was added to the chamber and after sealing, 
thermal equilibration at 37°C was allowed for around 30 seconds; each measurement 
lasted in the region of 30 minutes. For OCR determination at high glucose, a glucose 
concentration of 25 mM was used, adding concentrated glucose solution in the same 
preparation. OCR of encapsulated islets was assessed immediately after encapsulation in 
microcapsules and hollow fibres (day after the isolation process) and 1 day after 
encapsulation. Also for this series of measurements, islets of four different preparations 
were used for each encapsulation technique. Each sample contained on average 1060 IEQ 
(670-1500 IEQ) and was placed in the chamber for OCR measurement. During all 
measurements the suspension was stirred, using a magnetic plate at around 50 rpm. In 
some experiments, after OCR measurements, free and encapsulated islets were counted 
and resulted to be within 96% of the value estimated before OCR measurement.
Initially the OCR was estimated of free bovine islets in suspension for a three days period 
after isolation. As shown in Figure 5.7, estimated mean OCR averaged 1.39 ± 0.38 
(pmol/IEQ/min) immediately after isolation and numerically increased to 2.28 ± 0.64 
(pmol/IEQ/min) at the end of the observation period (n=4).
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Figure 5.7 OCR o f  free islets measured the day o f  isolation (0), 24 h after the isolation process (1), and 48 h
after (2).
To investigate the effect of changes in glucose concentration by OCR of free bovine islets, 
the day after isolation, aliquots of islet preparation were suspended either in M l 99 at low 
glucose (5.5 mM) or supplemented with high glucose (25 mM). Increase in glucose 
concentration significantly increased OCR as shown in the representative recording, 
Figure 5.8, calculated OCR averaged 1.98 ± 0.79 and 2.49 ± 0.97 (pmol/IEQ/min), 
respectively at low and high glucose levels (p<0.01, n = 12).
4 .0
3 ' 5 T
e 3,0 
E
Low glucose High glucose
Glucose concentration
Figure 5.8 OCR in free islets measured the day after the isolation process, exposed to low or to high glucose
concentration *p<0.01 low glucose vs. high glucose.
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For islets encapsulated in alginate microcapsules, at a density of 3 IEQ/pl, the day of 
encapsulation OCR averaged 2.12 ± 0.87 (pmol/IEQ/min) and the following day OCR 
averaged 2.26 ± 0.95 (pmol/IEQ/min); that difference not being statistically significant. 
Both values were also comparable to mean OCR calculated for free islets. As shown in 
Figure 5.9, OCR of islets embedded in hollow fibres averaged 1.75 ± 0.57 
(pmol/IEQ/min) the day of encapsulation and 2.21 ± 0.69 (pmol/IEQ/min) the following 
day (n=4), this difference not reaching statistical significance. Mean OCR of islets 
embedded in hollow fibres was also comparable to mean OCR measured for freely 
suspended islets.
□  Free islets 
H Microcapsules
3,5 | S  Hollow fibers
3,0
1 2 
Days after isolation process
Figure 5.9 OCR for free islets, islets in m icrocapsules and islets in hollow fibres, m easured 24 h (1) after the
isolation process or 48 h (2) after.
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Conclusion
In this chapter a simple laboratory method for rapid measurement of OCR in free or 
encapsulated islets has been described, as a quantitative method for islet preparation and 
quality assessment, which allowed for measurement of OCR of bovine pancreatic islets in 
different experimental conditions. An average value of 1.98 ± 0.79 pmol/IEQ/min was 
estimated for OCR in basal conditions. This is the first time that OCR of bovine islets has 
been determined and the values obtained are comparable to other estimates previously 
reported in literature for other species (6-9). The rate of oxygen consumption was found to 
range from 1.5 to 4.2 pmol/IEQ/min in mouse pancreatic islets, from 2 to 3 pmol/IEQ/min 
in rat islets and from 2.5 to 3.3 pmol/IEQ/min in human islets, these values increasing 
during metabolic activity induced by elevated glucose concentrations (10).
OCR of bovine islets exposed to low and high glucose concentration was also studied to 
assess functionality in addition to viability. Metabolism of glucose triggers insulin 
secretion, with acceleration of |3-cell activity (11). Mean OCR of these bovine pancreatic 
islets at low glucose concentration was found to be significantly higher when exposed to 
high glucose concentration. It has been previously reported that static incubation with low 
and high glucose concentration (the same used in the present study) increased insulin 
production rate by bovine islets (12). Moreover, mean calculated change in OCR (see 
Table 5.1) of 0.51±0.30 pmol/IEQ/min was estimated between low and high glucose 
conditions (n=12), these results are in line with those reported by Sweet et al. for mice and 
human islets (13). Finally, the measured increase in OCR in response to changes in 
glucose concentration will provide a useful and rapid in vitro assay to assess functionality 
and viability of islet preparations.
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Isolation
OCR
(pmol/(IEQ*min))
5.5mM glucose 25 mM glucose
AOCR
(pmol/(IEQ*min)) % increase
1 0.85 1.01 0.16 18.5
2 1.74 2.02 0.28 16.2
3 1.55 2.33 0.77 49.6
4 0.94 1.45 0.51 54.5
5 1.72 2.58 0.86 50.2
6 1.99 2.12 0.13 6.6
7 2.66 3.18 0.52 19.4
8 3.17 4.07 0.90 28.4
9 1.71 2.21 0.50 29.0
10 1.46 1.56 0.10 7.2
11 3,00 3.87 0.88 29.2
12 2.96 3.43 0.47 15.8
Mean 1.98 2.49* 0.5 27.1
SD 0.79 0.97 0.30 16.5
Table 5.1 OCR, AOCR and % increase in preparation of free islets exposed to low and high glucose
concentration, *p<0.01
OCR by encapsulated islets was also measured to evaluate whether immunoisolation 
barriers represent obstacles to diffusion of oxygen, limiting normal islet function and 
viability. Two types of immunoisolation device were tested: alginate microcapsules (850- 
900 pm diameter) and polysulphone hollow fibres (490 pm inner diameter, 70 pm wall 
thickness). There is theoretical and experimental evidence (14) to indicate that oxygen is 
a limiting factor for islet viability and function under immunoisolation conditions. Even 
though alginate gel is highly permeable to oxygen, the distance between islets in the 
capsules and oxygen source outside the capsule, may more than 400 pm. For islets in 
hollow fibre, the worst case distance is 315 pm between the central part of the islet and the
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outside of the device, thus this distance theoretically limits diffusion of oxygen. In these 
experimental conditions both immunoisolation barriers allowed recording of OCR values 
comparable to those measured in free islets. This demonstrates that at least for high 
external concentration of oxygen adequate diffusion takes place. This is consistent with 
frequently reported long-term function of islets in alginate capsules implanted in the 
peritoneal cavity of diabetic rats (15). OCR by islets encapsulated in polysulphone hollow 
fibre also indicated that there were no major obstacles to oxygen diffusion, and here also 
oxygen consumption was similar to that of free islets.
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In vivo evaluation glycaemic control in transplanted islets using
CGMS
Islet transplantation could be a solution for diabetic patients. Site of implantation and use 
of immunoisolation system have to been thoroughly explored and analyzed to evaluate 
which is the better solution. Several rats with syngeneic islets were transplanted into the 
sub-capsular space of the kidney or in the peritoneal cavity, using free or encapsulated 
islets. Here a method was set-up to evaluate the in vivo ability of the islets to respond to 
glucose stimulation using a new system. To measure glucose control the continuous 
subcutaneous glucose monitoring system was used (CGMS; Medtronic, Minneapolis, MN, 
USA, Figure 6.1) to calculate mean glucose concentration after glucose stimulation.
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Figure 6.1 M edtronic continuous subcutaneous glucose m onitoring system
CGMS has been previously used to measure glucose concentrations in subcutaneous 
interstitial fluid of the abdomen of human patients (1) (2) (3) and in previous studies,
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CGMS levels also correlated well with capillary plasma glucose (4). This technique has 
been used in our laboratory as it permits a continuous monitoring of glucose concentration 
without continuous separate measurements of capillary plasma glucose. The primary aim 
of this study was to assess the value of CGMS in rats implanted with islets. A second aim 
was to investigate any relationships between glucose concentrations after glucose 
stimulation and the kind of implantation, using healthy rats as control.
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6.1 Intraperitoneal glucose tolerance test
The intraperitoneal glucose tolerance test (IPGTT) is a commonly used technique to 
measure acute, first-phase insulin release in response to glucose load and therefore 
represents a useful method to assess pancreatic function (5) (6). The IPGTT was 
established as a standardised method for assessing compounds designed to improve 
pancreatic islet function.
6.1.1 Materials and methods
Highly inbred male Lewis rats were used as donors and recipients. Animals were divided 
in three groups: n=8 healthy rats, n=8 diabetic rats transplanted with islets in 
microcapsules and n=8 diabetic rats transplanted with islets beneath kidney capsules. 
Diabetes was induced by a single injection of streptozotocin (65 mg/kg body weight; 
Sigma, St. Louis, MO, USA) into the tail vein, and then non-fasting blood glucose levels 
and body weight were measured twice a week. Blood glucose concentration was 
determined by tail bleedings using the Glucocard Memory 2 system (Menarini, Firenze, 
Italy).
Islet isolation
In this kind of experiment the automatic method was applied and it has been used to 
process 10-14 pancreata of Lewis rats, as shown in Chapter 2, page 54. Briefly, rats were 
anesthetized with an intraperitoneal injection of sodium pentobarbital (7). For each rat the 
same procedure was followed: after main bile duct location at its entrance in the gut, it 
was legated with silk suture 4.0. The duct was cannulated with polyethylene tubing (PE 
50) connected to a 22-gauge cannula and the rat was sacrificed. The pancreas was 
distended with 10-12 ml of collagenase P solution and dissected free of small bowel,
143
In vivo evaluation of glycaemic control in transplanted islets using CGMS
stomach and spleen; then it was removed and then rinsed in a centrifuge tube containing 
cold HBSS. Distended pancreases were then loaded into the digestion chamber at 37°C 
with four stainless steel ball bearings. When optimum digestion time was reached, the 
chamber was flushed with cold HBSS (4°C). Digested tissue was collected and purified by 
centrifugation on Histopaque gradient. Islets, >95% purity, were counted and cultured at 
37°C in a cell incubator in humidified atmosphere with 5% CO2 in RPMI medium, 
supplemented with bovine serum.
Islet encapsulation in microcapsules and transplantation
For encapsulation and transplantation the same procedures described in Chapter 4 was 
applied, page 100. Briefly, after 24 hours in culture, for the production of capsules, 3000 
islets were suspended in a solution of 1.7% sodium alginate at a concentration of 1 
islets/pl. The islet-alginate mixture was then extruded through an air jet droplet generator 
into a solution of 100 mM CaCh solution. Gel beads resulted in having a diameter ranging 
from 800 to 950 pm. Implantation of microcapsules was into diabetic rats weighing 200- 
220 g, into the peritoneal cavity through a small (1-2 cm) midline incision under Avertin 
anaesthesia (8).
Islet transplantation under the kidney capsule
For transplantation the same procedures described in Chapter 3 was used, page 81. Briefly, 
the day after isolation, 3,000 islets were resuspended in HBSS. After centrifugation, they 
were inserted into a polyethylene catheter with an internal diameter of 500 pm, and islets 
were concentrated into pellets in the final delivery tubing used to transplant them under 
the kidney capsule. In the experimental facility, the rat was anaesthetized with Avertin and 
when the anaesthetic had taken effect, the left flank of the rat was shaven. After kidney 
location, just beneath the spleen, a small incision in the skin permitted the peritoneum 
visualization. Making a small incision also into the peritoneum, the kidney was exposed.
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The kidney and the abdomen of the rat were kept moist by the use of saline solution 
applications during the whole procedure. Using a 23 or 25 gauge needle, a small scratch 
on the right flank of the kidney was made, creating a nick in the kidney capsule, into 
which the PE50 tubing was carefully and slowly inserted, making a small pocket. Using a 
Hamilton syringe, islets were slowly advanced into this. The PE50 tubing was slowly 
removed and carefully the nick was cauterized with low heat. The kidney was then gently 
replaced into the peritoneum, prior to closing the rat with suture and skin staples.
IPGTT and continuous glucose monitoring system
Six hours before IPGTT, the rat was anesthetized with Avertin and when the anaesthetic 
had taken effect, its dorsal skin was shaven. A tiny glucose-sensing device (sensor, Figure 
6.2) was inserted just under the skin quickly and painlessly. After calibration, the sensor 
began to measure glucose levels in the tissue every 10 seconds and sent the information by 
wire to a pager-sized device (the receiver) positioned near rat’s cage.
Receiver
Sensor
Wireless — 
transm itter
Figure 6.2 Photograph o f  the system inserted on the back o f  a rat w ith all the com ponents specified
The system automatically recorded average glucose values every 5 minutes for up to 72 
hours. After 6 hours, the rat was injected intraperitoneally with sterile glucose solution. 
After 3 days, the sensor was removed and information stored in the CGMS was
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downloaded to a computer. The limit of glucose concentration measured from the system 
was 400 mg/dl. Over this value the system gave a reading of 400 mg/dl.
6.1.2 Results
First, a homogeneous state of normoglycaemia was observed in.the three groups, with no 
significant statistical differences over non-fasting glucose concentration, as shown in 
Table 6.1.
Group Glycaemia mg/dl (mean ± SD)
Healthy rats 91 ± 14
Microcapsules tx 90 ± 16
Kidney capsule tx 108 ± 22
Table 6.1 Values o f  non-fasting blood glucose concentration for the three experimental groups
Then values of glucose concentration were analyzed under stimulation, downloaded from 
each receiver, then were inserted in a Excel spreadsheet. Each group (healthy rats, diabetic 
rats transplanted with islets in microcapsules and diabetic rats transplanted with islets 
under the kidney capsules) was determined; a representative curve of values of glycaemia 
after glucose injection (t=0) is provided below.
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From these graphic values, areas under the curve (AUC) were calculated for each 
experiment and values obtained were expressed as mean ± SD in Table 6.2. Statistical 
significance was determined using the analysis of variance (software StatView, SAS 
Institute Inc. Cary, NC, USA) and specific comparisons between groups were calculated 
using Student’s t-test and with the Bonferroni correction (9). The level of significance was 
taken to be p<0.05
Group AUC m g/dl x min (mean ± SD)
Healthy rats 11055 ± 4 0 3 8
M icrocapsules tx 21883 ± 4 5 6 0
Kidney capsule tx 48411 ± 23062 *
Table 6.2 Values o f AUC for the three experimental groups. *p<0.05 vs. kidney capsule and microcapsules
These data were used to understand the process o f glucose elimination for each group of 
animals. Then it was elaborated a pharmacokinetic model that would best fit the 
experimental data.
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6.2 Pharmacokinetic model and fitting of experimental data
One of the most important outcomes in pharmacokinetic modelling is the ability to predict 
drug levels and dynamic types of behaviour of drugs in the body, another is the ability to 
deduce mechanistic insight into what events have been observed. Sometimes the question 
is not how realistic the models are but what is their consistency and adequacy in making 
predictions. Most models are simplifications of the reality, but they are easy to assemble, 
useful, and relevant.
Various approaches have emerged to predict blood/plasma and tissue concentration time 
profiles and to provide mechanistic insight into what events have occurred (10). 
Compartmental approaches are the simplest and most widely used. The premise is based 
on venous equilibration and mass transfer into and out of compartments. In recent 
decades, however, modelling techniques have become more sophisticated. There is some 
departure from the compartmental modelling approach to physiological modelling, in 
order to confer more significance to anatomy, flow, and discrete eliminatory and 
distributional organs in the body. In the case of the glucose elimination process after 
intraperitoneal injection a two compartments pharmacokinetic model was applied with 
first order absorption. The single compartment model assumes that the drug rapidly 
distributes throughout the homogeneous apparent distribution volume. However, the drug 
may distribute at different rates into different tissues of the body, and it may require an 
extended period of time before its concentration equilibrates between different tissue and 
fluid regions. Clearly, this is a complex process and a reasonable simplification is the two 
compartments model shown in Figure 6.3.
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n
c^ tissue
K pt K .P Jr
L
K.
plasm a
Elimination routes
Figure 6.3 Two compartments model with first order absorption
Glucose is introduced into the central compartment (plasma) and then slowly distributes 
into the remaining tissue and fluid space. The constants kpt and ktp represent rate constants 
describing first order transport between the plasma and tissue compartment. In this case 
insulin is the “elimination route” for glucose.
6.2.1 Materials and methods
Values of glycaemia recorded every 5 minutes by CGMS were inserted into software for 
non-linear regression (EasyPlot) to fit the experimental data. For fitting was used the two 
compartments model for first order absorption, where concentration of glucose in the 
tissue Ctissue is determined solving the mass balance equation for glucose written for the 
plasma and the tissue and the concentration of glucose in the tissue compartment given by
C,is,uei 0 = kotKn
- B t
+
e k' :
(ka - A ) ( B - A )  (ka - B ) ( A - B )  ( A - k a) { B - k a)
(6.1)
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where kpt is the rate constant describing the first order transport between the plasma (p) 
and the tissue (t) compartments, ka, is the rate constant describing absorption (a), n a 
numerical parameter dependent from on weight of the rat and the dose of glucose injected. 
A and B are the parameters determined by fitting. These parameters have dependence 
given by the following equations
where ktp is the rate constant describing the first order transport between the tissue and the 
plasma compartments and ktot is the constant describing the elimination process.
6.2.2 Results
From the model applied to fit the experimental data, using EasyPlot software, the 4 
unknown parameters in equation (6.1) were determined: A, B, ka and kp[. Solving the 
system of equations (6.2), ktot was calculated, results are in Table 6.3. Also in this case, 
statistical significance was determined using the analysis of variance (software StatView, 
SAS Institute Inc. Cary, NC, USA) and specific comparisons between groups were 
calculated using Student’s t-test and with the Bonferroni correction. The level of 
significance was taken to be p<0.05
AB
(6 .2)
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Group ka (mean ± SD) min'1 Kpt (mean ± SD) min'1 ktot (mean ± SD) min'1
Healthy rats 0.104 ± 0.018 A 0.040 ±0.015 0.217± 0.041 *
M icrocapsules tx 0.083± 0.031 0.046 ± 0.020 0.156 ±0.026
Kidney capsule tx 0.051 ±0.038 0.043± 0.027 0.110 ±0.041 **
Table 6.3 Values o f  ka, kpt and &/0,fo r  the three experim ental groups; Ap<0.05 healthy rats vs. kidney
capsule; *p<0.05 healthy rats vs. kidney capsules and m icrocapsules; **p<0.05 m icrocapsules vs. kidney
capsules
An example of fitting from each group is reported in the following figures: the fitting 
curve being in black, the experimental points in red.
For healthy rats:
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Diabetic rats transplanted with islets in microcapsules:
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Diabetic rats transplanted with islets beneath the kidney capsules:
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Only through a simple analysis o f the graphics it can be concluded that rats implanted with 
microcapsules had good glyceamic control, without any statistically significant difference 
from healthy rats. Rats with islets implanted beneath the kidney capsule showed 
glycaemic control which was significantly different from healthy and microcapsule islet 
groups.
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Conclusion
This work was performed to evaluate the efficacy of a given system of immunoisolation 
on functionality of the islets involved. Periodically glucose concentration in the blood was 
measured to control islet functionality in terms of normoglycaemia, and it was verified for 
both kinds of implantation (islets in microcapsules and free islets beneath the kidney 
capsules). But it was necessary to explore ability of islets to respond to glucose 
stimulation and thus this response was examined to determine whether it would be similar 
to the physiological one. A new technique was applied, avoiding continuous blood 
sampling in the tail of rats. This system, previously used in rats only once (3), allowed 
monitoring glucose concentration continuously, permitting achievement of good results in 
terms of measurements and analysis of data.
Firstly the values downloaded from the receiver were analyzed and the results showed that 
the AUC of rats implanted beneath kidney capsules was seen to be statistically different 
from AUC of healthy rats and those implanted with islets in microcapsules. To best 
analyze the data obtained, a pharmacokinetic model was derived that best fitted the 
experimental data. Results were thoroughly analysed as administration of glucose 
intraperitoneally would be similar to administration of a molecule for kinetic study in 
pharmacological application. Moreover, values describing the glucose elimination process 
would be a good index of islet functionality. Values of km were obtained for rats that were 
transplanted with islets beneath the kidney capsules, and these were statistically different 
from the other two groups, demonstrating that transplanted free islets responded to glucose 
stimulation but not like islets of healthy rats or like encapsulated islets. This result is
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important as it demonstrates that encapsulated islets function properly, permitting optimal 
glucose control, also under stimulation.
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Design of an immunoisolation device for islet transplantation
An ideal membrane for an immunoisolation device should have permeability properties 
that allow at the same time immunoprotection and tissue nutrition. If the pore size is too 
large, harmful factors such as antibodies or even immune cells may cross the membrane 
and damage the encapsulated graft. If the pore size is too small, this will interfere with the 
nutritional demands of the graft, jeopardizing graft survival (1).
Then, diffusion process of macromolecules of various molecular weights was studied 
through a semipermeable polycarbonate membrane designed for an immunoisolation 
device for pancreatic islets, designed and experimented in a European Project (BARP+, 
project n. NMP3-CT-2003-505614). Actually, the effective diffusivity of a solute within a 
porous medium (such as the alginate matrix or a polymeric membrane) is less than in bulk 
solution. Even if these materials have been used in several previous investigations (2) (3), 
quantification of hindered diffusion has not been provided yet. The objective of this work 
was to show the method used to estimate the solute diffusion within porous membrane, on 
the basis of experimental measurements of the geometrical characteristics of the 
membrane considered. The estimated diffusion coefficients were used in a mathematical 
model set-up and simulation of diffusion kinetics of glucose, insulin and antibodies within 
an immunoisolation device were performed.
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7.1 Determination of solute diffusivity
7.1.1 Solute diffusivity in porous membrane (4)
The recent application of nanotechnology techniques in the development of porous 
synthetic membranes opened the possibility to generate specific membranes for different 
applications.
An ideal semipermeable membrane must allow adequate diffusion of oxygen and nutrients 
to maintain islet viability and function but, at the same time, must be selective enough to 
prevent the permeation of host immune proteins. As stated before, effective diffusivity 
coefficient of solutes, like glucose and insulin, within a porous membrane is lower than in 
bulk solution. This phenomenon, known as “hindered diffusion”, depends from the size of 
solute molecules compared to the pore dimension and density. Beck and Shultz in 1970 
(5) studied solute diffusion for a variety of porous membranes. A summary of their results, 
for a number of neutral solutes is shown in Figure 7.1.
tiO :Cv'
Renkin 
aqyaitooG 0.4
Figure 7.1 Solute diffusivity o f  m olecules o f  radius (a) in pores o f  a membrane with radius (r)
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In this plot the ratio of solute diffusivity within the pore membrane (Dm) and the bulk 
diffusivity (D J are plotted as a function of the ratio between solute radius and pore radius 
(a/r). The solid line represents the best fit of the Renkin equation (6 ) to their experimental 
data using the following expression
D
( a \ 21- -
V r )
* ' a '
\ r j
+ 2.09*
/  \ 3 ' a x
\ r j
0.95*
/ \ 5 / a
\ r j
(7.1)
The first term in this equation takes into account that only a fraction of the pore transversal 
area is available to the molecule. This coefficient is known as the “partition coefficient” 
and represents the effect of steric exclusion. The second term accounts for the increase in 
hydrodynamic drag as the solute diffuses through the pore. Considering the effective 
diffusion of a solute in the overall membrane, the following equation can be written
A.
D„ = £> * *i 1 - —i * 1 -2 .1 * 1 -1  + 2 .09*1- 
r j I r
-0 .9 5 * 1 -  
r
(7.2)
where Ap is the pores area and Stot is the total surface area.
The bulk diffusivity of a solute with known radius = a in a solution with viscosity = \i can 
be calculated using the Stokes-Einstein equation
TD„ = k*
6 Jtfja
(7.3)
where
k =1.38054*1 O'23 Joule
K
T =293.15 °K
Boltzmann constant 
temperature in Kelvin
In case of islet immunoisolation, three important molecules were considered: glucose 
(a=2.47 A,(7)), insulin (a=16 A) and immunoglobuline (IgG a=55 A) (8 ). The bulk 
diffusivity constants were then calculated at 37°C and they are:
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D*, glucose= 9.02 * 1 O'4 mm2/sec 
D« insulin= 1.39 * lO^mnfVsec 
D.igG =4.05 * 10'5 mm2/sec
Experimental determination o f membrane pore diameter and density 
Pore dimension and density of polycarbonate membrane were analysed using scanning 
electron microscopy (SEM). On digitized images a morphometrical analysis was 
performed. For each image, pore number and area were calculated. A representative image 
of the membrane surface is shown in Figure 7.2.
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F IB  Im a g in g  =  S E M
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lutput To = Display/File |-------------
Figure 7.2 SEM o f  the nanoporous polycarbonate membrane
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Using a calibrated grid, the image resolution (pm/pixel) and the mean values of pore 
radius, Ap and Stot were calculated, using standard morphometrical technique. In each 
image the outline of the pore area was automatically traced and surface area measured.
0 9Mean pore radius averaged 31.45 nm and pore density 2.54*10 pores/cm . De was then 
calculated for each molecule considered:
De glucose= 6.62 * 10'5 mm2/sec = 0.241 mm2/h 
De insulin = 8.61 * 1 0 '6 mm2/sec = 0.031 mm2/h 
DeigG = 1.46 * 10'6 mm2/sec = 0.005 mm2/h
7.1.2 Solute diffusivity in alginate gel
This experience, in line with previous investigations reported in literature, suggests that 
alginate gel is attractive as matrix for immunoisolation devices because of its ability to 
eliminate convective mixing and its selectivity for molecules based on size, charge, and
chemical affinity. This gel is space-filling at low-volume fractions of the network material
(e.g., cross-linked polymer).
About the diffusion across a gel, the driving force is usually dependent from concentration 
gradients and the effective diffusivity (Deff) within the gel is given by
A * - <&*/>. (7.4)
where O is the partition coefficient of a solute molecule and D^ is the free solution 
diffusivity.
To estimate O from gel composition and solute radius (as), Ogston (9) developed a model 
based on the probability of a rigid sphere of radius as to be contained in a matrix 
composed of long cylindrical fibres of radius af. This relationship predict d> for uncharged, 
spherical macromolecules within a randomly oriented array of cylindrical fibres and it’s
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<J> = exp ~<t> 1 +
\  af )
(7.5)
where 0  is the volume fraction of the fibres and af is the radius of the fibre.
Considering the three molecules of interest their effective diffusivity was calculated in gel 
alginate solution of 2.7% assuming fibres of the polymer gel of 5 A radius:
Deffglucose= 8.49 * 1 0 '4 mm2/sec = 3.05 mm2/h 
Deffmsuiin= 8.65 * 1 0 '5 mm2/sec = 0.311 mm2/h
DeffigG = 8.30 * 10'7 mm2/sec = 0.003 mm7h
7.2 Mathematical model of an immunoisolation device for islet transplantation
Solute diffusion across porous membranes is only regulated by the concentration gradient 
between internal and external side. A theoretical model can be used to simulate solute 
trans-membrane transport using continuity equation and Fick’s laws, the principal laws 
that regulate diffusion process. Assuming that diffusion takes place in only one dimension 
( 10):
J  = - D ^ -  (7.6)
Ax
where AC is the concentration gradient of the molecule in x direction, perpendicular to 
membrane surface, D is the diffusivity constant and J the solute flux. For the conservation 
of mass applied to a control volume dV(dx,dy,dz), results
—  — —  (7.7)
d t dx
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Combining equation (7.6) and (7.7) the second Fick’s law was obtained
(7.8)dC d 2C
dt dx2
In this model, solute concentration is a function only of x and t (time dependent mono­
dimensional problem) and considering the membrane
dC - _ D d lQ ‘ (7.9)
dt dx2
where Cm is the solute concentration and Dm the effective diffusivity in the membrane. For 
the inner part of the device
dC;L = D d2C; (7.10)
dt a dx2
where Da is the effective diffusivity in alginate gel.
Each part of the device was divided in small volumes, one near the other, and mass 
balance equation for each volume was solved, considering initial and boundary conditions. 
The model represented in Figure 7.3 is one dimensional symmetric model.
Membrane x„ Alginate Xg
>4
— ►  J out ►X
AX
x=0
Figure 7.3 One-dimension model o f  the device
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Where the geometrical parameters are: 
na = number of elements in the alginate
AXa=Xa/na
nm = number of elements in the membrane 
Axm — xm / nm 
Jin = mass flux in 
J0ut= mass flux out
A numerical solution of equation (7.9) and (7.10) can be obtained using the finite 
differential method. Since the device was divided in a finite number elements (na+nm), the 
differential equations were transformed into a linear system of equations. To this purpose, 
the membrane (xm), the alginate (xa) and time (t) were divided into equal intervals, so that 
an x-t region covered by a grid of rectangles was create, as shown in Figure 7.4. 
Coordinates of a representative grid points can be written as (idxjdt) where i and j are 
integer. The value of C at the point (ickcjdt) was denoted by C,j with corresponding values 
at neighbouring points.
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Figure 7.4 x-t region covered by a grid o f  rectangles o f  side dx, dt. 
The value o f  C at the point (\dx, jdt) is denoted Q j
By using Taylor’s series in the t direction, keeping x constant, it can be written
Cij - Cij-1 + dt
(dC^
+
'd 2C^
d<2 >u-1
from which it follows that
<dC\ Cu - C u _t
\  dt h j - i dt
+ 0(dt) (7.12)
where 0(<5/) represents the major term neglected that is of the order of St. Similarly by 
applying Taylor’s series in the x direction, keeping t constant, it results
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on adding, it was obtained
dAC CMj  2C(- + Cw>j/
T 'V ' +0(dx)z (7.15)
(dx)y dX j
By substituting eq. (7.12) and (7.15) in the second Fick’s law and neglecting the error 
terms, after re-arrangements, it was found that
C >,J = C,,H  + -2 C U_, + Cw.,_,) (7.16)
dtFor a given value of — r , using eq. (7.12) values of C at all points of the grid can be
dx
calculated, providing initial starting values of C at t=0 and conditions on each of the 
boundaries. A formula such as (7.16) which enables unknown value to be expressed 
directly in terms of known values is called an “explicit finite difference formula”. To 
obtain C(x,t) for different times or in different x, a computer code in MatLab was 
developed and described in details in the Appendix A.
Determination o f  numerical analysis parameters:
Finite-difference methods provide reasonable approximation to the solution of partial 
differential equations. For code implementation, the right choice of parameters has to be 
done. There are serious limitations on the assumption of the value of the parameter
r = D -^ -  since equation (7.16) is based on approximations and neglected error terms.
dx
Smith et al. in 1965 (11) demonstrated that r = i  is a critical value, as shown in Figure 
7.5.
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Solution of the differential equation 
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Figure 7.5 Demonstration that r>0.5 is a critical point
In fact, for r=0.48 the finite difference solutions well agree with the analytical solution, 
but for r=0.52 oscillations develop and solution becomes unstable (errors increase without 
limit). For this reason, at the beginning of the code, was imposed a limitation on the value 
of r; if it’s >0.4, a warning message to the user is visualized. The following input 
parameters have been defined.
Assumed input parameters:
-  tmax: time of observation
-  xmax: thickness of the alginate gel=0.5 mm (xa)
-  Lm: thickness of the membrane=0.03 mm
-  Lmstep: number of the elements in the membrane=30
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-  xstep: total number of the elements (Lmstep x 5) = 150
-  tstep: number of the intervals in which the time period is divided
The value of dt is given by tmax/tstep. Inside the membrane <ix:=Lm/Lmstep, within the 
alginate gel dx=xmax/(xstep-Lmstep).
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7.2.1 Simulation o f glucose transport
A basal level of glucose equal 0 inside the entire device and a value of external 
concentration equal to 100 and constant in time were assumed. At t=0 a concentration 
gradient is present between intern part (Q) and external part of the device (Ce). Assuming 
constant glucose concentration outside the device, an increase of glucose concentration 
inside was reached with time. Then it was assumed :
For t<0 C i=C e= 0
For t=0 Q=0
Ce=100
The aim of the study was to calculate the time required for glucose to reach all the points 
internal to the device, diffusing through the immunoisolation membrane into alginate gel. 
Boundary conditions for this case (glucose diffusion) have been defined as follows:
-  d C fa t)  _ q -n x=(Xa+Xm) for the assumption of a symmetry plane, 
dx
no flow in the centre of the device 
dCt{x,t)D d C ^ x j)
dx
= D
dx
for continuity of mass flow at the alginate 
membrane interface
Assumed input parameters for simulation:
-  tmax: 1 2 0 0  seconds
-  xmax: 0.5 mm
-  Lm: 0.03 mm
-  tstep: 600000
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The values calculated using MatLab code for different times at the centre of the device 
(x=xstep) are reported in Figure 7.6.
100
80  -
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C /5X
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800 1 2 0 0200 4 0 0 6 00 1000
Time (seconds)
Figure 7.6 G lucose concentrations in x=xstep
The values of glucose concentration C(x,t) as a function of x and t are reported in Figure 
7.7, each line every 30 seconds. The diffusion process o f glucose ends in about 1200 
seconds with a uniform concentration equal to the external one, obtaining a dynamic 
balance.
171
Design o f an immunoisolation device for islet transplantation
300 sec
210 sec50 - time
90 sec
60 sec30 sec
0.4
x (mm)
Figure 7.7 Fam ily o f  curves C(x,t) in function o f  x at different times
The time at which the centre of the device reached 90% of glucose concentration was 
467 seconds (less than 8 minutes).
7.2.2 Simulation o f insulin transport
When the concentration of glucose arises, islets inside the device begin to produce insulin 
that as per diffusion will go to the external part of the device. A basal level of insulin 
equal 0 was assumed outside the device and constant with time and a value of internal 
concentration equal to 100.
It was assumed that:
For t<0 Ci=Ce=0
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For t=0 C i= 100
C e= 0
The aim of the study was to evaluate insulin kinetic, if insulin diffusion was rapid to 
obtain a good glycaemic control and if the membrane was an obstacle for insulin 
diffusion. Boundary conditions were defined for this case (insulin diffusion) as follows:
-  dCfat f )  _ Q jn x=xa+xm for the assumption of a symmetric model, no flow in the 
dx
centre of the device
dC^x^t)
-  D.
dx
= D dC;(x,t)
dx
for continuity of mass flow at the alginate- 
membrane interface
Input parameters:
-  tmax: 2  hours
-  xmax: 0.5 mm
-  Lm: 0.03 mm
-  tstep: 600000
The values calculated using MatLab code of insulin concentration c(x,t) as a function of x 
and t are reported in Figure 7.8, each curve every 5 minutes. The diffusion process of 
insulin ends in about 2  hours, obtaining a dynamic balance with the external compartment.
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Figure 7.8 Family o f  curves C(x,t) in function o f  x at different times
To study if this kinetic is acceptable for a glycaemic control, the code returns in output the 
value of the mass o f insulin inside the device and then the time in which the quantity of 
mass reach the maximum value as reported in Figure 7.9.
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Figure 7.9 Quantity o f  mass insulin mass in function o f  tim e
This curve represents the mass of insulin outbound from the device and the time in which 
it is greatest was estimate and resulted 30.06 minutes, which is quite acceptable. Kinetic of 
diffusion for insulin is slower than glucose. This is due to the difference between the 
dimensions of the molecules.
7.2.3 Simulation o f immunoglobulin (IgG) transport
As stated before, an ideal immunoisolation membrane must prevent the passage of 
cytotoxic cells, macrophages, antibodies and complement to remain effective. Previous 
studies indicated that immunoisolation could be attained if C lq  and IgG were completely 
retained (1). Moreover, if the cells implanted are xenogeneic, it seems that 
immunoisolation will require membranes that not only provide protection of the
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encapsulated tissue from the host immune system, but also have properties that diminish 
the release of xenogeneic antigens through reduced pore size. Evaluation of this 
membrane in terms of desired IgG diffusion kinetics was performed.
For the model we assumed that:
For t<0 Cj=Ce=0
For t=0 Cj=0
Ce=100
The aim of this study was to estimate if the membrane is an obstacle for IgG diffusion. 
Also in this case boundary conditions as follows were defined:
-  dCi(x ’ t)_ = o in x=xa+xm for the assumption of a symmetric model, no flow in the 
dx
-  D.
centre of the device
dCt(x,t)
dx
= D dCt{x,t)
dx
for continuity of mass flow at the alginate- 
membrane interface
Input parameters:
-  tmax: 24 hours
-  xmax: 0.5 mm
-  Lm: 0.03 mm
-  tstep: 600000
The values of IgG concentration C(x,t) calculated using MatLab code as a function of x 
and t are reported in Figure 7.10, each lines every 1/2 hour.
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Figure 7.10 Family o f  curves C(x,t) in function o f  x at different tim es
To study if this kinetic is acceptable for an immunoisolation membrane, the code 
calculated the value of IgG concentration just after the membrane (in x=Lmstep+l) and 
the time at which in this point 10% of IgG concentration was reached (Figure 7.11).
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Figure 7.11 IgG concentrations in x=Lm step+l
After 24 hours it was found that the percent o f IgG diffusion near the membrane was about 
75%. This value couldn’t be acceptable for an immunoisolation membrane. For this 
reason, in order to maintain glucose and insulin kinetics acceptable (in terms of time of 
diffusion) and to obtain complete antibodies obstruction MatLab analysis changing pore 
diameter and density were performed.
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Discussion and conclusion
An ideal immunoisolation membrane must have specific characteristics in order to allow 
good diffusivity of glucose and insulin and ability to retain antibodies to prevent islet 
destruction. The mathematical model and the numerical solution code developed in this 
investigation allowed to analyse the dynamic of diffusivity of these molecules, giving us 
useful determinations that permit to evaluate a membrane performance before effective 
use in experimental setting, i.e. with animal studies.
Polycarbonate membrane designed for the European Project BARP+ was not ideal for 
immunoisolation purposes because it permits a good kinetic of diffusion to insulin and 
glucose, but it is too permeable to IgG and the cells implanted (allogeneic or xenogeneic) 
would be expected to be rejected. Then, it was tried to define the properties that an 
hypothetical membrane must have, on the bases of the simulation tools developed. 
Different pore radius and density were adopted and the indexes of functionality were 
compared in order to identify an adequate membrane to be used for immunoisolation 
devices.
The following values of pore radius were adopted:
-  30 nm (like polycarbonate)
-  2 0  nm
-  1 0  nm
-  5 nm
with different pore density:
-  2.5 x 109 pores/cm2
0 9-  5 x 10 pores/cm
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-  7.5 x 109 pores/cm2
-  1 0  x 1 0 9 pores/cm2
For these different combinations, diffusion simulation were performed with the device 
using MatLab code for each molecule.
Glucose diffusion
Firstly, effective diffusivity (De) was calculated in each case and results are shown in 
Table 7.1
^ ^ ^ I l a d i u s
D en sity^ ^ '^ ^ 30 nm 20 nm 10 nm 5 nm
2.5 X109 
5 x 109
7.5 x 109 
10 x 109
6.16E-05
1.23E-04
1.85E-04
2.46E-04
2.69E-05
5.38E-05
8.08E-05
1.08E-04
6.39E-06
1.28E-05
1.92E-05
2.56E-05
1.60E-06
3.20E-06
4.80E-06
6.40E-06
Table 7.1 Glucose diffusivity in different cases (mm2/sec)
For each case the value of time at which the centre of the device was reached by 90% of 
glucose (T900/0) was determined and results obtained are shown in table 7.2 and plotted in 
Figure 7.12.
' ' ' '^ R a d iu s
D e n s i t y ^ ^ ^ ^ 30 nm 20 nm 10 nm 5 nm
2.5 x 109 467 479 555 967
5 x 109 462 468 504 692
7.5 x 109 461 465 488 607
10 x 109 460 463 480 567
Table 7.2 Time at which 90% o f  glucose reach the centre o f  device (in seconds)
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Figure 7.12 Time at which 90%  o f  glucose reach the centre o f  device in function o f  pore density
It can be easily conclude that if  pore radius is 10-30 nm, pore density didn’t influence 
glucose kinetics. If pore radius is 5 nm, only with high density of pores acceptable values 
of glucose diffusion were obtained.
—♦«— 30 nm 
—• —20 nm 
10 nm 
  K— 5 nm
2 4 6  8 10 12
Pore density (x lO A9)
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Insulin di ffusion
Also in this case, effective diffusivity (De) was calculated in each case and results are 
shown in Table 7.3
^ ^ ^ ^ R a d iu s
D e n s i t y ^ ^ ^ 30 nm 20 nm 10 nm 5 nm
2.5 x 109 
5 x 109
7.5 x 109 
10 x 109
2.84E-02
5.68E-02
8.51E-02
1.14E-01
1.13E-02
2.25E-02
3.38E-02
4.51E-02
1.99E-03
3.98E-03
5.98E-03
7.97E-03
2.45E-04
4.90E-04
7.35E-04
9.81E-04
Table 7.3 Insulin diffusivity in different cases (mm2/h)
For each case with MatLab code the time in which the mass flow reaches the maximum 
value (Tmax) was determined and results were shown in table 7.4 and represented in Figure 
7.13.
^ ^ -^ IR a d iu s
D e n s i t j r " ^ ^ 30 nm 20 nm 10 nm 5 nm
2.5 xlO 9 30.06 30.42 33.72 47.40
5 x 109 29.94 30.12 31.62 42.78
7.5 x 109 29.88 30.00 30.96 39.72
10 x 109 29.82 29.94 30.66 37.68
Table 7.4 Time at which quantity o f  mass reach the maximum value (in minutes)
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Figure 7.13 Tim e at which quantity o f  mass reach the m axim um  value (in minutes) in function o f  pore
density
It can be conclude that also in this case if pore radius is 10-30 nm, pore density didn’t 
influence insulin kinetics and the maximum value of mass quantity is reached after 30-35 
minutes. If pore radius is 5 nm, only with high density of pores acceptable values of 
insulin diffusion were obtained, even if they are about 20% higher then the others.
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Immunoglobulin (IzG) diffusion:
First of all, in the membrane effective diffusivity (De) was calculated in each case and 
results are shown in Table 7.5. Since IgG radius is more than 5 nm, no value of diffusivity 
for membrane with these pores was determined.
^  ^ R a d iu s  
D e n s ity ^ ^ ^ ^ 30 nm 20 nm 10 nm 5 nm
2.5 x 109 4.71E-03 1.39E-03 9.96E-05 no
5 x 109 9.42E-03 2.79E-03 1.99E-04 no
7.5 x 109 1.41E-02 4.18E-03 2.99E-04 no
10 x 109 1.88E-02 5.58E-03 3.98E-04 no
Table 7.5 IgG diffusivity in different cases (mm2/h)
For each case MatLab code returns in output the time at which the value of IgG 
concentration just after the membrane (in x=Lmstep+l) reached 10%. Results were shown 
in table 7.6 and represented in Figure 7.14.
D e n s ity ^ ^ ^ ^ 30 nm 20 nm 10 nm 5 nm
2.5 x 109 10 16 99 never
5 x 109 8.8 12 57 never
7.5 x 109 8.3 10 42 never
10 x 109 8.1 9.6 34 never
Table 7.5 Time at which the value o f  IgG concentration just after the membrane (in x=Lm step+l) reached
10% (in minutes)
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Figure 7.14 Tim e at which the value o f IgG concentration ju s t after the m em brane (in x=L m step+ l) reached
10% in function o f  pore density
It can be concluded that, if pore radius is ranging from 20-30 nm, pore density does not 
influence IgG kinetics and the 10% of IgG quantity passes the membrane after 10-20 
minutes. If pore radius is reduced to 10 nm, with low density of pores acceptable values of 
IgG transport obstruction are obtained, and the transport o f IgG with the entire alginate 
volume is expected to be very long, thus protecting the implanted material.
The results of these calculations allow to derive some interesting conclusions.
1) The actual pore-size adopted in previous studies, around 30 nm, is too large for 
immunoprotection. More efficient size-selectivity must be obtained with pore-size 
less that 20 nm.
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2) From the values of IgG diffusivity within the pore membrane and within the 
alginate matrix, it is evident that a more efficient blockade of large macromolecule 
movement can be obtained both in alginate than in the pore membrane. Thus, using 
more selective matrix material, dependently from the membrane pore dimension, 
would give more effective results in making macromolecule diffusion more slow 
with the possibility for small molecules to show adequate diffusion.
In general this approach showed that more careful determination of the performance of an 
immunoisolation device can help a lot in performing less but more successful 
experimental evaluations.
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Conclusions
The current conventional approaches for treating type I diabetes are based on exogenous 
insulin therapy and intensive glucose monitoring. Only in exceptional cases pancreas 
transplantation is performed. Although daily glucose monitoring and exogenous insulin 
administration are the standard therapy since the discovery of insulin, the non optimal 
control of blood glucose with important fluctuations leads to many severe complications 
including neuropathy, nephropathy, retinopathy, heart disease, and atherosclerosis (1) (2) 
(3). In 1993, the Diabetes Control and Complications Trial showed that strict control of 
blood glucose levels reduced the risk of developing diabetes-related complications (4). 
Within the past 20 years, pancreatic islet transplantation has become a clinical reality and 
an option in the treatment of diabetes. Islet transplantation has a distinct advantage over 
whole pancreas transplantation in regards to reduce peri-procedure morbidity. Islet 
transplantation involves the isolation of pancreatic islets from cadaveric, multiorgan 
donors. These islets are then injected into the liver of the diabetic patient by the portal 
vein, from where they get deposited in liver sinuses. Islet transplantation, beside being less 
invasive than whole pancreas transplantation, can provide certain advantages that are not 
available with pancreas transplantation, including the potential for modifying tissue 
immunogenicity through in vitro culture or gene therapy approaches, tissue encapsulation 
for immunoisolation, potential for engraftment in immunoprivileged sites, and the 
possibility of using alternative tissue sources including xenogenic islets or stem cell 
derived (3-cell lines. Widespread clinical application of this procedure, however, is 
currently limited by the need for lifelong immunosuppression and the need for two to four 
donor pancreases per recipient. Additional drawbacks include complications of
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immunosuppression such as nephrotoxicity with chronic treatment with Sirolimus and 
Tacrolimus. The need for relatively large masses of insulin-producing cells to achieve 
insulin independence has led to the use of multiple donors (sequential or pooled islet 
preparations) per recipient. This may increase the risk for allosensitization to multiple 
anti-human leukocyte antigen (HLA) antibodies, limiting the possibility of future solid 
organ transplantation (5). Then, immunoisolation of islet was deeply explored to open the 
possibility of alio- or xeno- islet transplantation without the use of pharmacological 
immunosuppression and avoiding allosensitization of the patient (6).
The present work reports the results of scientific research activity performed with the aim 
of improving technical and biological aspects of islet transplantation using 
immunoisolation device.
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8.1 Goals achieved
8.1.1 Islet isolation
The challenges to successful transplantation of islets include improvements in isolation 
process, islet culture, characterization and preservation. The results obtained and their 
relevance are presented in the following.
Automatic method for islet isolation: an islet isolation process that is automated was set 
up and validated. It provides most of the advantages of an automated system. It provides 
ease of operation with minimum number of process operating personnel. With the 
introduction of a newly designed digestion chamber, in different phases of the procedure a 
single operator can control various components of the process. Moreover, after the 
application of the automatic procedure, the number of the islets obtained from each 
isolation significantly increased.
Process Standardization: The application of this automated islet isolation protocol ensured 
that each pancreas goes through a similar process environment. The process has been 
standardized and the results were comparable and can be easily analysed.
Data collection: The automated process allows collection of large data contained in a 
single file for each islet isolation being carried out. These files contain several 
informations like type and amount of enzyme used, time of digestion, time for 
purification, type and quantity of solutions used. This large pool of data can further be 
analyzed to find out how the process was run during isolation and to possible correlation 
between the isolation parameters and the final outcome of the process.
In vitro and in vivo tests o f functionality: The application of the automated method allows 
large numbers of islets to be obtained used to perform different type of tests to evaluate 
islet functionality and viability. A method for the in vitro evaluation of each islet 
preparation was set up, measuring the oxygen consumption rate of free islets under
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different experiment conditions (i.e. at low and high glucose concentrations). Moreover, in 
vivo tests of free islet transplantation were performed under the kidney capsule. These 
transplantation experiments indicate that, to obtain normalization of hyperglycaemic state 
using allogeneic or xenogeneic islets, a barrier must be created to avoid tissue rejection 
but allowing diffusivity of glucose, insulin, oxygen and other metabolically active 
products, to insure islet functionality and therapeutic effectiveness. For this reason two 
types of immunoisolation devices were examined, as described in the following 
paragraphs,
8.1,2 Islet transplantation by immunoisolation
Applications for biomaterials in improving islet engraftment by immunoisolation of the 
transplanted tissue through semipermeable membranes are increasing. Immunoisolation of 
transplanted islet tissue is an attractive strategy that aims to solve the problem of host 
immune destruction of transplanted tissue by blocking access of the host immune system. 
Solute permeability o f  membrane for cell immunoisolation: To select an appropriate 
membrane for device construction, membrane permeability properties were characterized 
and a computational model was developed. This theoretical provided for investigation of 
solute transport through different membranes on the basis of the diffusivity constant being 
experimentally determined. On the basis of the geometrical parameter obtained for real 
membranes, the best combination of pores density and pore radii of an hypothetical 
suitable membrane were estimated to obtain immunoisolation function. Theoretically 
increasing molecular weight cut-offs (7) would eliminate the escape of shed antigens, 
however, using smaller pore size would most probably limit the diffusion of essential 
nutrients to the encapsulated cells below the survival threshold. As Desai et al. suggest (8) 
the control of pore size down to tens nanometers can prevent protein binding and
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overcome some of immunological challenges, at least hinder the passage of small 
cytokines and cell-secreted antigens. The results presented, in line with suggestion by 
other groups, indicate that control of membrane pore parameters is the only way to 
achieve functional immunoisolation (9) (10). Moreover, production of new membranes 
with more calibrated pore dimensions and density could allow to development of efficient 
immunoisolation devices, opening the possibility of clinical applications.
Design o f immunoisolation device: In the present work two types of immunoisolation 
systems were studied, one for subcutaneous implantation (hollow fibres device) and one 
for the implantation in the peritoneal cavity (gel microcapsules). The hollow fibres device
j
is compact and thin enough to be used for a subcutaneous implantation in the rat. An 
advantage of this site is that it requires a minimally invasive surgery and allows easy 
recovery in case of failure. Hollow fibre devices were tested in xenogeneic and syngeniec 
protocols, showing that the formation of a non-specific fibrotic capsule in vivo hinders the 
diffusion of metabolites like oxygen, causing the central necrosis of the islet cells. Then in 
vitro the permeability of these immunoisolation devices to oxygen was tested, showing 
that both polysulphone hollow fibers and alginate were not actually reducing oxygen 
diffusion and consumption within the devices. Through glucose tolerance test in vivo 
functional response of transplanted encapsulated or free islet was also studied. Continuous 
glucose monitoring was performed in diabetic animals receiving islet immobilized in 
alginate gel or inserted under the kidney capsule or in normal animals for control. In 
animals with islets in alginate capsules the glycaemic profile upon glucose challenge was 
comparable to that of normal controls while, in animals receiving islet under the kidney 
capsule, the metabolic control was delayed. This result is important because it 
demonstrates that islet encapsulation allows adequate function and optimal glucose 
control, also under stimulation. - -
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Overall these experimental results indicate that islet transplantation using alginate gel 
microcapsules in the peritoneal cavity successfully control glycaemia in diabetic animals. 
This positive result, however, is not possible to translate in human application for the 
implantation site. Then an alternative strategy was developed based on membrane device 
to be used in the subcutaneous space. Despite permeability properties of the device have 
been proved to be adequate, the functional response of transplanted islet in hollow fibre 
device was only temporary. The reason of this lack of sustained function is likely 
dependent on the cellular response of the recipient and the development of fibrotic tissue 
around the device.
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8.2 Future perspective
The research activity described in this thesis was focused on development of techniques to 
improve pancreatic islet isolation and to set up a device for immunoisolation of islets for 
transplantation without immunosuppression. In both tasks improvements have been 
accomplished and significant advancements have been obtained over previously reported 
results. There is, however, necessity to further improve this immunoisolation device to 
obtain final proof of function in experimental animals and to open the possibility for 
human experimentation.
The use of a theoretical model allows evaluation and selection of new membrane materials 
for islet immunoisolation. In future studies these new membranes could be further 
investigated. The next step is then to design experimental protocols that, in great detail, 
study membrane biocompatibility and effective permeability properties. After the selection 
of such new membranes, device function can be studied in vitro, maintaining device 
containing islets in culture for different periods of time and with different density of islets 
and investigating islet function, tested at different glucose concentrations. The in vivo 
efficacy of these new devices would need to be determined by performing alio- or xeno­
transplantations into diabetic recipients. Finally, another issue to investigate is exploring 
new sites of implantation that minimize surgical procedures and reduce implant failure.
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Appendix
1)))/((Lm/Lmstep)A2); 
end
for i=Lmstep+1:xstep-1
C (i,j)=C(i,j-1)+(Dalginato*T*(C(i-1,j-1)-2*C(i,j-1)+C(i+1,j-1)))/(XA2);
end
C(xstep,j)=C(xstep,j — 1) + (Dalginato*T*(C(xstep-1,j-1)-C(xstep,j-1))-
0)/(XA2) ;
disp(sprintf('tstep %d su %d',j,tstep));
end
% vectors for data analysis on concentration 
CFref=zeros([tstep/100,1]) ; 
for k=l:tstep/100
CFref(k)=C(xstep,100*k-99);
end
Ci=zeros([tstep/15,1]) ; 
for k=l:tstep/15
Ci(k)=C(2,15* k-14);
end
% vectors for plot
xa = linspace(0,Lm,Lmstep);
xm = linspace(Lm,xmax+Lm,xstep-Lmstep+1);
xg = zeros([1,xstep]); 
xg(1,1:Lmstep)=xa; 
xg(1,Lmstep:xstep)=xm; 
t = linspace(0,tmax,tstep);
for nplot=l:15000:600000
plot(xg,C(:,nplot), 'b- ') ; 
hold on;
end
plot([Lm Lm],[0 100],'r-');
xlabel('Axis x'); 
ylabel ( 1C (x,t) '); 
print('-dtiff','Cfunzdix')
figure;
plot (t,C (xstep,:), 1b-'); 
xlabel(1 tempo (ore)'); 
ylabel('C(xstep,t)'); 
print('-dtiff', 'C (x=xstep) ' )
figure;
plot(t,C(Lmstep, :),'b- '); 
xlabel('tempo (ore)'); 
ylabel('C(Lmstep,t)'); 
print('-dtiff',’C(x=Lmstep)')
figure;
plot(t,C(Lmstep-2,:),'b— '); 
xlabel('tempo (ore)'); 
ylabel('C (Lmstep-2,t) ' ) ; 
print('-dtiff', ’C(x=Lmstep-2) ')
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Insulin
% alginate in millimetres 
% membrane thickness in millimetres 
% time in hours
% elements in the membrane
% elements in total (space)
% elements in which time is divided
% dt
X=xmax/(xstep-Lmstep); % dx
D=0.028375; % mmA2/h, membrane diffusivity Dalginato=0.3114;
% mmA2/h, alginate diffusivity
% Stability conditions
rmem=D*T/((Lm/Lmstep)A2);
if (rmem>0.4)
disp('rmem troppo grande!!!'); 
disp(rmem); 
return;
end
ralg=Dalginato*T/XA2;
if (ralg>0.4)
disp(1ralg troppo grande!!!*); 
return;
end
% definition of matrix C(x,t) in which there are 
% concentration values in x and t 
C=zeros(xstep,tstep);
% premise and boundary conditions 
C (1:Lmstep,1)=0;
C(Lmstep:xstep,1)=100;
C(l,:) =0 ;
% insulin diffusion 
for j =2:tstep
for i=2:Lmstep
C(i,j)=C(i,j-l) + (D*T*(C(i-1,j-l)-2*C(i, j-1)+C(i+1, j-
1)))/((Lm/Lmstep)A2); 
end
for i=Lmstep+l:xstep-1
C (i,j)=C(i,j-l)+(Dalginato*T*(C(i-1,j-1)-2*C(i,j-1)+C(i+1,j-1)))/(XA2);
end
C(xstep,j)=C(xstep,j-l)+(Dalginato*T*(C(xstep-l,j-l)-C(xstep,j-1))-
0)/(XA2);
disp(sprintf('tstep %d su %d',j,tstep));
end
% vectors for data analysis on concentration 
CFref=zeros([tstep/100,1]); 
for k=l:tstep/100
CFref(k)=C(xstep,100*k-99);
end
Ci=zeros([tstep/15,1]); 
for k=l:tstep/15
Ci(k)=C(2,15*k-14);
end
clear all; 
close all;
% Parameters 
xmax=0.5;
Lm=0.03; 
tmax=2; 
Lmstep=30; 
xstep=5*Lmstep; 
tstep=600000;
% Code
T=tmax/tstep;
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% vectors for data analysis on insulin mass 
Massa=zeros([tstep,1]);
QMassa=zeros([tstep,1]);
MaxQmassa=0. 00;
Kmassa=0;
TMaxma s s a= 0.0 0;
for j=l:tstep
Massa(j)=Massa(j)+C(l,j)*0.5*Lm/Lmstep; 
for i=2:Lmstep
Massa(j)=Massa(j)+C(i,j)*Lm/Lmstep;
end
for i=Lmstep+l:xstep-1
Massa(j)=Massa(j)+C(i,j)*X;
end
Massa(j)=Massa(j)+C(xstep,j)*0.5*X;
end
for k=l:tstep
QMassa(k)=Massa(k)*(k-1)*T;
end
for k=l:tstep
if (MaxQmassa<QMassa(k))
MaxQmassa=QMassa(k);
Kmassa=k;
end
end
TMaxmassa=Kmassa*T;
disp(sprintf('max Qmassa= %i in t= %i ore',MaxQmassa,TMaxmassa));
% vectors for plot
xa = linspace(0,Lm,Lmstep);
xm = linspace(Lm,xmax+Lm,xstep-Lmstep+1);
xg = zeros([1,xstep]); 
xg(1,1:Lmstep)=xa; 
xg(1,Lmstep:xstep)=xm; 
t = linspace(0,tmax,tstep);
for nplot=l:25000:600000
plot(xg,C(:,nplot),'b-'); 
hold on;
end
plot([Lm Lm], [0 100],'r- ') ;
xlabel('Axis x '); 
ylabel('C(x,t)'); 
print('-dtiff','Cfunzdix')
figure;
plot(t,C(xstep, :), ' b-'); 
xlabel('tempo (ore)'); 
ylabel('C(xstep,t)'); 
print('-dtiff',’C(x=xstep)')
figure;
plot(t,C(Lmstep, :), 'b- ') ; 
xlabel('tempo (ore)'); 
ylabel('C(Lmstep,t)'); 
print('-dtiff','C(x=Lmstep)')
figure;
plot (t,C(Lmstep-2, :), 'b— ');
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xlabel('tempo (ore)');
ylabel('C(Lmstep-2,t)');
print('-dtiff*,'C(x=Lmstep-2)')
figure;
plot(t,C(2,:),'b-'); 
xlabel('tempo (ore)'); 
ylabel ( ’C ( 2 , t)') ;  
print('-dtiff','C(x=2)')
figure;
plot(t,Massa(:),'r-'); 
figure;
plot(t,QMassa(:),'r-');
I s G
clear all; 
close all;
% Parameters 
xmax=0.5;
Lm=0.03; 
tmax=2 4;
Lmstep=30; 
xstep=5*Lmstep; 
tstep=600000;
% Code
T=tmax/tstep; % dt
X=xmax/(xstep-Lmstep); % dx
D=0.005; % mmA2/h, membrane diffusivity Dalginato=0 .003;
% mmA2/h, alginate diffusivity
% Stability conditions 
rmem=D*T/((Lm/Lmstep)A2); 
if (rmem>0.4)
disp('rmem troppo grande!!!');
disp(rmem);
return;
end
ralg=Dalginato*T/XA2; 
if (ralg>0.4)
disp ( 'ralg troppo grande!!!'); 
return;
end
% definition of matrix C(x,t) in which there are 
% concentration values in x and t 
C=zeros(xstep,tstep);
% premise and boundary conditions 
C (1:Lmstep,1)=0;
C(Lmstep:xstep,1)=0 ;
C(l, :)=100;
% IgG diffusion 
for j =2:tstep
for i=2:Lmstep
C(i, j)=C(i, j-l) + (D*T*(C(i-1,j-1)-2*C(i,j-1)+C(i+1,j-
1)))/((Lm/Lmstep)A2); 
end
% alginate in millimetres 
% membrane thickness in millimetres 
% time in hours
% elements in the membrane
% elements in total (space)
% elements in which time is divided
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for i=Lmstep+l:xstep-1
C (i,j)=C(i,j-1)+ (Dalginato*T*(C(i-1,j-1)-2*C(i,j-1)+C(i + 1, j-1) ) )/(XA2);
end
C(xstep,j)=C(xstep,j-l)+(Dalginato*T*(C(xstep-l,j-l)-C(xstep, j-1))- 
0)/(XA2);
disp(sprintf('tstep %d su % d j,tstep));
end
% vectors for data analysis on concentration 
CFref=zeros([tstep/100,1]); 
for k=l:tstep/100
CFref( k ) = C (xstep,100*k-99);
end
Ci=zeros([tstep/15,1]); 
for k=l:tstep/15
Ci(k)=C(2,15*k-14) ;
end
% vectors for plot
xa = linspace(0,Lm,Lmstep);
xm = linspace(Lm,xmax+Lm,xstep-Lmstep+1);
xg = zeros([1, xstep])/ 
xg (1,1:Lmstep)=xa; 
xg(1,Lmstep:xstep)=xm; 
t = linspace(0,tmax,tstep);
for nplot=l:12500:600000
plot(xg,C(:,nplot),'b-'); 
hold on;
end
plot([Lm Lm],[0 100],'r-');
xlabel("Axis x'); 
ylabel(1C(x,t) ') ; 
print('-dtiff1,'Cfunzdix')
figure;
plot(t,C(xstep,:),'b-'); 
xlabel('tempo (ore)'); 
ylabel('C(xstep,t)'); 
print('-dtiff','C(x=xstep)')
figure;
plot(t,C(Lmstep,:),'fo— '); 
xlabel('tempo (ore)'); 
ylabel('C(Lmstep,t)'); 
print('-dtiff','C(x=Lmstep)')
figure;
plot(t,C(Lmstep-2,:),'b-'); 
xlabel('tempo (ore)'); 
ylabel('C(Lmstep-2,t)'); 
print('-dtif f', 'C(x=Lmstep-2) ')
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B. Standard Operating Procedure for Human Islet Isolation
HUM AN PANCREATIC ISLET ISOLATION
PURPOSE: To outline the process for the isolation of islet cells from a hum an 
pancreas for clinical transplantation
RESPONSABILITY: Cell Transplant Supervisor or designee.
SCOPE: All trained personnel working in the Clinical Cell Transplant Islet 
Laboratory.
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I. INTRODUCTION:
A. This procedure must be performed under the strictest sterile conditions possible.
B. Frequent changing of sterile gloves will be necessary to maintain sterility. At least two 
people are needed throughout this procedure - one will remain sterile at all times and 
work within the hood ("sterile person"). The other ("Non-Sterile person") will pass 
and receive all necessary materials, reagents and supplies to the sterile person and 
document all necessary information throughout the procedure.
C. Utilizing sterile technique while opening sterile packaging involves removing the 
outer cover and placing the item inside the hood without touching the inside 
packaging.
D. The manufacturer, lot number and expiration dates of all media, reagents, enzymes or 
solutions used in this procedure must be documented. Throughout the procedure, this 
is best accomplished by placing all bottles or containers before use in one designated 
location, then recording the lot numbers at the beginning and throughout the 
procedure.
E. Record the manufacturer, lot number and expiration dates of all disposables (if not 
previously done) and record the autoclave cycle number, autoclave dates and 
chemical control results of all autoclaved non disposables .
F. Note that additional ingredients are needed to supplement CMRL and they must be 
added at the time of use. CMRL without additives cannot be used to culture the islets.
G. Pancreas will be delivered to NIT at the local procurement laboratory (Villa Camozzi, 
1 floor). The on-call person will be notified when the organ has arrived. The on-call 
person or designee must pick up the pancreas. When the pancreas is from the local 
procurement laboratory, request and obtain a copy of the donor chart (also referred to 
as the coordinator's chart) and bring back with the pancreas.
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II. MATERIALS & EQUIPMENT
A. Reagents & Media
• CMRL 1066, Supplemented, MediaTech or equivalent
• Human Serum Albumin (HAS) Kedrion S.p.A or equivalent
• Hanks Balanced Salt Solution (HBSS), MediaTech or equivalent
• University of Wisconsin Solution
• Biocoll Gradients (1.100 and 1.077 densities), Biochrom or equivalent
• Dithizone (DTZ) Sigma or equivalent
• Dimethyl Sulphoxide (DMSO) Sigma or equivalent
• Liberase HI Enzyme by Roche (Boeringher-Mannheim)
• Sterile commercially prepared water for injection, SALF or equivalent
B. Instruments, Equipment & N on Disposables
• Instruments
o Portable pipet-aid 
o Micropipettor for 50 ml 
o Timer
o 3 peristaltic pumps 
o Heated water bath (37°C and 45°C) 
o 1 refrigerated floor centrifuge 
o 1 microscope
o 1 temperature monitor with attached temperature sensor holder 
o Trip balance
o Biological Safety Cabinets/Hoods: #1 and #2 
o Vacuum pump 
o Holders for red biohazard bags 
o 1 refrigerated COBE 2991 Cell Washer
• Sterile Human Islet Isolation Pack
o Large stainless steel tray 
o  Medium stainless steel tray
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o Small stainless steel tray containing surgical instruments:
■ 1 large scissors with blunt ends
■ 1 small scissors with blunt ends
■ 2 large sharp scissors
■ 4 klemmer or mosquito clamps
■ 1 large clamp
■ 1 small clamp
o 2 beaker of 1 L
o 2 beaker of 400 ml
o 2 beaker of 250 ml
o Sterile catheters 
o  Sterile 4.0 silk suture
• Sterile Human Chamber Isolation Pack
o 1 screen (500 mm)
o 500 ml stainless steel isolation chamber with lid 
o 2 rubber ring 
o 7 stainless steel beads 
o 1 heating coil 
o silicone tubing
- 3 size 1 /4 " -3 /8 "
• Sterile Human Purification Pack
o silicone tubing
o  Sterile Cobe couplers and processing sets 
o Teflon coated magnetic bar
• Disposables I (into a drawer in the Islet Lab)
o Sterile wide mouth pipettes: 1, 2 ,5 ,1 0  and 25 ml 
o Sterile syringes: 10ml and 60ml 
o Sterile 3.5 ml plastic transfer pipettes
o Sterile 10 X 35 counting and petri dishes & 100 X 15 petri dishes 
o Sterile 18G needles
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o Sterile 150 ml and 600 ml transfer bags
o Sterile disposable sheets
Disposables II
o 2 Freeze packs . , 
o Sterile 250 ml conical centrifuge tubes
o Sterile tissue culture flasks, vented: T-75 Sarsted 
o Sterile disposable gloves, gown, shoe covers, head cover and mask
, f,
o  Large and small red biohazard bags
o Large and small sharps containers
III. PROCEDURE
fA. - Islet Laboratory Set Up ,
1. Enter the hand-washing room and wash hands
2. Remove the outer plastic bags from a packaged sterile gown and sterile gloves 
without touching the inner packaging.
3. Put shoe covers, sterile gown and sterile gloves in that order. Street clothes 
cannot be worn under the green scrubs.
4. Enter the clean room (Islet lab) and put on eye protection.
5. Perform the following tasks:
a) Ensure that blower is on in the #1 hood and that ultraviolet (UV) light 
is off. Turn on light and thoroughly wipe interior with 10% bleach or 
Lachisan using a disposable yellow dusters. Repeat this for the other 
hood. .
b) After cleaning, allow blower to run for at least 10 minutes before 
using the hood.
c) Turn on the power for the refrigerated centrifuge, wipe interior with 
10% bleach or Lachisan using a disposable yellow dusters. Ensure 
that the temperature is set to 4°C, close the lids and run them (empty) 
for 5 minutes. This will allow the temperature to reach 4°C.
d) Wipe down all counters with 10% bleach or Lachisan.
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e) Ensure that fresh empty red bags (double bagged) are in bag holders 
and that several new sharps containers are in place.
f) Assemble the vacuum collection system near the #2 hood by 
attaching one end of the vacuum tubing to the pump and the other 
end to the sterile 2 ml pipette without cotton.
g) Fill the water bath with distilled sterile water, turn on water bath and 
warm to 45° C.
h) Obtain the following and place all on a desk in the islet lab: 
o Sterile Islet Isolation Pack
o All items listed in "Disposables II".
B. Hood and Chamber Apparatus Set Up & Reagent Preparation
1. All individuals performing the procedure must scrub and gown but one will 
be designated as "sterile" and the others as "non-sterile".
5. Sterile Person: 6. Non-Sterile Person:
a) Open to completely cover the sterile surface 
of the hood while avoiding the non-sterile 
vented areas.
b) Accept the chamber.
c) Put the rubber ring on the chamber and on 
the lid
d) Connect one silicone tube to the inlet port of 
the chamber and to the outlet port of the 
chamber lid.
e) Connect the free end of the silicone tube 
connected to the inner port to the outlet port4
of the glass coil. Connect the last tube to the 
inner port of the glass coil.
a) Remove packaging from sterile half sheet 
in #1 hood
b) Open the wrap of the chamber pack
c) Open the wrap of the rubber ring pack
d) Open the wrap of three silicone tube packs
e) Open the wrap of the coil pack
f) Open the wrap of 400 ml beaker pack
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f) Bring the coil out of the hood.
g) Place the tube that enter in the pump in a 400 
ml glass beaker
h) When tubing circuit is complete, place the 
temperature probe into the side port of the 
chamber. Insert and screw the probe into the 
port on the bottom of the chamber. The other 
flat end of the probe is inserted into the 
temperature sensor .
i) Instruct the non-sterile person to adjust the 
pump speed to 320 m l/m in  (range of 200-350 
m l/m in  acceptable), and start filling the 
circuit.
j) The chamber must be filled from the bottom, 
via the silicone tubing through the inlet port 
at the bottom of the chamber.
k) Make sure that the circuit doesn't lose.
g) Place the coil in the water bath filled with 
distilled autoclaved water warmed to
45°C
h) Place the silicone tube connected to the 
inlet port of the coil in the pump head and 
secure.
i) Fill the 400 ml beaker with 300 ml 2% 
Hanks when requested by the sterile 
person.
j) Adjust the pump speed to 320 m l/m in  
(range of 200-350 m l/m in  acceptable), and 
start filling the circuit at the sterile 
person's request
k) Prepare dithizone (DTZ) solution
1) Prepare enzyme (see section D, "Enzyme 
Preparation"). Do not warm the enzyme 
until instructed to do so by the sterile 
person.
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C. Pancreas Cleaning & Cannulation
Sterile person: 2. Non-Sterile person:1.
a) All processes performed by the sterile person 
must be performed in the #1 hood.
b) Open to completely cover the freeze packs 
and sterile surface of the hood while avoiding 
the non-sterile vented areas
c) Place the large tray inside the larger tray with 
the slush and instruct the non-sterile person 
to add approximately 500 ml of cold UW 
solution to the medium tray.
d) Using sterile technique, open the pancreas 
container and remove 2-3 ml of the UW-1 
solution (which the pancreas is transported 
in) from the pancreas transport container 
using a sterile plastic 3.5 ml pipette. Pass this 
to the non-sterile person for sterility tests.
e) Instruct the non-sterile person to heat the 
enzyme approximately 10 minutes before 
completion of cleaning and cannulation.
f) Move the pancreas to the tray with the UW 
solution and clean off the fat and connective 
tissue using sterile scissors and forceps:
• Spread the scissors in a "spreading, 
closing" motion to separate the 
connective tissue from the pancreas.
• Remove fat and connective tissue using a 
blunt dissection technique.
a) Remove packaging from sterile half sheet 
in #1 hood
b) Put the freeze packs on the working plate 
of the #1 hood
c) Open the small stainless steel tray 
containing surgical instruments on the 
working plate of the #1 hood
d) Remove packaging from the large tray
e) Accept plastic pipette with the sample for 
sterility testing and aseptically place in 
the #2 hood.
f) Open the outside wrap of the pancreas 
container and pass the inside sterile 
container inside the hood to the sterile 
person.
g) Accept transport container from the 
sterile person, open it, measure the 
temperature of UW solution in which
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/• Do not trim the pancreas too closely as 
leaks may develop.
• Note that the fat floats while the 
pancreatic tissue does n o t
• During cleaning locate ducts exiting the 
pancreas from the non-dissected end and 
clamp with mosquito clamps to facilitate 
distention.
g) Place the cleaned pancreas in the sterile 250 
mi beaker (included in the isolation pack), 
cover with foil and pass to the non-sterile 
person for weighing.
h) Note the amount of fat, presence of edema, 
whether pancreas is flushed, and the texture 
of the pancreas by gently examining it. 
Communicate this information to the non- 
sterile person so that it can be documented
i) Use a No. 10 scalpel to cut the pancreas at the 
neck, just below the head.
Appendix
the pancreas is transported using the 
second temperature probe and record the 
temperature.
h) When instructed by the sterile person, 
place the enzyme in the waterbath 
warmed to 45°C and slide the end of the 
probe hanging out of the bottle (flat end) 
into the temperature sensor attached to 
the temperature monitor and clip it in 
place. Note that the side with the 2 holes 
is placed facing the sensor wires.
i) Allow the enzyme to warm to 30°C. 
Gently swirl bottle before reading. the 
temperature registered on the 
temperature monitor and ensure that the 
monitor is not reading "room  
temperature".
j) Weigh the cleaned pancreas when  
instructed to do so by the sterile person 
as follows:
• Accept the empty foil covered beaker 
and use to tare the scale.
• Weigh beaker and pancreas.
• Hold the beaker under hood #1 so 
that sterile person can retrieve the 
pancreas and then remove beaker 
from hood.
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j) Remove the needle from the 18 G catheters 
before cannulation to prevent the catheters 
from falling out after cannulation. 
k) Locate the large pancreatic duct and 
cannulate both the head and tail portions 
with the catheters.
1) Secure the catheter in the duct of the pancreas 
body as follows:
• Insert the straight needle (2.0 black silk 
attached) on one side, close to surface of 
the cut, but not too close to the cannula.
• Pull the needle through leaving a length 
of silk adequate to tie several knots.
• Reinsert the needle on the other side in 
the same manner and cut the needle off 
from the silk.
• Use both ends of the silk to tie the 
catheter in place.
• Before tightening, reinsert the needles 
into the catheters to avoid crushing the 
plastic cannula and bend the needle (at 
the top) to prevent it from coming out of 
the tip of the catheter.
• Repeat the tying three times and place an 
additional tie after twice wrapping the 
silk around the catheter. Tie the. loose 
ends of the silk into a loop and use this to 
pick up and transport the pancreas.
k) Record this and all other required 
information. Communicate with the 
sterile person for verbal assessment of 
the pancreas and document this 
information.
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• The catheter is secure when it does not 
slide out of the duct even after gently 
trying to pull it out. 
m) Repeat this procedure (outlined in section n, 
above) for the head of the pancreas, 
n) Once both catheters are in place and tied in, 
wait for the collagenase solution to be heated 
then pass the large tray with the iced saline to 
the non-sterile person for removal from the 
hood. The gland is now ready to be 
distended.
D. Enzyme Preparation
.
1. The Non-Sterile person performs this activity and all processes are to be 
performed under the #2 hood.
2. Place a bottle of plain Hanks and a bottle of commercially prepared sterile 
water for injection in the #2 hood.
3. Remove the enzyme package from the -70° C freezer in the Islet lab, remove 
and discard the package and let bottle stand in the #2 hood at room  
temperature for a few minutes.
4. Record the enzyme lot number and expiration date.
5. Remove the rubber lid from the enzyme bottle by inserting a sterile needle 
through one side of the rubber lid to the other side then gently lifting the cap 
off using the needle as an anchor.
6. Avoiding bubbles, add 15 ml of sterile water for injection to the contents of the 
enzyme bottle (0.5 g lyophilized pellet) and do not shake the bottle. Let the 
bottle sit at 4°C for 30 minutes. Avoid any introduction of bubbles that will 
affect the action of the enzyme.
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7. After the enzyme pellet has dissolved, transfer the contents of the bottle to the 
upper chamber of the 500 ml filter (0.2 jum size) system. Wash the enzyme 
bottle several times with plain Hanks and add to the upper chamber of the 
filter system.
8. Add plain Hanks to the upper chamber to reach a total volume of 350 ml 
(bottle has measurement markings on the side). This will result in a final 
enzyme concentration of 1.4 m g/m l (0.5 g /  350 ml).
9. Connect the free end of the vacuum tubing to the filter bottle inside the hood 
and turn the vacuum pump on (on the ground nearby) using your foot. Once 
the vacuum is on, filtering will be automatic.
10. Immediately after sterile filtering, remove the upper chamber from the bottle, 
remove the clear cap from one end of the probe and aseptically place the probe 
inside the bottle while allowing the flat end of the probe to hang outside. 
Tightly cap the bottle without breaking the wire of the probe and place it in the 
refrigerator until ready for warming.
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1. Sterile Person:
2.
a) Perform all activities in this section in hood #1.
b) Pour out the UW solution from the medium
sized tray (used to clean the pancreas) into the
large saline bath tray and pass to the non- 
sterile person.
c) Distend the head of the pancreas with -150 ml 
of collagenase solution using a 60 cc syringe 
connected to the catheter -  forcefully push the 
plunger of the syringe to force the enzyme into 
the pancreas and avoid creating bubbles. The 
pancreas will enlarge if there are no leaks or 
cuts.
d) When leaks are observed, use a sterile
hemostat to clamp off the area, preventing the
enzyme from leaking.
e) The tail of the pancreas is distended next using 
-200 ml of enzyme solution. It may again be 
necessary to check for leaks and to close them 
off with hemostats.
f) Occasionally, a portion of the pancreas does 
not distend well. This may be due to the 
presence of an accessory duct or to technical 
problems. The poorly distended region may be 
injected intraparenchymally (using an 18 or 20 
Gauge needle attached to a 60 cc syringe) to
3. Non-Sterile Person:
a) Accept the large tray from the sterile 
person and discard contents.
b) When the temperature of the enzyme
solution reaches 30°C, remove the 
bottle of enzyme from the water bath.
c) Open the bottle containing the enzyme 
solution under hood #1 and aseptically 
pour its contents into a 400 ml beaker 
supplied in the pack without touching 
anything under the hood.
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achieve proper distention.
g) While the pancreas is being distended, drain 
the solution from the chamber system into a 1L 
beaker as follows:
• Instruct non-sterile person to stop the 
pump and reverse the direction of the flow.
• Remove the end of the large tubing to a 250 
ml beaker and start the pump again. The 
solution will flow in a different direction; 
the chamber will empty via two ports at 
the bottom of the chamber and small 
tubing connected to the ports.
• Discard the recirculating fluid from the 
chamber system.
h) Continue cleaning the pancreas. Remove as 
much "non-pancreatic" tissue as possible as 
well as cannulas and sutures. Do not discard 
these.
d) After the system has drained, stop the 
pump and reverse direction of the flow.
e) Weigh removed tissue, sutures and 
cannulas in order to determine true 
weight of the pancreas during the 
digestion. Calculate weight and record 
it.
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1. Sterile Person:
a) Open the chamber. Place distended pancreas 
cut in 7 pieces inside the chamber and fill the 
chamber with collagenase solution up to the 
filter level.
b) Put screen (430 pm) in the chamber and the top 
of the chamber and tighten securely.
c) Pour all the remaining collagenase solution 
into the 250 ml beaker placed in the ring stand 
and instruct non-sterile person to begin 
pumping solution through the system at a rate 
of 225 ml / min while the circuit is filling.
2. Non-Sterile Person:
a) Begin pumping solution through the 
system at a rate of 225 m l/m in  while 
the circuit is filling.
b) Add more 2% Hanks to the beaker 
(without touching anything under 
hood #1) in order to fill the system  
completely and to eliminate air from 
the circuit.
c) As soon as circuit is complete and no 
air bubbles are observed in the system, 
adjust the pump speed to 150 m l/m in  
(100-150 m l/m in  range is acceptable).
d) Begin recording the temperature in the 
chamber. The desired rate of heating is
2°/ min until 37°C is reached.
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d) After 8 minutes of digestion, take a 3 ml 
sample from the end of the large
Tubing (one minute before the sample is taken, 
the chamber must be shaken vigorously to 
assure that a representative sample is 
collected).
e) Place a few drops of digest in a small, 10 x-35 
mm petri dish and pass to the Non-Sterile 
person.
e) Pull the tubing extending from the top 
and bottom of the chamber through the 
plastic rings attached to the hood to 
make sure that the tubing does not 
interfere with the machine.
f) Swirl the collection flask gently during 
the collection of the first 100 ml.
g) Temperature should not increase above 
37° C during the digestion.
h) The length of digestion time varies but 
in general, once the temperature has
reached 37°C inside the chamber, the 
digestion is continued for about 20-25 
minutes. Regulate the temperature in 
the chamber by taking the heating coil 
partially or completely out of the water 
bath when the temperature reaches 
37°C.
i) Add a few drops of dithizone (DTZ) 
solution to the digest and observe 
under the microscope. DTZ stains the 
islets a red color by the binding of zinc 
to insulin granules. Conversely, the 
acinar tissue appears unstained. Record 
all observations. Normally, fat cells are 
seem first, followed by acinar and an 
occasional islet fragment.
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f) Accept and unwrap the flasks and place them  
on either side of the ring stand.
g) As the digestion nears completion, instruct the 
non-sterile person to fill one of the flasks with 3 
L of 10% RPMI (uptake flask) and pour 1L of 
10% RPMI in the other flask which will be used 
to collect the digest (collection flask) without 
touching anything in Hood #1.
j) There is an increase in the amount of 
acinar tissue as digestion proceeds. The 
digestion is considered complete when  
an increase in the amount of tissue 
liberated from the chamber is observed, 
most or all of the islets are free of the 
surrounding acinar tissue, intact islets 
are observed, and the acinar tissue 
becomes finer (smaller cell clusters).
k) While the digestion is in progress, 
aseptically pass 2 chilled sterile 4L 
flasks to the sterile person.
1) When instructed by the sterile person, 
pour 3 L of 10% RPMI in the uptake 
flask without touching anything in the 
#1 hood.
m) Pour 1 liter of 10% RPMI to the 
collection flask in the same manner 
when instructed to do so by the sterile 
person.
n) Place a sterile tray with sterile ice in the 
#2 hood.
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Stop the digestion process (switch to dilution), .
regardless of the number of free islets in the *
sample when most islets are free, even if lightly
embedded. In the case of heavily embedded or
mantled islets, the digestion can be prolonged
to the point before the islets become irregular
in shape, before small irregular islet fragments
. . . .
are seen, and/or before acinar tissue becomes
too fine (overdigestion).
G. Dilution and Collection of the Digest
1. Sterile Person: 2. Non-Sterile Person:
a) When digestion is judged complete, the
dilution phase. This is carried out in hood #1.
b) At this time, instruct the non-sterile person to a) Turn the pump off when instructed to
turn the pump off and simultaneously place do so by the sterile person.
the end of the smaller tubing into the flask
containing 3 L of 10% RPMI (uptake flask) and
place the end of the large tubing into the
collection flask which contains 1 L of 10%
RPMI.
c) Pour the contents of the 250 ml beaker 4
containing the digest into the collection flask,
rinse this beaker with 100 ml of FBS and add to%
the collection flask to help inactive the enzyme
in the digest.
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d) Instruct the non-sterile person to turn the 
pump back on, adjust the speed to provide a 
flow of 320 m l/m in  (200-350 m l/m in  range is 
acceptable), remove heating coil from the water 
bath to allow the chamber to be cooled, and 
start to shake the chamber vigorously
e) Begin collecting digest solution into the 
collection flask until 2-3 L of fluid is obtained.
f) Replenish the uptake flask (flask with large 
tubing) continuously with more 10% RPMI as 
and when needed.
g) Once the flask has 3 liters, cover with  
aluminum foil and pass it to the Non-Sterile 
person w ho will transfer it to the
#2 hood, where tissue can be collected by 
centrifugation.
h) Move the end of the large tubing to a labeled 1 
L sterile bottle and continue collecting the 
tissue. Once a bottle is full, cap it tightly and 
pass it to the Non-Sterile person to place in the 
refrigerator. Repeat this as many times as there 
is still digest to be collected.
i) The dilution phase lasts 15-45 minutes or until 
islets are no longer detected in a sample.
j) Weigh and record the weight of the undigested 
pancreas. Do not subtract the weight of the 
undigested pancreas from the total weight of 
the pancreas!
b) When instructed by the sterile person, 
turn the pump back on, adjust the 
speed to provide a flow of 320 ml /  min 
(200-350 m l/m in  range is acceptable), 
remove heating coil from the water 
bath to allow the chamber to be cooled, 
and start to shake the chamber 
vigorously
c) Take out 4-6L of 10% RPMI from the 
refrigerator when needed by the sterile 
person and replenish the uptake flask 
without touching anything in hood #U
d) In the #2 hood, mix well and then pour 
digest solution from the collection flask 
into sterile 1 L beakers and cover with 
foil. Pour digest from beakers into 250 
ml conical centrifuge tubes, cap and 
close tightly. Fill as many tubes as 
possible -  4 conicals can be centrifuged 
at the same time
e) Balance the tubes and centrifuge them
at 1000 rpm for 2 minutes at 4°C.
f) When the spin is over, remove tubes 
from centrifuge and place in #2 hood.
g) In the #2 hood, add 180 ml cold UW  
solution and 20 ml FBS to a sterile flat 
bottomed jar or beaker and place this 
on sterile ice located in the hood. UW 
solution prevents the acinar from
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k) Proceed to Section H, Separation of Islets Using 
Discontinuous Gradients and perform steps 1-
16.
becoming edematous.
h) Discard supernatant with a single 
smooth motion (progressing slowly to a 
135° angle between conical and flask 
and without creating air bubbles that 
could disrupt the pellet) into the empty 
collection flask now labeled as "waste". 
Leave a small amount of liquid in the 
lip of the conical to resuspend the 
pellet.
i) Detach the pellet from the bottom of 
the conical tube using a quick circular 
motion, pour pellet into the jar or 
beaker containing 20 ml of FBS and 180 
ml of UW solution on ice.
j) Repeat steps d-i, above, using all of the
digest (from the 4L flask and all bottles 
placed in the refrigerator) until all the 
tissue is centrifuged and collected 
using fresh sterile 250 conicals each 
time.
k) If there is a large amount of tissue, use
a second jar or beaker for collection 
containing 20 ml FBS and 180 ml UW 
solution.
1) Keep resuspending the tissue as more
is - added , to the tube by slowly 
aspirating up and down using a 25 ml 
pipette.
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m) Once all of the tissue has been 
collected, take a lOOpl sample for pre­
purification count from 100 ml of tissue 
suspension using a micropipette with 
extender (see section I on "Counting of 
Islets")
n) Centrifuge tubes at 1000 rpm for 5 
minutes.
Record the comments on the condition 
| of the acinar tissue and percentage of 
free islets.
o) Resuspend the tissue in 250 ml stock 
Biocoll solution, combining pellets if 
more than one conical was used, 
p) After gentle resuspension of the tissue, 
divide the suspension in 2 or more 250 
ml conicals depending on the size of 
the digest pellet (20 ml per conical).
H. Separation of Islets Using Discontinuous Gradients
- «•     —
1. Face shield must be worn at all times when operating the Cobe. Position Cobe 
and turn power on. Open the Plexiglas cover by removing the metal latch. 
Remove the locking glass bowl cover and remove Plexiglas cover and 
underlying foam ring from the bowl area.
2. Place centrifuge Cobe bag inside the bowl. This is done by carefully rolling the 
bag around the rotating seal into a cigar shape and sliding it through the 
opening in the glass bowl cover. Care must be taken not to damage the 
rotating seal.
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3. Position the bag over the four central posts in the bowl. Tuck the perimeter of 
the bag into the bowl so that the bag lies smoothly on the bottom of the bowl 
with the edge curving up the sides of the bowl. Position the sampling port so 
that the stem lies flat and parallel to the side of the bowl.
4. Place plastic collar (around tubing at the center of the bag) below the rotating 
seal. Lower the locking glass cover and lock it in place. Take care not to catch 
any part of the bag in the slots at the edge of the bowl which holds the bowl 
cover. This could result in damage to the bag.
5. Close the sliding Plexiglas cover and place the metal latch over the posts and 
the rotating seal. The rotating seal may require minor manipulation in order to 
position it to slide into the slot in the weight. Let it use its own weight to lock 
the cover and hold the rotating seal. Do not push down on the weight as this 
could damage the seal.
6. Turn the locking rod to the down position.
7. Place the tubing into the valve slots on the Cobe (but outside the pinch valves), 
using the color-coding to determine position. The tubing is not loaded into the 
pinch valves, but merely held in place in the tubing guides.
8. Clamp each tube using hemostats.
9. Place sterilized silicon tubing (size 16) into the Masterflex pump heads located 
inside the #2 hood.
10. Label 4 sterile conicals for each Cobe run as "1" for top, "2" for second layer, 
"3" for third layer and "S" for supernatant layer and place in rack(s) in the #2 
hood.
11. Aseptically spike the silicone tubing by placing the plastic end of the green or 
red tubing from the Cobe into the end of the silicone tubing. Place the other 
end of the sterile silicone tubing into a sterile 250 ml conical.
12. Heat-seal the purple, blue and yellow lines between the T-junction and valve 
slots.
13. In the #2 hood, place a 60cc wide mouth syringe in a ring stand clamp.
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14. Handle only the barrel of the syringe, as this will be used to load the 
suspended tissue into a 600 ml transfer bag.
15. Remove the plunger and place upright with the barrel touching the flat surface 
of the hood. Remove the tip cover of the syringe.
16. Attach a sterile piece of tubing to the tip of the syringe. Connect the other end
of the tubing to the non-spiked end of the Cobe coupler. Spike the other end of 
the Cobe coupler/adapter into a 600 ml transfer bag labeled with the HP #. 
Use the side port of the 600 ml transfer bag.
17. Tie a loose knot in the tubing of the 600 ml transfer bag.
18. If more than 20 ml of tissue was collected, two syringe set ups, two Cobe set
ups, and two sets of the solutions below are necessary.
19. Remove the solutions for the discontinuous gradients from the refrigerator. 
Biocoll gradients are pre prepared in 75 ml aliquots. Solutions needed for each 
Cobe run are listed below:
Bottom layer: 75 ml of Biocoll (1.100)
Middle layer: 75 ml of Biocoll (1.096)
Top layer: 75 ml of Biocoll (1.037)
Plain Hanks: 50 ml
20. Remove aliquot(s) of 300 ml Biocoll stock solution from the refrigerator.
21. Remove all but approximately 20 ml of supernatant from the centrifuged tissue 
using a bacteriological pipette (no cotton) connected to the vacuum system. 
Use caution so that the pellet is not disturbed while most of the supernatant is 
removed at the same time.
22. The last 20 ml of supernatant should be removed using a manual pipet aid to 
minimize the risk of pellet aspiration.
23. Mix well together the digest in the conical with a small amount of stock Biocoll 
(so that mixing can be thorough) in a sideways or upright circular motion to 
avoid creating bubbles.
24. Thoroughly resuspend tissue in conical(s) using, if necessary, a sterile 
disposable 10 ml pipette to break up any clumps.
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25. Pour the above suspension(s) into the 60cc syringe connected to the 600 ml 
transfer bag(s) and allow to flow by gravity via the set-up described above.
26. Add Biocoll stock from each bottle to each conical to rinse conical(s) and then 
pour into respective syringes after the pellet mixture containing islets have all 
entered the solution. The total volume of stock Biocoll should be 300 ml.
27. Plunger may be used to force the stock Biocoll into the bag once all of the 
tissue has entered the transfer bag.
28. Tighten the loose knot in the line of the bag and heat seal bag.
29. Immediately attach the filled transfer bag(s) to the red or green Cobe tubing 
and hang on the metal rail of the Cobe, with red and green color tubing 
clamped with hemostats.
30. Release clamp on the tube attached to the transfer bag so tissue flows into the 
Cobe bag in the centrifuge bowl.
31. Once the tissue has entered the centrifuge bag, the tubing attached to the 
transfer bag is clamped, the tubing attached to the silicone tube is unclamped 
and the most dense of Biocoll layers (1.100) is pumped through this tubing up 
to the T-junction.
32. When the solution reaches the T-junction, stop the pump and clamp the tubing 
connected to the silicone tube.
33. Unclamp tube connected to the transfer bag.
34. Remove air in the centrifuge bag as follows:
• Set Cobe speed at 2,000 rpm. (the speed should be maintained at this
setting throughout the whole procedure).
• Hit "Start"button.
• When centrifuge reaches 2,000 rpm, push "SuperOut" button.
• Immediately adjust SuperOut rate to 150ml/min (Solution will be
pushed-up through the tubing towards the T-junction).
• Press "HOLD" button.
• Clamp red tubing as solution reaches T-junction and simultaneously 
press "Stop/Reset" button.
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35. When machine stops, reset dial of SuperOut rate to "0" but do not press 
SuperOut button.
36. Press "Start" button again.
37. When the centrifuge has attained speed, unclamp tubing connected to the 
silicone tube, start the pump and begin pumping the Biocoll solutions of 
varying density at a rate of approximately 90 m l/m in. This is accomplished by 
placing the end of the masterflex tubing in the designated conicals and moving 
the tubing to the next designated conical (stop the pump while moving the 
tubing between conicals to avoid the introduction of air into the Cobe). 
Sequence for solution movement is as indicated below:
• Pump in 75 ml of 1.108 Biocoll on top of the 300 ml pellet layer, which contains tissue,
resuspended in Ficoll stock.
• Pump in 75 ml of 1.096 Biocoll on top of the 75 ml preceding 1.108 layer.
• Pump in 75 ml of 1.037 Biocoll on top of the 75 ml preceding 1.108 layer.
• Pump in 50 ml of plain Hanks until the fluid/air interface reaches midway down the tubing
leading to the rotating seal. Plain Hanks is necessary to remove proteins from the rotating 
seal. In the presence of proteins, the seal would break during the high speed rotation phase.
38. Turn off the pump and clamp the tubing connected to the silicone tube.
39. Adjust SuperOut valve to "0" ,
40. Press "SuperOut" and im m ediately open the red or green tube to relieve the 
excess pressure, then reclamp the tubing.
41. Let spin for 5 min.
42. Before collection, make sure that the pump head is open and tubing inside it 
is com pletely released.
43. Collect fractions through the tubing connected to the silicone tube using the 4 
sterile conicals labeled 1, 2, 3 and S. .
44. Unclamp the tubing connected to the silicone tube and adjust the dial of the 
SuperOut rate up to about 175 -  do not press the SuperOut button!
45. Normally, 4 fractions are collected:
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• Between fractions the machine is put on Hold while the green tubing is 
moved to the next 250 ml conical bottle to prevent spillage and tissue 
loss.
• The first layer has a volume of 100-125 ml and it should be visible. 
Collect 75 ml of this layer in the conical labeled "S". When the distinct 
layer reaches the inside metal rim, wait 3 seconds, press "HOLD" and 
then switch tubing to the next conical labeled "1".
• Fractions 1, 2 and 3 are approximately 75 ml each and the layers 
should be visible. When 75 ml is collected or the visible layer reaches 
the inside metal rim, wait 3 seconds, press "HOLD" and then switch 
tubing to the next conical labeled "2".
• When 75 ml are collected or the visible layer reaches the inside metal 
rim, wait 3 seconds, press "HOLD" and transfer the tubing to the 
conical labeled "3".
• Collect 100 ml of the "3" fraction and press "STOP/RESET" on the 
machine.
• Discard the "S" fraction after taking a sample to confirm that it does 
not contain islets and keep fractions labeled as "1", "2", and "3".
46. Once the fractions are collected, stop the machine. Dilute fractions with 10% 
RPMI (fill conical to the top) and spin at 1500 rpm for 5 minutes at 4°C.
47. Heat seal tubing leading to centrifuge bag, cut tubing and take bag out of the 
bowl. Take a sample of the pellet through the port on the centrifuge bag 
(using sterile technique) using a Cobe coupler.
48. Place this sample in petri dish, add a few drops of DTZ solution and some 
saline in order to estimate if there are any islets in the pellet.
49. If a significant number of free islets are observed in the pellet, collect the entire 
pellet by using the Cobe coupler inserted it into the port of the Cobe bag. 
Collect pellet in a 250 ml conical and centrifuge at 1500 rpm for 5 minutes at 
4°C. Aspirate supernatant and purify islets in the pellet by using Cobe.
50. Use a micropipettor with extender to take 3, 100 pi samples of each fraction 
("1", "2", and "3") from 100 ml of tissue suspension and place in counting
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dishes (see section I, "Counting of Islet Cells"). Add DTZ and saline and 
observe under the microscope for the presence of islets. Discard fraction "3" if 
there are no islets detected.
51. Aspirate the supernatant and resuspend the pellets in 10% RPMI for a second
wash and spin at 1000 rpm for 5 minutes at 4°C.
52. Resuspend the final pellet in 250 ml of CMRL-1066 (supplemented) and mix 
well. At this time, islets can be counted.
1. Mix the final islet suspension well before taking a sample.
2. Add a small volume of saline to cover the bottom of the counting dishes before 
taking triplicate 100 pi samples, using a micropipettor with a sterile pipet tip
extender attached to a wide mouth pipet tip, from the final islet preparation 
and place each sample in the 10x35 mm counting dish containing saline.
3. Add a few drops of DTZ solution to the 100 pi sample contained in the
counting dish and count the islets under the microscope following the steps 
below.
4. After staining the islets, it is possible to count the islets, which will appear red. 
Count the islet sample using the 10X eyepiece and the 4X objective to give a 
total magnification of 40X. Use the calibrated grid in the left eyepiece of the 
phase contrast microscope.
5. Since islet volume is approximately proportional to the cube of the islet radius, 
it is crucial that the islets are divided into diameter (size) classes. 50 pm  
diameter range increments are used, without considering particles smaller 
then 50 pm  since their contribution to the total volume of the preparation is 
insignificant.
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6. The distance between two lines on the calibrated grid in the eyepiece will 
equal 50 Jim. Using the eyepiece (40X total magnification), use the chart below  
as a guide:
Number of Lines 
2
4
6
8
10
Size of Islets 
50 Jim
100 Jim
150 Jim
200 pm 
250 pm
7. Count the number in each group using the manual cell counter, and record 
numbers as well as the purity and conversion to islet equivalents.
8. Calculates the actual islet number (IN) as well as the islet equivalent (IEQ).
9. Islet number (IN) and islet equivalent (IEQ) calculations can be done manually 
as well. The table below indicates the mean volume for each diameter class 
and the relative conversion factor into islets of 150 [Am diameter. These factors
make it possible to convert the total islet number from any preparation into 
islet equivalent (IEQ). In place of IEQ, the total islet volume of the final 
preparation can be also estimated.
islet diameter conversion into islets
50-100 n/6.00
100-150 n/1.50
150-200 n x  1.7
200-250 n x 3.5
250-300 n x 6.3
300-350 n x l 0 . 4
>350 n x 15.8
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C. Project of Islet Laboratory
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